=> d his

L1

(FILE 'HOME' ENTERED AT 10:05:34 ON 29 APR 2004)

FILE 'STNGUIDE' ENTERED AT 10:05:44 ON 29 APR 2004

FILE 'HOME' ENTERED AT 10:06:18 ON 29 APR 2004

FILE 'REGISTRY' ENTERED AT 10:06:21 ON 29 APR 2004

STRUCTURE UPLOADED

L2 QUE L1

L3 34 S L2

L4 659 S L2 SSS FUL

FILE 'CAPLUS' ENTERED AT 10:06:44 ON 29 APR 2004

L5 40 S L4

L6 ANALYZE L5 1- RN HIT : 659 TERMS

FILE 'REGISTRY' ENTERED AT 10:07:05 ON 29 APR 2004

L7 100 S 193752?/RN

L8 3 S L4 AND L7

L9 656 S L4 NOT L8

FILE 'CAPLUS! ENTERED AT 10:09:43 ON 29 APR 2004

L10 30 S L9

L11 27 S L10 AND PATENT/DT

L12 3 S L10 NOT L11

L13 3 S L12 AND PD>1999

=> d 12

L2 HAS NO ANSWERS

L1 STR

Structure attributes must be viewed using STN Express query preparation. L2 QUE ABB=ON PLU=ON L1

10/075,635

LIY ANSWER 1 OF 27
ACCESSION NUMBER:
ACCESSION NUMBER:
DOCUMENT NUMBER:
INVENTOR(S):

PATENT ASSIGNEE(S):
DOCUMENT TYPE:
LANGUAGE:
DOCUMENT TYPE:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

KIND DATE APPLICATION NO. DATE US 2004033970
PRIORITY APPLM. INFO.:
OTHER SOURCE(S):
GI A1 20040219

Antibacterial erythromycin derivs. I, wherein Rl is H, Ac, Bz, TMS, triethylsilyl, R2 is -CH-CH-, -C.tplbond.C-; R3 is heterocycle, tetra-azolyl, furanyl, imidazolyl, iso-thiazolyl, isoxazolyl, naphthyl, 1,2,3-oxadiazolyl, oxazolyl, Ph, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrcolyl, 1,3,4-thiadiazolyl, thiazolyl, pyridyl (pyridinyl), thianyl, pyrcolyl, 1,3,5-triazolyl); X is H, heterocycle; with improved pharmacokinetic profiles and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds, and intermediates used in the processes, compns. containing the compds, and methods for prophylawis and treatment of bacterial infections using the compds. are disclosed. Thus, (3s,4,7R,9R,10R,115,13R,15R,15AR)-10-((25,3R,45,6R)-4-(dimthylamino)-3-hydroxy-6-methyletrahydro-2H-pyran-2-yl) oxy)-4-ethyl-7-fluoro-3a,7,9,11,13,15-hexamethyl-11-((2E)-3-(5-(2-

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

619296-72-9 CAPLUS
2H-Tetrazole-Z-propanenitrile, 5-[5-[3-[[(3as,4R,7s,9R,10R,11R,13R,15R,15a
R)-4-ethyl-7-fluorotetradecahyd:o-3a,7,9,11,13,15-hexamethyl-2,6,8,14tetraoxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-p-D-xylohexpyranoxyl]oxyl-Z-rovacyclotetradecino(4,3-d)oxazol-11-yl]oxy]-1propynyl]-2-thienyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

619296-73-0 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-{[3-[6-(2-methyl2H-tetrazol-5-yl)-3-pyridinyl]-2-propynyl]oxy]-10-{[3,4,6-trideoxy-3(dimethylamino]-8-D-xylo-hexopyranoxyl]oxyl
(dis,7s,9r,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) methyl-2H-tetrazol-5-yl) thien-2-yl)prop-2-enyl)oxy)octahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazole-2,6,8,14(1H,7H,9H)-tetrone was prepd, and tested as antibacterial agent. The daily therapeutically effective ant. of the compds, administered to a patient in single or divided doses range from about 0.1 to about 200 mg/kg body wt. preferably from about 0.25 to about 100 mg/kg body wt. Compds. of this invention displayed antibacterial activity superior to the control, which control demonstrated no antibacterial activity. The pharmacokinetic profiles were evaluated using cassette dosing protocols in dog at a dose of 1 mg/kg.

IT 619286-66-1P 619296-71-8P 619296-72-9P 619296-73-0P 621375-51-9P 621375-61-P 623175-61-P F23175-61-P F33175-61-P F33175-61

S23175-68-BP 623175-69-9P
RI: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); TRU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation); USES (Uses) (preparation of antibacterial erythromycin derivs. with improved pharmacokinetic profiles) (B1296-66-1 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,4-ethyl-7-fluorootahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-15-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propynyl]oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-9-0-xylo-hexopytranoxyl)oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

619296-71-8 CAPLUS
2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[(2E)-3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-6-D-xylo-hexopycanosyl]oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-6-D-xylo-hexopycanosyl)oxyl-,
03s,4R,75,9R,10R,11R,13R,15R,15aR)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

619296-74-1 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(2-methyl-2Htetrazol-5-yl)-2-propynyl)oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)B-D-xylo-hexopyranoyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15R)(9CI) (CA INDEX NAME)

Absolute stereochemistry.

619296-75-2 CAPLUS
2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-[5-{2-methyl-2H-tetrazol-5-yl)-2-thiazolyl)-2-propnynlloxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranoxyl]oxy]-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

RN 619296-80-9 CAPLUS
CN 2H-Tetrazole-2-acetic acid, 5-[5-[3-[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylanino)-B-D-xylo-hexopyranoxyl)oxyl-2H-oxacyclotetradecino[(4,3-d]oxazol-11-yl]oxy]-1-propynyl]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 619296-81-0 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14 (1H,7H,9H)-tetrone,4-ethyl-7-fluoroctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-[2-(2-propenyl)-2H-tetrazol-5-yl]-2-thienyl]-2-propynyl] oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,(3a5,4R,75,9R,10R,11R,13R,15R,15aR)- (9CT) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 623175-53-1 CAPLUS
CN 2H-Tetrazole-2-propagenitrile, 5-[5-[3-[[(3aS,4R,75,9R,10R,11R,13R,15R,15a]R]-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]-2-thienyl]- (9C1) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 623175-54-2 CAPLUS
CN 2R-Tetrazole-2-acetic acid, 5-[5-[3-[[(3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorocteradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranoxyl]oxyl-2H-oxacyoloetradecino(4,3-d)oxacol-11-yl]oxy]-1-propenyl]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 623175-51-9 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-f[uoroctahydro-3a,7,9,11,13,15-hexamethyl-11-[[(2E)-3-(2-methyl-2H-tetrazol-5-yl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)β-D-xylo-hexopytranosyl]oxy]-, (3aS,4R,7S,9R,1OR,11R,13R,15R,15aR)(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 623175-52-0 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-[5-[2-(2-propenyl)-2H-tetrazol-5-yl]-2-thienyl]-2-propenyl) oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl) oxy]-,
(3a5,48,75,9R,10R,11R,13R,15R,15aB)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 623175-55-3 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14 (1H,7H,9H) -tetrone,
4-ethyl-7-fluorootahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[6-(2-methyl2H-tetrazol-5-yl)-3-pyridinyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3(dimethylamino)-8-D-xylo-hexpoyranoxyl]oxy]-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 623175-56-4 CAPLUS
CN 2H-Oxacyclotatradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluoroctahydro-3a,7,9,11,13,15-hexamethyl-11-{(3-[2-(2-methyl-2H-tetrazol-5-yl)-5-thiazolyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-8D-bxylo-hexopyranosyl]oxy]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

623175-57-5 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-0-xylo-hexopyranosyl]oxy]-,
(3aS,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

623175-58-6 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluoroootahydro-3a,7,9,11,13,15-hexamethyl-11-{{3-{5-(1-methyl-1H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy}-10-{{3,4,6-trideoxy-3-(dimethylamino)-8-p-xylo-hexopyranosyl]oxy}-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

623175-68-8 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-{5-(1-methylH-tetrazol-5-yl)-2-thienyl]-2-propynyl]oxy)-10-[[3,4,6-trideoxy-3(dimethylamino)-8-D-xylo-hexopyranoxyl]oxy)-,
(3a5,4R,75,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

623175-69-9 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(1H-tetrazol-5-y1)-2-thienyl]-2-propynyl]oxyl-10-[{3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl-, (3aS,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

(Continued) L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

623175-59-7 CAPLUS
2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-(5-(1Htetrazol-5-yl)-2-thienyl)-2-propenyl)oxyl-10-[(3,4,6-trideoxy-3(dimethylamino)-8-D-xylo-hexopyranoxyl)oxyl(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

623175-67-7 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[2-(2-methyl-2H-tetrazol-5-y])-5-thiazolyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

619296-70-7

RL: RCT (Reactant): RACT (Reactant or reagent)
(preparation of antibacterial erythromycin derivs. with improved pharmacokinetic profiles)
619296-70-7 CAPLUS
2H-Oxacyclotetradcino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-bex.oy_1-3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hex.oyyranoxyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[2-[5-(2-methyl-Z-tetrazol-5-yl)-2-thazolyl]-2-propyyl]oxy]-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

412046-92-59 619296-51-4P 619296-59-2P
619296-60-5P 619296-62-7P
RL: RCT (Reactant), SPN (Synthetic preparation), PREP (Preparation), RACT (Reactant or reagent)
(preparation of antibacterial erythromycin derivs, with improved pharmacokinetic profiles)
412046-92-5 CAPLUS
2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H.7H.9H)-tetrone,
10-{[2-0-bex.oyl-3,4,6-tr.ideoxy-3-(dimethylamino)-β-D-xylo-hex.oyloyloxy|-4-ethyl-7-fluorocotahydro-3a,7,9,11,13,15-hex.amethyl-11-(2-propynyloxy)-, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

619296-51-4 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,9,14(1H,7H,9H)-tetrone,
10-[{2-0-bexozyl-3,4,6-trideoxy-3-(dimethylamino)-B-D-xylohexozyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11[[3-[5-(2-methyl-2H-tetrazol-5-yyl)-2-thienyl]-2-propyyl]oxy]-,
[3aS,4R,7S,9R,1DR,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

619296-59-2 CAPLUS
Boronic acid, [(1E)-3-[(3as,4R,7s,9R,10R,11R,13R,15R,15aR)-10-[(2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl)oxy]-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tcraoxo-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) Absolute stereochemistry.

1.11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

619296-60-5 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,9,14(1H,7H,9H)-tetrone,
10-[{2-0-bexoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11[[(2E)-3-[5-(2-methyl-2H-tetrazol-5-yl]-2-thlenyl]-2-propenyl]oxy]-,
[3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

619296-62-7 CAPLUS
2H-Owacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-f[uorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propynyloxy)-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl-loxy)-,
3as,4a,75,9a,10a,11a,13a,15a,15a)- [9c1] (CA INDEX NAME)

ANSWER 2 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN COSSION NUMBER: 2004:60129 CAPLUS COUNTY NUMBER: 140:122755

140:12275
9-Oxime macrolide antibacterials
Seatle, Xenia Beeber Djuric, Stevan; Ma, Zhenkun;
Yang, Fan
USA
USA
US. Pat. Appl. Publ., 18 pp.
CODEN: USXXCO
Patent
English
1 INVENTOR(S):

PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

US 2004014691 A1 20040122
PRIORITY APPLN. INFO.:
OTHER SOURCE(S): A1 20040122 US 2003-420391 20030422 MARPAT 140:122755 2002-375361P P 20020425

Antibacterial compds. I (R1 = alkyl, (CH2)alkenyl, (CH2)alkynyl, etc.; R2 = H, alkyl, (CH2)alkenyl, (CH2)alkynyl, etc.; R3 = H, hydroxyl protecting group; one of R4 and R5 = H and the other = OH; or R4 and R5 = -O; X1 = H, P) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates used in the processes, compns.

making the compute and account and the compute and the compute, and methods for prophylaxis or treatment of bacterial infections using the compute, are disclosed. Compute displayed antibacterial activity of 0.008-128 µg/mL against Staphylococcus aureus, Streptococcus pyogenes, S. pneumoniae, Enterococcus faecalis, E. faecium, Moraxella catarchalis, Haemophilus influenzae, and Escherichia

faccium, Morawella catarrnalis, naemopulies anticonnect, coli.
640858-19-99 640858-20-2P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(9-Oxine macrolide antibacterials, their preparation and compns., for treatment of bacterial infections)
64858-19-9 CAPLUS
2H-Oxacyclotetradecino{4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(3-quinolinyl)-2-propynyl]oxyl-10-[(3,4,6-trideoxy-3-(dimethylamino)-9-0-xylo-hexopyranosyl]oxyl-, 14-(0-methyloxime), (3as,4R,7s,9R,10R,11R,13R,14E,15R)

L11 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN ,15aR) - (9CI) (CA INDEX NAME) (Continued)

Absolute stereochemistry. Double bond geometry as shown.

648858-20-2 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3s,7,9,11,13,15-hexamethyl-11-{(3-{5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino]-9-D-xylo-hexopyranoxyl]oxy]-, 14-(O-methyloxime),
(3a5,4R,75,9R,10R,11R,13R,14E,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown

648858-19-9D, salts, prodrugs 648858-20-2D, salts,

ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN SSION NUMBER: 2003:892791 CAPLUS LENT NUMBER: 139:381701 139:381701
Preparation of antibacterial erythromycin derivatives with improved pharmacokinetic profiles
Clark, Richard F., Djuric, Stevan M., Ma, Zhenkun;
Phan, Ly, Rupp, Michael J.
Abbott Laboratories, USA
PCT Int. Appl., 50 pp.
CODEN: PIXXD2
Patent INVENTOR (5): PATENT ASSIGNEE(S): SOURCE: DOCUMENT TYPE: Patent LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2003093288 A1 20031113 WO 2003-U512970 20030425

W: CA, JP, HX

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IT, LU, MC, NL, PT, RO, SE, SI, ST, TR

US 2003207820 A1 20031106 US 2002-136715 20020430

PRIORITY APPLN. INFO.: US 2002-136715 A 20020430

US 2003-422384 A 20030424

OTHER SOURCE(S): HARPAT 139:381701 OTHER SOURCE(S):

Antibacterial erythromycin derivs. I, wherein Rl is H, Ac, Bz, TMS, triethylsilyl, RZ is -CH-CH-, -C.tplbond.C-; R3 is heterocycle, tetra-azolyl, furanyl, imidazolyl, iso-thiazolyl, isoxazolyl, naphthyl, 1,2,3-oxadiazolyl, oxazolyl, Ph, pyrazinyl, pyrazolyl, pyridazinyl, pyrindinyl, pyrrolyl, 1,3,4-thiadiazolyl, thiazolyl, pyridyl (pyridinyl), thianyl (thiophenyl), 1,3,5-triazolyl; X is H, F, heterocycle; with improved pharmacokinetic profiles and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates used in the processes, compns. containing the compds., and methods for prophylaxis and treatment of bacterial infections using the compds. are disclosed. Thus, (3a5,4R,7R,9R,10R,11S,1RR,1SA,15AN)-10-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-ZH-pyran-2-

L11 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) hexopyranosyl]oxy]-, 14-(0-methyloxime), (3a5,4R,75,9R,10R,11R,13R,14E,15R,15R,1-6C1), (CA INDEX MAKE)

Absolute stereochemistry. Double bond geometry as shown.

648858-20-2 CAPLUS
2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-{5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-nylo-hexopyranoxyl]oxy]-, 14-(0-methyloxime),
(3a5,4R,75,9R,10R,11R,13R,14E,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
yl) oxy)-4-ethyl-7-fluoro-3a,7,9,11,13,15-hexamethyl-11-(((2E)-3-(5-(2methyl-2H-tetrazol-5-yl)thlen-2-yl)prop-2-enyl)oxy)octahydro-2Hoxacyclotetradecino[4,3-d][1,3]oxazole-2,6,8,14(1H,7H,9H)-tetrone was
prepd. and tested as antibacterial agent. The daily therapeutically
effective ant. of the compds. administered to a patient in single or
divided doses range from about 0.1 to about 200 mg/kg body wt., preferably
from about 0.25 to about 100 mg/kg body wt. Compds. of this invention
displayed antibacterial activity superior to the control, which control
demonstrated no antibacterial activity. The pharmacokinetic profiles were
evaluated using cassette dosing protocols in dog at a dose of 1 mg/kg.

IT 619286-66-19 619286-74-19 619296-72-99
619236-73-09 619286-74-19 619296-72-99
619236-73-09 619296-71-09 623173-51-99
623173-52-09 623173-53-79 623173-61-79
623173-58-66 623173-59-99
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic
preparation); TRU (Therapeutic use); BIOL (Biological study); PREP
(Preparation) of antibacterial erythromycin derivs. with improved
pharmacokinetic profiles)

RN 619296-66-1 CAPLUS
CH-Ovacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorocotahydro-3a,7,9,11,13,15-hexamethyl-1-[[3-[5-(2-methyl2H-tetrazol-5-yl)-2-thlenyl-2-propayl)oxyl-10-[[1,4,6-ttideoxy-3(dimethylamino)-P-D-sylo-hexopycanosylloxyl-,
(335,4R,75,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

619296-71-8 CAPLUS
2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[((2E)-3-[5-{2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyyranoxyl)oxy]-,
(3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

RN 619296-72-9 CAPLUS
CN 2H-Tetrazole-2-propanenitrile, 5-[5-[3-[{(3a5,4R,75,9R,10R,11R,13R,15R,15a}], R)-4-ethyl-7-[fuorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-{[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl)oxy]-2H-oxacyclotetradecino(4,3-d]oxazol-11-yl]oxy]-1-propynyl]-2-thienyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 619296-73-0 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorocotahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-kylo-hexopyranosyl)oxy]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 619296-80-9 CAPLUS
CN 2H-Tetrazole-2-acetic acid, 5-[5-[3-[(3as, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR) 4-ethyl-7-fluoroctetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14tetraoxo-10-[[3, 4, 6-trideoxy-3-(dimethylamino) -P-D-xylohexopyranoxyl) oxyl-2H-oxacyclotetradecino[4, 3-d) oxazol-11-yl] oxy] -1propynyl]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 619296-81-0 CAPLUS
CN 2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-[2-(2-propenyl)-2H-tetrazol-5-yl]-2-thienyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamio-)-B-0-xylo-hexopycanoxylloxy]-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued

RN 619296-74-1 CAPLUS
CN 2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tettone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(2-methyl-2Htetrazol-5-yl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)β-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15R)(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 619296-75-2 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluoroctahydro-3a,7,9,11,13,15-hexamethyl-11-[{3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thiazolyl]-2-propynyl]oxy]-10-[{3,4,6-trideoxy-3(dinethylanino]-9-D-xylo-hexopyranosyl]oxy](3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 623175-51-9 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[(2E)-3-(2-methyl-2H-tetrazol-5-yl)-2-propenyl] oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-sylo-hexopyranosyl] oxy]-, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 623175-52-0 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H]-tetrone,
4-ethyl-7-f(lucrooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-[2-(2-propenyl]-2H-tetrazol-5-yl]-2-thienyl]-2-propenyl]oxy}-10-[[3,4,6-trideoxy-3-(dimethylamino-)-P0-Rylo-hexopyranosyl]oxy](3as,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

RN 623175-53-1 CAPLUS
CN 2H-Tetrazole-2-propanenitrile, 5-[5-[3-[{(3as,4R,7s,9R,10R,11R,13R,15R,15a}],-4c+tetrazole-2-propanenitrile, 5-[5-[3-[{(3as,4R,7s,9R,10R,11R,13R,15R,15a}],-4c+tetrazono-10-[{(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl)oxyl-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxyl-1-propenyl]-2-thienyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 623175-54-2 CAPLUS
CN 2H-Tetrazole-2-acetic acid, 5-[5-[3-[[{3as, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15ar}-4-ethyl-7-fluorocteradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraxoro-10-[[3, 4, 6-tridexy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl] oxyl-2H-oxacyclotetradecino[4, 3-d] oxazol-11-yl]oxy]-1-propenyl]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 623175-57-S CAPLUS
CN 2H-Oxacyclotatradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorocotahydro-3a,7,9,11,13,15-hexamethyl-11-{[3-[5-(2-methyl2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-[0-[[3,4,6-trideoxy-3(dimethylamino)-9-0-xylo-hexpyranosyl]oxy]-,
(3a5,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 623175-58-6 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorocotahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(1-methylHH-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3(dimethylamino)-9-D-xylo-hexopyranosyl]oxy]-,
(3as,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown. Lll ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 623175-55-3 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorocotahydro-3a,7,9,11,13,15-hexamethyl-11-[{3-[6-{2-methyl-2H-tetrazol-5-yl]-3-pyrtidinyl]-2-propenyl]oxy}-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-kylo-hexopyranosyl]oxy]-,
(3as,4R,7S,9R,10R,11H,13R,15R,15aB)-(GCI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 623175-56-4 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[2-(2-methyl-2H-tetrazol-5-yl)-5-thiazolyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino]-B-D-xylo-hexopyranoxyl]oxy]-,
(3a5,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 623175-59-7 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-[5-(1Htetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3(dimethylamino)-BD-Bxylo-hexpyranoxyl]oxy]-,
(3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 623175-67-7 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluoroctahydro-3a,7,9,11,13,15-hexamethyl-11-{[3-[2-(2-methyl2H-tetrazol-5-yl)-5-thiazolyl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3(dimethylamino)-80-xyl)-6-hexpyranosyl]oxy]-,
(3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

623175-68-8 CAPLUS
2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[{3-[5-(1-methyl-1H-tetrazol-5-yl)-2-thienyl]-2-propynyl] oxyl-10-[{3,4,6-trideoxy-3-(dimethylamino)-8-0-xylo-hexopyranoxyl]oxyl-,
(3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

623175-69-9 CAPLUS 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(1H-tetrazol-5-yl)-2-thienyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-wylo-hexopyranosyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) (2-propynyloxy)-, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

619296-51-4 CAPLUS
2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-([2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxyl-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thisnyl]-2-propynyl]oxyl-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

619296-59-2 CAPLUS
Boronic acid, [(12)-3-[[(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-10-[(2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14tetraoxo-24-moxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

619296-70-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of antibacterial erythromycin derivs. with improved pharmacokinetic profiles)
619296-70-7 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[(2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosylloxy|-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thiazolyll-2-propynylloxy]-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

412046-92-5P 619296-51-4P 619296-59-2P
619296-60-5P 619296-62-7P
RL: RCT (Reactant): SPN (Synthetic preparation): PREP (Preparation): RACT (Reactant or reagent)
(preparation of antibacterial erythromycin derivs. with improved pharmacokinetic profiles)
412046-92-5 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[(2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorocotahydro-3a,7,9,11,13,15-hexamethyl-11-

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



619296-60-5 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-{[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-0-xylohexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11[[2E]-3-[5-{2-methyl-2H-tetrazol-5-yl]-2-thienyl]-2-propenyl]oxy]-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

619296-62-7 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propynyloxy)-10[(3,4,6-trideoxy-3-(dimethylamino)-9-D-sylo-hexopyranoxyloxy)-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(prepn. of erythromycin owime macrolides as antibacterial agents)
RN 620155-58-0 CAPLUS

620155-58-0 CAPUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-(3-quinolinyl)2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylohexopyranoxyl]oxy]- 14-(O-methyloxime), (3a5,4R,75,9R,10R,11R,13R,15R,15a
R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

620155-60-4 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-{{3-{5-(2-methyl-2H-tetrazol-5-yl)-2-thlenyl]-2-propynyl]oxyl-10-[{3,4,6-trideoxy-3-(dimethylamino)-#p-0-sylo-hexopyranosyl]oxyl-7,14-(0-nethyloxime), (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

620155-66-0P 620155-68-2P 620155-70-6P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of erythromycin oxime macrolides as antibacterial agents) 620155-66-0 CAPLUS

Page 11

ANSWER 4 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN SION NUMBER: 2003:875124 CAPLUS 139:365172

DOCUMENT NUMBER:

139:365172
Preparation of erythromycin 9-oxime macrolides as antibacterial agents
Searle, Kenia Beebe, Djuric, Stevan; Ma, Zhenkun; Yang, Fan
Abbott Laboratories, USA
PCT Int. Appl., 64 pp.
CODEN: PIXNO2
Patent
English INVENTOR(S):

PATENT ASSIGNEE(S):

DOCUMENT TYPE: LANGUAGE: English 1

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

WO 2003090761 A1 20031106 WO 2003-US12478 20030423
W: CA, JP, MX
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, MC, NL, PT, RO, SE, SI, SK, TR
PRIORITY APPLN. INFO.: US 2002-131851 A 20020425
GI PATENT NO. APPLICATION NO. DATE

Antibacterial erythromycin 9-oxime macrolides I, wherein XI is H, F; RI is alkyl. -(CH2) alkenyl. -(CH2) alkynyl, R2 is hydrogen, alkyl. -(CH2) alkenyl. -(CH2) alkynyl, R3 is hydrogen or R, in which R is a hydroxyl protecting moiety; one of R4 and R5 is hydrogen and the other is -OH; or R4 and R5 together are -O1 and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds, and intermediates used in the processes, compns. containing the compds., and methods for prophylaxis or treatment of bacterial infections using the compds. are disclosed. Thus, I [R1 = 3-(quinolin-3-yl)prop-2-ynyl) R2 = methyl: R3 = hydrogen; R4 and R5 taken together are - O; and X = fluoroj was prepared and tested in vitro antibacterial agent. Compds. of this invention displayed in vitro antibacterial activity in the range of about 0.008 µg/mL to greater than about 128 µg/mL.

1

L11 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[13-(1,5naphthyridin-3-yl)-2-propynyl)oxyl-10-[13,4,6-trideoxy-3-(dimethylamino)B-D-Rylo-hexopyranoxyl)oxyl-10-(ethyloxime),
(3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

620155-68-2 CAPLUS
2H-Owacyclotetradecino[4,3-d]owazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(6-quinoxalinyl)-2-propynyl]owy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,14-(0-methyloxime),
(3aS,4R,75,9R,10R,11R,13R,15R,15RR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

620155-70-6 CAPLUS
2H-Owacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-{(3-[5-(2-pycidinyl)-2-thienyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-9-D-xylo-hexopytanosyl]oxy]-, 14-(O-methyloxime),
(3aS,4R,75,9R,10R,11R,13R,15R,15AB)- (9CI) (CA INDEX NAME)

L11 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN Double bond geometry unknown. (Continued)

REFERENCE COUNT:

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
intermediates used in the processes, compns. contg. the compds., and
methods for prophylaxis and treatment of bacterial infections using the
compds. are disclosed. Thus, (385,48,78,78,108,115,138,158,158)-10((125,38,45,68,-4-dimethylamino)-3-hydroxy-6-methylletrahydro-2H-pyran-2ylloxy)-4-ethyl-7-fluoro-3a,7,9,11,13,15-hexamethyl-11-(((28)-3-15-(2methyl-2H-tetracol-5-yllhien-2-yllpop-2-enylloxy)-dethydro-2Hoxacyclotetradecino(4,3-d[[1,3]oxazole-2,6,8,14(1H,71,91)-tetrone was
prepd. and tested as antibacterial agent. The daily therapeutically
effective amt. of the compds. addinistered to a patient in single or
divided doses range from about 0.1 to about 200 mg/kg body vt., preferably
from about 0.25 to about 100 mg/kg body vt. Compds. of this invention
displayed antibacterial activity superior to the control, which control
demonstrated no antibacterial activity. The pharmacokinetic profiles were
evaluated using cassette dosing protocols in dog at a dose of 1 mg/kg.

IT 619296-66-1V 619296-71-8V 619296-72-9V
619296-73-0V 619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
619296-73-0V
6192

Absolute stereochemistry.

619296-71-8 CAPLUS
2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamehyl-11-[[(2E)-3-[5-(2-methyl-2-H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown

ANSVER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN
SSION NUMBER: 2003:874954 CAPLUS
139:350908
Preparation of antibacterial erythromycin derivatives
with improved pharmacokinetic profiles
(TOR(S): Clark, Richard F.; Djuric, Stevan; Ma, Zhenkun; Phan,
Ly; Rupp, Michael
USA
U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
MENT TYPE: Patent
LyGE: English

PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: LANGUAGE:

INVENTOR (S):

English 2 FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

> PATENT NO. KIND DATE APPLICATION NO. DATE 20031106 US 2003207820 WO 2003093288 A1 A1 US 2002-136715 20020430 WO 2003-US12970 20030425 20031113

W: CA, JP, MX
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, HC, NL, PT, RO, SE, SI, SK, TR
PRIORITY APPLN. INFO: US 2002-136715 A 20020430

A 20020430 A 20030424 US 2003-422384

OTHER SOURCE(S): MARPAT 139:350908

Antibacterial erythromycin derivs. I, wherein Rl is H, Ac, Bz, TMS, triethylsilyl, RZ is -CH=CH-, -C.tplbond.C-, R3 is heterocycle, tetra-zolyl, furanyl, indizaclyl, iso-thizaclyl, iso-zolyl, naphthyl, 1,2.3-oxadiazolyl, oxazolyl, Ph, pyrazinyl, pyrazolyl, pyridazinyl, pyrindinyl, pyrrolyl, 1,3.4-thiadiazolyl, thiazolyl, pyridyl (pyridinyl), thianyl (thiophenyl), 1,3.5-triazinyl, 1,2.3-triazolyl X is H, F, heterocycle; with improved pharmacokinetic profiles and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and

L11 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

619296-72-9 CAPLUS
2H-Tetrazole-2-propanenitrile, 5-[5-[3-[{(3aS,4R,7S,9R,10R,11R,13R,15R,15aR,15aR,14-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-p-D-xylo-hexopyranoxyloxyl-2R-oxacyclotetradecino(4,3-d)oxazol-11-yl]oxy]-1-propynyl]-2-thienyl]- (9CI) (CA INDEX NAME)

619296-73-0 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(lH,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]-2-propynyl]oxy]-10-[{3,4,6-trideoxy-3-(dimethylamino]-8-D-xylo-hexopyranosyl]oxy]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)


619296-74-1 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-{[3-(2-methyl-2Htetrazol-5-yl)-2-propynyl)oxy}-10-[[3,4,6-trideoxy-3-(dimethylamino)B-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15RR)(9CI) (CA INDEX NAME)

Absolute stereochemistry.

619296-75-2 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-[5-(2-methyl2H-tetrazol-5-yl)-2-thiazolyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3(dimethylamino)-8-D-xylo-bexopyranoxyl]oxy]-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-\teta-b-xylo-hexopyranoxyl)\text{oxyl}-ZR-oxacyclotetradecino[4,3-d]\text{oxacyl-11-yl}\text{oxyl}-1-propynyl]-2-thienyl]-, methyl ester [9CI) (CA INDEX NAME)



619296-81-0 CAPLUS
2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorootahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-[2-(2-propenyl)-2H-tetrazol-5-yl]-2-thienyl]-2-propynyl] oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-9-D-nylo-hexpyranoxyl]oxy]-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


619296-70-7 619296-82-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of antibacterial erythromycin derivs. with improved pharmacokinetic profiles)
619296-70-7 CAPUS
2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
1D-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl] oxyl-4-ethyl-7-fluoroocathydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thiazolyl]-2-propyyl) oxyl-,
(3aS,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

619296-77-4 CAPLUS
2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14 (1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[(2E)-3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopycanosyl]oxy]-(3aS,4R,7R,9R,10R,11R,13R,15R,15R)- (9Cl) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.



619296-80-9 CAPLUS
2H-Tetrazole-2-acetic acid, 5-[5-[3-[[(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-

L11 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

619296-82-1 CAPLUS
2H-Owacyclotetradecino[4,3-d]owazole-2,6,8,14(IH,7H,9H)-tetrone,
10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11[[3-(2-methyl-2H-tetrazol-5-yl)-2-propynyl]oxy]-,
[3aS,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

412046-92-5P 619296-51-4P 619296-59-2P
619296-60-5P 619296-62-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of antibacterial erythromycin derive, with improved pharmacokinetic profiles)
412046-92-5 CAPLUS
2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[{2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propynyloxy)-, (3as,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

RN 619296-51-4 CAPLUS
CN 2H-Oxacyclotetradcino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11[[3-[5-(2-methyl-2H-tetrazol-5-yl]-2-thienyl]-2-propynyl]oxyl-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry

RN 619296-59-2 CAPLUS
CN Boronic acid, [(1E)-3-{{(3aS,4R,7s,9R,10R,11R,13R,15R,15aR)-10-[{2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxyl-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-terraxoo-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxyl-1-propenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

L11 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 619296-60-5 CAPLUS
CN ZH-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-sylohexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11[(2E)-3-[5-(2-berkyl-ZH-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-,
(3a5,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 619296-62-7 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propynyloxy)-10[(3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl)oxy]-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

IN ANSWER 6 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN
ACESSION NUMBER:
2003:591015 CAPLUS
139:133786
Preparation of erythromycin A derived amido-macrolides
for use in pharmaceutical compositions for treatment
of bacterial infections
Ashley, Gary; Shaw, Simon James; Li, Yandong
Kosan Biosciences, Inc., USA
PCT Int. Appl., 120 pp.
CODEN: PIXXD2
Patent
LANGUAGE:
PAMENT INFORMATION:
English
1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2003061671 A1 20030731 W0 2003-US1399 200301117

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, II, IN, IS, DY, KE, KG, KP, KR, KZ, LC, LX, LL, LX, LS, LT, LU, LV, MA, HD, MG, MK, MM, MV, MZ, MZ, NO, NZ, OM, PH, PL, PT, NO, RU, SC, SD, SE, SS, SK, SL, TJ, TM, TM, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW, ZW, AM, AZ, BY, KG, KZ, HD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, ML, MT, NE, SN, TD, TG

US 200319458 A1 20031023 US 2003-347512 20030117

PATORITY APPLIA. INFO::

MARPAT 139:133786

GI

Me Me Me R5 OH CH3 OR3

AB Erythromycin A derived amides, such as I [Rl = alkyl, alkenyl, alkynyl, aryl, arylalkyl, biarylalkyl, etc.; R2 = H, alkyl, alkenyl, alkynyl; R3 = H, COPh, alkanoyl; R4 = H, OH; R5 = H, OH, alkoxy, alkenyloxy, alkynyloxy;

L11 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

R6 = H, OMe: X = (CH2)s: n = 0-2], were prepd. for therapeutic use as antibacterial agents. These erythromycin A derivs. are useful for treating bacterial infections resulting from bacteria selected from the group consisting of Gram pos. bacteria, Gram meg. bacteria selected from the group consisting of Gram pos. bacteria, Gram meg. bacteria and anaerobic bacteria, such as Staphylococcus aureus, Streptococcus progenes, enterococci, Morawella catarrhalis, and Haemophilus influenzae. Infections and diseases that may treated using the agents include community-acquired pneumonia, acute exacerbated chronic bronchitis, acute sinusitis, tonsillitis, pharyngitis, upper respiratory tract infection, lower respiratory tract infection, sin infection, soft tissue infection, lower respiratory tract infection, sin infection, joint infection and gastric motility diseases, such as gastro-esophageal reflux disease (GERD), postoperative ileus, diabetes, and gastropacesis. Thus, 15-(6-quinolinecarboxamido)erythromycin A I [R1 = 6-quinolinyl, R2 = R3 = H, R4 = R5 = OH, R6 = OMe, X = (CH2)2] was prepd. via a series of steps which included bio-mediated conversion of (i)-(25', 3R')-5-chloro-3-hydroxy-2-methylpentanoate
N-propionylcysteamine thioester to 15-chloro-6-deoxyerythronolide B using Streptomyces coelicolor, conversion of the 15-chloro-macrolide to 15-azido-6-deoxyerythronolide B, a second bio-mediated conversion of the 15-azido-sucythromycin A with 6-quinolinecarboxylic acid. The prepd. erythromycin A derivs. were tested for anti-microbial activity against organisms, such as S. aureus CC4172 and H. influenzae ATCC49766.

15 S6629-20-9P
RL: BRN (Biosynthetic preparation); PAC (Pharmacological activity), RCT (Reactant); SFM (Synthetic preparation) THU (Therapeutic use). BIOL

568629-20-9P
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES

(Biological study); PREP (Preparation); Roc. (Naucum) (Uses) (preparation of erythromycin A derived amido-macrolides for use in pharmaceutical compns. for treatment of bacterial infections) 56629-20-9 CAPLUS Benzeneacetamida, N-[2-[3a5,4R,7s,9R,10R,11R,13R,15R,15aR]-10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosylloxy]-7-fluorotetradecahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-2H-oxacyclotetradecino(4,3-d]oxazol-4-yl]ethyl]-3-(2-furanyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

568629-96-9 CAPLUS
Benzeneacetam.de, N-[2-[{3as,4R,7s,9R,10R,11R,13R,15R,15R},-7fluorotetradecahydro-11-hydroxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14tetraoxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-#-D-xylohexopyranoxyl)oxyl-2H-oxacyyclotetradecino[4,3-d]oxazol-4-yl]ethyl]-3-(2furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

568631-10-7 CAPLUS
Benzeneacetamide, N-[2-[(]as,4R,7s,9R,10R,11R,13R,15R,15R)-7-fluorotetradecahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(]a,4,6-trideoxy-3-(dimethylamino)-P-D-sylo-hexopyranosyl]oxyl-ZH-oxacyclotetradecino[4,3-d]oxazol-4-yl]ethyl]-2-(2-furanyl)- (9C1) (CA INDEX INME)

Absolute stereochemistry.

L11 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

568629-24-3P 568629-96-9P 568631-10-7P
558631-18-5P 568631-28-7P
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); SPN
(Synthetic preparation); TRU (Therapeutic use); BIOL (Biological study);
PREF (Preparation); USES (Uses)
(preparation of erythromycin A derived amido-macrolides for use in
pharmaceutical compns. for treatment of bacterial infections)
568629-24-3 CAPLUS
Benzeneacetamide, N=[2-[(3a5,4R,75,9R,10R,11R,13R,15R,15aR]-7fluorotetradecahydro-11-methoxy-3a,7,9,11,13,15-hexamethy1-2,6,8,14tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranoxyl)cxyl -2H-oxacyclotetradecino[4,3-d]oxazol-4-yl]ethyl]-3-(2furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

568631-18-5 CAPLUS
1,2-Benzisoxazole-3-acetamide, N-[2-[{3aS,4R,7s,9R,10R,11R,13R,15R,15aR}-7-fluorotetradecahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranoxyl]oxyl-2H-oxacyclotetradecino[4,3-d]oxazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

568631-28-7 CAPLUS 2-Oxazoleacetamide, N-[2-[(3as,4R,7s,9R,10R,11R,13R,15R,15aR)-7-fluorotetradecahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl]oxy]-2H-oxacyplotetradecino[[4,3-d]oxazol-4-yl]ethyl]-4-methyl-5-phenyl- (9CI) (CA INDEX NAME)

568629-08-3P
RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagant) BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagant) of the study o

Absolute stereochemistry.

1

REFERENCE COUNT:

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

The present invention includes erythromycin ketolides I wherein: X is hydrogen or halide; R is hydrogen or a substituted or unsubstituted moiety wherein the moiety is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocycloalkenyl, heterocycloalkyl, heterocycloalkyl, heterocycloalkyl, heterocycloalkyl, heterocycloalkyl, heterocycloalkyl, is hydrogen or a substituted or unsubstituted moiety wherein the moiety is selected from the group consisting of methyl; alkyl, alkenyl, alkynyl, aryl, heterocycloalkyl, arylalkenyl, arylalkenyl, arylalkenyl, arylalkerocycloalkyl, aryl, and heterocycloalkyl, R2 is hydrogen, acyl, or a hydroxy protecting group; R3 is hydrogen, hydroxyl, or -ORa wherein Ra is a substituted or unsubstituted moiety selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocycloalkynyl, arylalkenyl, arylalkenyl, arylalkyl, heterocycloalkyl, heterocycloalkynyl, arylalkenyl, arylalkenyl, arylalkenyl, heterocycloalkyl, heterocycloalkynyl, heterocycloalkynyl, heterocycloalkynyl, heterocycloalkynyl, heterocycloalkynyl, heterocycloalkynyl, and the pharmaceutically acceptable salts, esters and pro-drug forms thereof. These compds, possess anti-infective activity and are useful for the treatment of bacterial and protozoal infections. Thus, I (X - F, R = IH-imidazo(4,5-b)pyridin-1-ylbutyl, R1 = F, R2 = CHe, was prepared and tested in vitro as antibacterial agent against S. pneumoniae (MIC \$0.015).
300841-16-19 301320-09-29 413592-00-4P 413592-17-39 413592-17

Absolute stereochemistry.

ANSWER 7 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN SION NUMBER: 2003:524045 CAPLUS 139:69471

Preparation of erythromycin ketolides as antibacterial agents agents
Hlasta, Dennis; Henninger, Todd C.; Grant, Eugene B.;
Khosla, Chaitin; Chu, Daniel T. W.; Ashley, Gary
Ortho-Honeil Pharmaceutical, Inc., USA
U.S., 43 pp., Cont.-in-part of U.S. Ser. No. 550,045.
CODEN: USXXXAM
Patent INVENTOR(S):


PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: LANGUAGE:

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT INFORMATION:			
PATENT NO.		APPLICATION NO.	DATE
			20001018
US 6590083		US 2000-691540 US 2000-548568	20001018
US 6458771	B1 2002100	US 2000-548584	20000413
05 6395710	B1 20020320	US 2000-550045 US 2000-551162 WO 2001-US32119	20000414
05 0451700	B1 2002091	05 2000-551162	20000414
WO 2002032918	A3 2003010		20011012
		, AZ. BA. BB. BG. BR. BY	ng 61 61 61
		DM, DZ, EC, EE, ES, FI	
		. 15, JP, KE, KG, KP, KK . MG, MK, MN, MW, MX, MZ	
		SI, SK, SL, TJ, TM, TR	
		AZ. BY. KG. KZ. MD. RU	
		SD, SL, SZ, TZ, UG, ZW	
		GR. IE. IT. LU. MC. NL	
		GN, GQ, GW, ML, MR, NE	
EP 1345953	A2 2003092	AU 2002-13214 EP 2001-981580	20011012
		FR. GB. GR. IT. LI. LU	
		MK, CY, AL, TR	, 141, 35, 110, 11,
		ZA 2001-9444	20011115
US 200155029	A1 2003021	US 2002-124988	20020417
PRIORITY APPLN. INFO	. AT 2002102	US 1999-129729P P	19990416
PRIORITI ALIMA INTO	•••	US 1999-131383P P	
		US 1999-140175P P	
		US 1999-172154P P	
		US 1999-172159P P	
		US 2000-548568 A2	
		US 2000-548584 A2	
			20000414
			20000414
		US 1999-173804P P	19991230
		US 1999-173805P P	
		US 2000-691540 A	
		WO 2001-US32119 W	
OTHER SOURCE(S):	MARPAT 139	: 69471	

L11 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



301320-09-2 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,7-fluoroocathydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-{(3-(3-quinolinyl)-2-propenyl]oxy]-10-{(3,4,6-trideoxy-3-(dimethylamino)- β -Dxylo-hexopyranoxyl]oxy]-, (3aS,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) INDZX (NAME)

Absolute stereochemistry.

Double bond geometry unknown.

413592-00-4 CAPLUS ZH-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14 (1H,7H,9H) -tettone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(6-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,7S,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

413592-04-8 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-[[3-(6-methoxy-3-quinolinyl)-2-propenyl]oxy]-3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-6-b-xylo-hexopyranoxyl]oxy]-, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

413592-07-1 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(6-quinoxalinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B--xylo-hexopyranoxyl]oxy]-, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

413592-17-3 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
11-[[3-(6-holoro-3-quinolinyl]-2-propenyl]oxy]-7-fluorooctahydro3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)6-p-xylo-hexopyranoxyl]oxy]-, (3a5,4R,7S,9R,10R,11R,13R,15R,15R,15AR)(GCI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

413592-22-0 CAPLUS 2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(3-pyridinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(disethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


413592-12-8 CAPLUS ZH-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[(3-(7-quinolinyl)-2-propenyl]oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopycanosyl]oxy]-, (3as,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

413592-15-1 CAPLUS 413592-15-1 CAPLUS
2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone,
7-fluoro-11-[[3-(6-fluoro-3-quinoliny1)-2-propeny1)oxy]octahydro3a,7,9,11,13,15-hexamethy1-4-propy1-10-[[3,4,6-trideoxy-3-(dimethylamino)B-D-xylo-hexopyranoxylloxy]-, (3a5,4R,7S,9R,1OR,11R,13R,15R,15aR)(9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

L11 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



301320-11-6
RL: RCT (Reactant): RACT (Reactant or reagent)
(preparation of erythromycin ketolides as antibacterial agents)
301320-11-6 CAPLUS
2H-Oxacyclotetradecino(4,3-d) oxazole-2,6,8,14 (1H,7H,9H)-tetrone,
10-([2-0-berozyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-heropyranosyl)oxyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propenyloxy)-4-propyl-, (3a5,4R,75,9R,10R,11R,13R,15R,15R)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
10/075,635
                                                         ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN
255ION NUMBER:
2003:472523 CAPLUS
139:53251
Price of a control of 6-0-acyl ketolide derivatives of erythromycin useful as antibacterials
Price of a control of a cont
               PATENT ASSIGNEE (S):
               DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
```

.1 20031127 US 2002-301412 20021121 US 2001-338566P P 20011205 US 2002-392513P P 20020628 MARPAT 139:53251

OTHER SOURCE(S):

6-O-Acyl ketolide antibacterials of formula I: wherein R1 is H, halogen, OH; 2 is NH(CH2)n, (CH2)n, O-(CH2)n, NH-alkenyl, O-alkenyl, NH-alkynyl,

Lil ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN 545416-08-5P 345416-06-6P 545416-07-7P 545416-08-6P 345416-08-6P 545416-07-7P 545416-10-8P 545416-11-3P 545416-13-5P 545416-14-6P 545416-13-7P 545416-13-7P 545416-13-7P 545416-13-7P 545416-13-7P 545416-13-7P 545416-21-5P 345416-21-5P 545416-22-0P 545416-22-1P 545416-22-9P 545416-22-9P 545416-22-9P 545416-23-1P 545416-28-2P 545416-33-9P 545416-33-P 545416-42-P 545416-42-P 545416-43-P 545416-43-P 545416-43-P 545416-43-P 545416-43-P 545416-53-P 545416-62-4P 545416-53-P 545416-53-P 545416-62-4P 545416-53-P 545416-62-4P 545416-53-P 545416-62-4P 545416-53-P 545416-62-4P 545416-53-P 545416-62-4P 545416-63-P 545416 (Continued) RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of acyl ketolide derivs. of erythromycin useful as antibacterials)
545414-71-9 CAPLUS
Carbonic acid. (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecin(4,3-d)oxaco-11-yl (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

Lil Answer 8 of 27 Caplus Copyright 2004 Acs on STN (Continued)
O-alkynyl; n is 0-5; R2 is H, aryl, heteroaryl; R3 is H, alkyl, alkenyl,
alkynyl, heteroaryl, heterocycloalknyl, arylalkenyl, arylakynyl,
heterocycloalkyl, heterocycloalknyl, heterocycloalkynyl, cycloalkyl,
cycloalkenyl, alkoxyalkyl, alkylthioalkyl; R4 is H, hydroxy protecting
group W is substituted pyrcole, alkoxy, oxime, anine, heterocycle; X and
X1 are together with the carbon atom to which they are attached form CO,
CKOH, C:NRS, C:NONS; Y and Y1 together with the carbon atom to which they
are attached form CO, CHOH, C:NRS, C:NONS; R5 is independently H, alkyl,
alkenyl, alkynyl; are as described herein and in which the substituents
have the meaning indicated in the description. These compds: are useful
as antibacterial agents. Thus, I (R1 = R4 = H, ZR2 = H, R3 = Et, XX1 = YY1

- O; W is 1-pyrrole) was prepd. and tested in vitro as antibacterial agent
(KIC = 0.06 to > 16 µg/alb.) Compds. of the present invention were
tested against a variety of Gram pos. and Gram neg. pathogenic bacteria
resulting in a range of activities depending on the organism tested.

17 365414-73-py 36414-73-py 365414-73-2p 365414-73-2p

565414-73-py 36414-73-py 365414-73-2p

565414-73-py 36414-30-0p 365414-80-1p

565415-03-2p 365415-30-0p 365415-1p-0p

565415-03-2p 365415-30-0p 365415-30-0p

565415-03-2p 365415-30-0p

565415-03-2p 365415-30-0p

565415-03-2p 365415-30-0p

565415-03-2p 365415-30-0p

565415-03-2p 365415-30-0p

5654

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

PAGE 2-A

545414-73-1 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7.9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl]oxyl-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl phenylmethyl ester (9CI) (CA INDEX
NAME)

Absolute stereochemistry.

Page 18

RN 545414-74-2 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-6-0-sylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl 2-phenylethyl ester (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

RN 545414-75-3 CAPLUS
Carbonic acid, (3a5.48,75,98,108,118,138,158,15a8)-4-ethyl-7fluorotetradeshydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3.4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl 3-phenyl-2-propynyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545414-78-6 CAPLUS
Cn Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3.4,6-trideoxy-3-(dimethylamino)-B-D-sylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxazol-11-yl (2E)-3-phenyi-2-propenyl ester
(SCI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 545414-80-0 CAPLUS
CN Carbonic acid, (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxyl-ZHoxacyolotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(4-pyrimidinyl)phenyl]-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown. L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545414-76-4 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7.9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,5-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl)oxy]-ZKoxacyclotetradecino[4,3-d]oxazol-11-yl 3-phenylpropyl ester (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

RN 545414-77-5 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7[luorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-p-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl 4-phenylbutyl ester (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

RN 545414-81-1 CAPLUS
CN Carbonic acid, (3a5,48,75,98,108,118,138,158,1588)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecino(4,3-d) oxazol-11-yl (2E)-3-[4-(5-pyrimidinyl)phenyl]-2propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)

PAGE 1-A

PAGE 2-A

545414-82-2 CAPLUS
Carbonic actd, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl (2E)-3-[3-(2-pyrimidinyl)phenyl]-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)

PAGE 1-A

PAGE 2-A

545414-84-4 CAPLUS
Carbonic acid, (3a5,48,7s,98,108,118,138,158,15a8)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-bexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-9-D-sylo-bexopyranosyl]oxy]-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(3-pyridinyl)phenyl]-2propenyl ester (9C1) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


545414-83-3 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[(4,3-d)oxaco-11-yl (2E)-3-[4-(2-pyridinyl)phenyl]-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)

PAGE 1-A



PAGE 2-A

545414-85-5 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotatradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-PD-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl (2E)-3-[4-(4-pyridinyl)phenyl]-2propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued) PAGE 1-A

PAGE 1-A

PAGE 2-A

545414-86-6 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl (2E)-3-(4-pyrazinylphenyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)

PAGE 1-A

PAGE 2-A

545414-88-8 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetracxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-0-xylo-hexopyranosyl]oxyl-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(1H-pyrazol-1-yl)phenyl]2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

PAGE 2-A

545414-87-7 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydco-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-wylo-hexopyranosyl)oxy]-ZHoxacyclotetradecino[4,3-d]oxacyo-11-yl (2E)-3-[4-(3-pyridazinyl)phenyl]-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)

PAGE 1-A

PAGE 2-A

545414-90-2 CAPLUS
Cathonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-9-0-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-d]oxacyclot-11-yl (2B)-3-[4-(HH-1,2,4-triazol-1yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)

PAGE 1-A

PAGE 2-A

RN 545414-91-3 CAPLUS
CN Carbonic acid, (3aS,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino[4,3-d]0xazol-11-yl (2E)-3-[4-(4H-1,2,4-triazol-4yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

When the page of the

↓ ↓ ↓ Me


PAGE 2-A

RN 545414-93-5 CAPLUS
CN Carbonic acid, (385,48,75,98,108,118,138,158,1588)-4-ethyl-7fluorotetradecalydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-y|(2E)-3-[4-(1H-imidazol-1-yl)phenyl]2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 545414-92-4 CAPLUS
CN Carbonic acid, (3as, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 9, 14-tetraoxo-10[(3, 4, 6-trideoxy-3- (dimethylamino) -P-0-xylo-hexopyranoxyl)oxy]-2Hoxacyclotetradecino(4, 3-d) oxacol-11-yl (2E)-3-(4-(1H-1, 2, 3-triazol-1yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




RN 545414-94-6 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino[4,3-4]oxzol-11-yl (2E)-3-[4-(1-methyl-1H-pyrazol-3yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A

RN 545414-95-7 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl)oxy]-ZHoxacyclotetradecino(4,3-d)oxacol-11-yl (2E)-3-(4-(1-methyl-1H-pyrazol-5yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545414-97-9 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino[4,3-d]oxzol-11-yl (2E)-3-[3-fluoro-4-(1H-pyrazol-1yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

PAGE 2-A

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

PAGE 2-A

He O O Et


RN 545414-96-8 CAPLUS
CN Carbonic acid, (3aS, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosylloxy)-2Hoxacyclotetradecino(4, 3-d)oxazol-11-yl (2E)-3-(3-methoxy-4-(1H-pyrazol-1yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

PAGE 2-A



RN 545414-98-0 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradesahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-p-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino[4,3-d)oxacol-11-yl (2E)-3-[2-fluoro-4-(1H-pyrazol-1yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

545414-99-1 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino[4,3-d]oxazo-11-1yl (28]-3-[3-f]uoro-4-(HB-1,2,4triazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

> PAGE 1-A PAGE 2-A

545415-02-9 CAPLUS
Carbonic acid, [3a5, 48, 75, 98, 108, 118, 138, 158, 15a8)-4-ethyl-7fluorotetradacahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4, 3-d)oxacol-11-yl (2E)-3-(1-phenyl-1H-pyrazol-4-yl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


PAGE 1-A

PAGE 2-A

545415-01-8 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotteradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotteradecino(4,3-d)oxaco-1-11-yl (2E)-3-[6-(H-pyrazol-1-yl)-3pyridinyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



545415-03-0 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-9-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino[4,3-d]oxaco-11-yl (2g)-3-[1-(2-pyrimidinyl)-1Himidazol-4-yl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



545415-04-1 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotteradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-terraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-wylo-hexopyranosyl]oxyl-ZHoxacyclotetradecino(4,3-d]oxazol-11-yl (28)-3-(1-pyrazinyl-1H-imidazol-4yl)-2-propenyl ester (9CI) (CA INDEX NAME)

545415-05-2 CAPLUS
Carbonic acid, (345,4R,75,9R,10R,11R,13R,15R,15R)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-4] oxazol-11-yl (2E)-3-(2-quinolinyl)-2-propenyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545415-06-3 CAPLUS Carbonic actd, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotatradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) oxacyclotetradecino[4,3-d]oxacol-11-yl (2E)-3-(3-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

545415-07-4 CAPLUS
Carbonic acid, (JaS,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-Ja,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecin(4,3-d)oxazol-11-yl (ZE)-3-(4-quinolinyl)-2-propenyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545415-08-5 CAPLUS
Carbonic acid, (385,4R,75,9R,10R,11R,13R,15R,15R)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3.4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranoxyl]oxy]-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(5-quinolinyl)-2-propenyl
ester (9C1) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545415-10-9 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7.9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3.4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosylloxy]-2Hoxacyclotetradecino(4,3-d)oxazol-11-yl (2E)-3-(6-quinolinyl)-2-propenyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545415-11-0 CAPLUS
Carbonic acid, (385,48,75,98,108,118,138,158,1588)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(7-quinolinyl)-2-propenyl
ester (9CI) (CA INDEX NAME)

RN 545415-12-1 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-0-xylo-hexopytanosyl]oxy]-2Hoxacyclotetradecino(4,3-0]oxacol-11-yl (2E)-3-(8-quinolinyl)-2-propenyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 545415-13-2 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,5-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(2-quinoxalinyl)-2-propenyl
ester (9C1) (CA INDEX NRME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545415-15-4 CAPLUS
CN Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-6-D-xylo-hexopyranosyl]oxyl-ZHoxacyclotetradectno(4, 3-d) oxazol-11-yl (2E)-3-(4-isoquinolinyl)-2-propenyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 545415-16-5 CAPLUS
CN Carbonic acid, (2E)-3-(6-bromo-3-pyridinyl)-2-propenyl
(3as, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15R)-4-ethyl-7-fluorotetradecahydro3a, 79, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraowc-10-[(3, 4, 6-trideoxy-3(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2H-

Page 26


L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545415-14-3 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexasethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl)oxyl-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl (2E)-3-(6-quinoxalinyl)-2-propenyl
ester (9C1) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 545415-17-6 CAPLUS
Cn Carbonic actd, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-4]oxazol-11-yl (2E)-3-[4-(2-oxazolyl)phenyl]-2propenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A

RN 545415-18-7 CAPLUS
CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranoayl]oxy]-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl (2E)-3-[4-(5-oxazolyl)phenyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 545415-21-2 CAPLUS
CN Carbonic acid, (3a5,48,75,98,108,118,138,158,158)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl (2E)-3-[4-(2-thienyl)phenyl]-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A


PAGE 2-A

RN 545415-19-8 CAPLUS
CN Carbonic acid, (3aS, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino)-B-0-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4, 3-d) oxazol-11-yl (2E)-3-[4-(2-thiazolyl)phenyl]-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 545415-22-3 CAPLUS
CN Carbonic acid, (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopycanosyl]oxy]-2Hoxacyclotetradecaho(4,3-d)oxacol-11-yl (2E)-3-[4-(3-isoxazolyl)phenyl]-2propenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 545415-23-4 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxaco-11-yl (2E)-3-(4-(1,3,4-oxadiazol-2yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


PAGE 2-A

RN 545415-25-6 CAPLUS
CN Carbonic acid, (3aS, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-p-D-wylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4, 3-d) Oxazol-11-yl (2E)-3-(4-(1, 2, 4-oxadiazol-5yl)phanyl]-2-propanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 545415-24-5 CAPLUS
CArbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecahor(4,3-d)oxacol-11-y1 (2E)-3-((1,2,4-oxadiazol-3yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 545415-26-7 CAPLUS
CACADONIC acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[13,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-4]oxazol-11-yl (2E)-3-(1-methyl-1H-benzimidazol-2yl)-2-propenyl ester (9CI) (CA INDEX NAME)

545415-27-8 CAPLUS
Carbonic acid, (2E)-3-(5-bromo-2-pyrimidinyl)-2-propenyl
(3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[13,4,6-trideoxy-3(dimethylamino)-8-0-xylo-hexopyraonayl)oyl)-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

545415-28-9 CAPLUS
Carbonic acid, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(5-fluoro-2-pyrimidinyl)-2-

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545415-30-3 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl (2E)-3-(4-methyl-2-pyrimidinyl)-2propenyl ester (9C1) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545415-32-5 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7.9,11,13,15-hexamethyl-2.6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-9-0-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradacino[4,3-d]oxazol-11-yl (2E)-3-(4-methoxy-2-pyrimidinyl)-2propenyl ester (9Ci) (CA INDEX NAME)

Page 29

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN propenyl ester (9CI) (CA INDEX NAME) (Continued)

Absolute stereochemistry.
Double bond geometry as shown.

545415-29-0 CAPLUS
Carbonic acid, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorcottardecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-9-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl (2E)-3-(5-ethyl-2-pyrimidinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.

545415-33-6 CAPLUS
Carbonic actd, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotteradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-0-xylo-hexopyranosylloxy]-2Hoxacyclotetradecino[4,3-d]oxaco-11-yl (2E)-3-(6-methyl-3-pyridazinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545415-34-7 CAPLUS

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,1,1,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino(4,3-d)0xazol-11-yl (2E)-3-(6-methoxy-3-pyridazinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 545415-35-8 CAPLUS
Cn Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-mylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl (2E)-3-[5-(2-pyridinyl)-2-thienyl]2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

N 545415-38-1 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-β-D,xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecin(4,3-d]oxacol-11-y' (2E)-3-[4-(2-pyridinyl)-2-thienyl]2-propenyl ester (9CI) (CA INDEX NAME)

RN 545415-39-2 CAPLUS
CN Carbonic acid, (3aS, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino)-6-0-xylo-hexopyranoxyl)oxy]-2Hoxacyclotetradecino(4, 3-d) oxazol-11-yl (2E)-3-(4-(2-pyrimidinyl)-2thionyl)-2-propenyl ester (9CI) (CA INOEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545415-36-9 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxaco-11-1y1 (2E)-3-[5-(2-pyrimidinyl)-2thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

RN 545415-37-0 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl (2E)-3-(5-pyrazinyl-2-thienyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

N 545415-41-6 CAPLUS
Carbonic acid, (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-8-D-sylo-hexopyranosyl)oxyl-2H-oxacyclotetradecino[4,3-d]oxacol-11-yl (2E)-3-(4-pyrazinyl-2-thienyl)-2-propenyl ester (9CI) (CA INDEX NAME)

RN 545415-42-7 CAPLUS
CA Carbonic acid, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,9,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-mylo-hexopycanopyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[5-(2-pyridinyl)-3-thienyl]2-propenyl ester (9CI) (CA INDEX NAME)

RN 545415-43-8 CAPLUS
CN Carbonic acid, (3aS, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4, 3-d) oxazol-11-yl (2E)-3-[5-(2-pyrimidinyl)-3thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

RN 545415-44-9 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl (2E)-3-(5-pyrazinyl-3-thienyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) (dimethylamino) -8-D-sylo-hexopyranosyl) coxyl-2H-oxacycloterradecine(4, 3-d] oxazol-11-yl ester (SCI) (CA INDEX NAME)

RN 545415-48-3 CAPLUS
CN Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-B-O-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4, 3-d]oxazol-11-yl (2E)-3-[4-(2-pyrimidinyloxy)phenyl]2-propenyl ester (9C1) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

PAGE 1-A

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545415-45-0 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl (2E)-3-(2-phenyl-5-pyrimidinyl)-2propenyl ester [9CI] (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 545415-46-1 CAPLUS
CN Carbonic acid, (ZE)-3-[2,2'-bithiophen]-5-yl-2-propenyl
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 545415-49-4 CAPLUS
CN Carbonic acid, [3a5,4x,75,9x,10x,11x,13x,15x,15ax]-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino(4,3-d]oxazol-11-y1 (2E)-3-[2-fluoro-4-(2pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

PAGE 2-A

545415-50-7 CAPLUS
Carbonic actd, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotteradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-0-xylo-hexopyranosyl)oxyl-ZHoxacyclotetradecino[4,3-d]oxacyl-11-yl (3E)-4-[4-(2-pyrimidinyl)phenyl]-3butenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545415-51-8 CAPLUS
Carbonic actd, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino(4,3-djoxazol-11-yl [4-(2-pyrimidinyl)phenyl]methyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545415-53-0 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorcotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl]oxyl-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl (4-pyrazinylphenyl)methyl ester
(9C1) (CA INDEX INME)

Absolute stereochemistry.

RN 545415-54-1 CAPLUS

Page 32

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545415-52-9 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[{3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl}oxyl-2Hoxacyclotetradecino(4,3-d]oxazol-11-yl {4-(3-pyridazinyl)phenyl}methyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Carbonic acid, (3a5, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-haxamethyl-2, 6, 8, 14-etracavo-10[3,4,6-tridecay-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl 3-[4-(2-pyrimidinyl)phenyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

545415-55-2 CAPLUS
Carbonic acid, (3as,4m,7s,9m,10m,11m,13m,15m,15am)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacycl-11-yl 3-[4-(4-pyrimidinyl)phenyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

545415-56-3 CAPLUS
Carbonic acid, (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7fluorottertadecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacycl-11-yl 3-[4-(5-pyrimidinyl)phenyl]-2propynyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) Absolute stereochemistry.

545415-57-4 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotteradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-p-D-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl 3-[4-(2-pyridinyl)phenyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

545415-59-5 CAPLUS
Carbonic acid, (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl 3-[4-(3-pyridinyl)phenyl]-2propynyl ester (9C1) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN Absolute stereochemistry. (Continued)

545415-61-0 CAPLUS
Carbonic acid, (Jas, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotteradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl 3-[4-(3-pyridazinyl)phenyl]-2propynyl estec (9CI) (CA INDEX NAME)

Absolute stereochemistry.

545415-63-2 CAPLUS
Carbonic acid, (3aS, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-d]oxacycl-11-yl 3-[4-(lH-pyrazol-1-yl)phenyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.

545415-59-6 CAPLUS
Carbonic acid, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,9,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxaco-11-yl 3-[4-(4-pyridinyl)phenyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

545415-60-9 CAPLUS
Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3.4,6-tridecxy-3-(dimethylamino)-B-D-xylo-hexopycanosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl 3-(4-pyrazinylphanyl)-2-propynyl
ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545415-64-3 CAPLUS
Carbonic acid, (345,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecin(4,3-d)oxacyo-11-yl 3-[4-(1H-1,2,4-triazol-1-yl)phenyl]2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

545415-65-4 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacycl-11-yl 3-[4-(4H-1,2,4-triazol-4-yl)phenyl]2-propynyl ester (9CI) (CA INDEX NAME)

RN 545415-66-5 CAPLUS
CN Carbonic acid, (3aS, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecino [4, 3-d] Oxazol-11-y1 3-[4-(1H-1, 2, 3-triazol-1-y1)phenyl]2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 545415-67-6 CAPLUS
CN Carbonic acid, (3aS,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxyl-ZHoxacyclotetradecino[4,3-6]oxacol-11-yl 3-[4-(1H-imidazol-1-yl) phenyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545415-70-1 CAPLUS
CN Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl)oxyl-2Hoxacyclotetradecino(4, 3-d)oxacyc-11-yl 3-(1-phenyl-1H-pyrazol-4-yl)-2propynyl ester (9CI) (CA INDEX NAME)

RN 545415-71-2 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecino(4,3-d)oxazol-11-yl 3-(2-quinolinyl)-2-propynyl ester
(9C1) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545415-68-7 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecshydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranoyyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxzol-11-yl 3-[4-(1-methyl-1H-pyrazol-3yl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 545415-69-8 CAPLUS
CN Carbonic acid, (3as, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4, 3-d)oxazol-11-yl 3-{4-(1-nechyl-1H-pyrazol-5yl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545415-73-4 CAPLUS
CN Carbonic acid, (3aS, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino(4, 3-d)oxacol-11-yl 3-(3-quinolinyl)-2-propynyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

No. 10 Meg N. 10 Me

RN 545415-74-5 CAPLUS
CN Carbonic acid, (3aS, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranoxyl]oxy]-ZHoxacyclotetradecino[4, 3-d]oxazol-11-yl 3-(4-quinolinyl)-2-propynyl ester
(9CI) (CA INOEX NAME)

545415-75-6 CAPLUS
Carbonic acid, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl 3-(5-quinolinyl)-2-propynyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

545415-76-7 CAPLUS
Carbonic acid, (3as, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-p-D-xylo-hexopyranosyl]oxyl-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl 3-(6-quinolinyl)-2-propynyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545415-79-0 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-héxamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-b-xylo-hexopyranosyl)oxyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl 3-(2-quinoxalinyl)-2-propynyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

545415-80-3 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl]oxyl-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl 3-(6-quinoxalinyl)-2-propynyl ester
(9C1) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


545415-77-8 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorottardecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-\$-D-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino(4,3-d]oxazol-11-yl 3-(7-quinolinyl)-2-propynyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

545415-78-9 CAPLUS
Carbonic actd, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorcotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-mylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl 3-(8-quinolinyl)-2-propynyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



545415-82-5 CAPLUS
Carbonic actd, (3as,48,7s,98,108,118,138,158,15a8)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-bexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-mylo-bexopyranosyl]oxy]-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl 3-(4-isoquinolinyl)-2-propynyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

545415-83-6 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopycanosyl]oxy]-2Hoxacyclotetradecino(4,3-d]oxazol-11-yl 3-[4-(2-oxazolyl)phenyl]-2-propynyl
ester (9CI) (CA INDEX NAME)

RN 545415-84-7 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxazol-11-yl 3-{4-(5-oxazolyl)phenyl]-2-propynyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 545415-85-8 CAPLUS
CN Carbonic acid, (3a5,48,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl 3-[4-(2-thiazolyl)phenyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545415-88-1 CAPLUS
CR Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-mylo-hexopyranosyl]oxy]-ZHoxacyclotetradecino[4,3-d]oxacol-11-yl 3-[4-(1,3,4-oxadiazol-2-yl)phenyl]2-propynyl ester (9Cl) (CA INDEX NAME)

RN 545415-89-2 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl 3-[4-(1,2,4-oxadiazol-3-yl)phenyl]2-propynyl ester (9C1) (CA INOEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 545415-86-9 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosylloxy]-2Hoxacyclotetradecino(4,3-d-0xazol-11-yl 3-(4-(2-thienyl)phenyl]-2-propynyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 545415-87-0 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradechydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-0]oxzol-11-yl 3-[4-(3-isoxazolyl)phenyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-90-5 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-B-D-mylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl 3-[4-(1,2,4-oxadiazol-5-yl)phenyl]2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

NO OH OH R R R R OH R

RN 545415-92-7 CAPLUS
CARDONIC acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Eoxacyclotetradecino[4,3-d]oxacol-11-yl 3-(1-methyl-1H-benzimidazol-2-yl)-2propynyl ester (9CI) (CA INDEX NAME)

RN 545415-93-8 CAPLUS
CN Carbonic acid, 3-(5-bromo-2-pyrimidinyl)-2-propynyl
(3as, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7-fluorotetradecahydro3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10-[(3, 4, 6-trideoxy-3(dimethylamino)-BD-sylo-bropyranoyl]oxyl-2Hoxacyclotetradecino[4, 3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

RN 545415-94-9 CAPLUS
CN Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4, 3-d) oxacol-11-yl 3-(5-fluoro-2-pyrimidinyl)-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545415-97-2 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl 3-(4-methoxy-2-pyrimidinyl)-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 545415-98-3 CAPLUS
CN Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecánydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-p-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4, 3-d) oxazol-11-yl 3-(6-methyl-3-pyridazinyl)-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 545415-95-0 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl)oxy)-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl 3-(5-ethyl-2-pyrimidinyl)-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 545415-96-1 CAPLUS
CN Carbonic acid, (3a5, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-tridecxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4, 3-d)oxacol-11-yl 3-(4-methyl-2-pyrimidinyl)-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-99-4 CAPLUS
CN Carbonic acid, (3a5, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino(4, 3-d) oxacol-11-yl 3-(6-methoxy-3-pyridazinyl)-2propynyl ester (9CI) (CA INDEX NAME)

RN 545416-01-1 CAPLUS
CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7.9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecino[4,3-d]oxazol-11-y1 3-[3-(2-pyridinyl)-5-isoxazolyl]-2propynyl ester (9CI) (CA INDEX NAME)

RN 545416-02-2 CAPLUS
CN Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopycanosyl)oxy]-2Hoxacyclotetradecino[4, 3-d]oxacol-11-yf 3-[5-(2-pyridinyl)-2-thienyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 545416-03-3 CAPLUS
CN Carbonic acid, (3as, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-β-0-kylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4, 3-d]oxazol-11-yl 3-[5-(3-pyridinyl)-2-thienyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

N 545416-06-6 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorottradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)-2H-oxacyclotetradecino(4,3-d)oxazol-11-yl 3-(5-pyrazinyl-2-thienyl)-2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 545416-07-7 CAPLUS
CN Carbonic acid, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl 3-[4-(2-pyridinyl)-2-thienyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 545416-04-4 CAPLUS
CN Carbonic acid, (3as, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecalpydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-djoxzol-11-yl 3-[5-(4-pyridinyl)-2-thienyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 545416-05-5 CAPLUS
CN Carbonic acid, (3a5, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosylloxy]-2Hoxacyclotetradecino[4, 3-d]oxacol-11-yl 3-[5-(2-pyrimidinyl)-2-thienyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545416-08-8 CAPLUS
CR Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopy(anosyl)oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl 3-[4-(3-pyridinyl)-2-thienyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 545416-09-9 CAPLUS
Cn Carbonic acid, (3as, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7-fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10-[[3, 4, 6-trideoxy-3-(dimethylamino)-6-D-xylo-hexopy(anosyl]oxy]-2K-oxacyclotetradecino[4, 3-d] Oxazol-11-yl 3-[4-(4-pyridinyl)-2-thienyl]-2-propynyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004, ACS on STN (Continued)

545416-10-2 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(disethylamino)-B-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl 3-[4-(2-pyrimidinyl)-2-thienyl]-2propynyl ester (9CI) (CA INDEX NAME)

545416-11-3 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazo-11-yl 3-[5-(2-pyridinyl)-3-thienyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545416-15-7 CAPLUS
Carbonic acid, 3-[2,2'-bithiophen]-5-yl-2-propynyl
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[3,4,6-trideoxy-3(dimethylamino)-\(\theta\)-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino(4,3-d]oxacol-\(\frac{1}{2}\)-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

545416-16-8 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorcotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-p-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl 3-[4-(2-pyrimidinyloxy)phenyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

545416-13-5 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxaco-11yyl 3-[5-(3-pyridinyl)-3-thienyl]-2propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

545416-14-6 CAPLUS
Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7-fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10-[[3, 4, 6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranoxyl]oxy]-2H-oxacyclotetradecino(4, 3-d)oxacyl-11-yl 3-[5-(2-phenyl-5-pyrimidinyl)-3-thienyl]-2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545416-17-9 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-mylo-hexopyranosyl]oxy]-ZHoxacyclotetradecino[4,3-d]oxacol-11-yl 4-[4-(2-pyrimidinyl)phenyl]-3butynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

545416-18-0 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7.9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl 5-[4-(2-pyrimidinyl)phenyl]-4pentynyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545416-19-1 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-ByD-sylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-d]oxazol-11/yl 3-[4-(2-pyrimidinyl)phenyl]propyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

545416-20-4 CAPLUS
Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxyl-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl 3-(4-pyrazinylphenyl)propyl ester
(9C1) (CA INDEX NAME)

Absolute stereochemistry.

545416-24-8 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7.9,11,13,15/hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-6-0-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecino(4,3-d]oxazol-14-yl 3-{4-(lH-pyrazol-1-yl)phenyl)propyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

545416-25-9 CAPLUS
Carbonic acid, (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(1H-1,2,4-triazol-1yl)phenyl]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

545416-21-5 CAPLUS
Carbonic acid, (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl/3-[4-(3-pyridazinyl)phenyl]propyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

545416-23-7 CAPLUS
Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorottertadecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino) -β-D-xylo-hexopytanosyl]oxyl-2Roxacyclotetradecino[4, 3-d]oxazol-11-yl 3-[4-(2-pyridinyl)phenyl]propyl
ester (9C1) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) (CH₂) 3

545416-26-0 CAPLUS
Carbonic acid, (3as,4R,7s,9R,10R,11R,13R,45R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-8-p-sylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-d]oxazol-11-yl 3-[4-(1H-1,2,3-triazol-1yl)phenyl]propyl ester (9CI) (CA_MOEX_NAME)

Absolute stereochemistry.

545416-27-1 CAPLUS
Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotteradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclottardecino[4,3-d]oxazol-11-yl 3-(4-(1-methyl-1H-pyrazol-3yl)phenyl]propyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545416-28-2 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,16R,15R,15R)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-F-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl 3-(2-quinolinyl)propyl ester (9CI)

Absolute stereochemistry.

RN 545416-29-3 CAPLUS
CN Carbonic acid, (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranoxyl)oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl 3-(3-quinolinyl)propyl ester (9CI)
[CA INDEX NAME]

Absolute stereochemistry.

. L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545416-33-9 CAPLUS
CN Carbonic acid, (3aS, 4R,75,9R,10R,11,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-1-(dimethylamino)-6-D-mylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl 3-(6-quinolinyl)propyl ester (9CI)
(CA INDEX MAME)

Absolute stereochemistry.

RN 545416-34-0 CAPLUS
CA Carbonic acid, (3aS, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7-fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10-[[3, 4, 6-trideoxy-3-(dimethylamino) -β-D-xylo-hexopyranosylloxyl-2H-oxacyclotetradacino(4, 3-d)oxazol-11-yl 3-(7-quinolinyl)propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545416-31-7 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-6-D-xylo-hexopyranosyl)oxyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl 3-(4-quinolinyl)propyl ester (9CI)
(74 YMDEY NAME)

Absolute stereochemistry.

N 545416-32-8 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopycanoxyl)oxy]-2H-oxacyclotetradecino[4,3-d]oxatol-11-yl 3-(5-quinolinyl)propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

N 545416-35-1 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxyl-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(8-quinolinyl)propyl ester (9CI) (CA INDEX NAME)

RN 545416-36-2 CAPLUS
CN Carbonic acid, (3aS, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7-fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10-[3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranoxyl]oxy]-2H-oxacyclotetradecino(4,3-d)oxazol-11-yl 3-(2-quinoxalinyl)propyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545416-37-3 CAPLUS
CN Carbonic acid, (3a5,48,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)/6-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazoly11-yl 3-(6-quinoxalinyl)propyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 545416-38-4 CAPLUS
CN Carbonic acid, (3aS, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4, 3-d)oxazol-11-yl 3-[4-(2-oxazolyl)phenyl]propyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 545416-42-0 CAPLUS
CN Carbonic acid, 3-(1H-benzimidazol-1-y1)propyl
(335.48, 75, 98, 108, 118, 138, 158, 158), -4-ethyl-7-fluorotetradecahydro3a, 7, 9, 11, 13, 15-bexamethyl-2/6, 8, 14-tetraoxo-10-[[3,4,6-trideoxy-3(dimethylamino)-β-D-xylo-bexopyranoxyl)oxyl-2Hoxacyclotetradecino(4,3-d)pxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 545416-43-1 CAPLUS
CN Carbonic acid, (3aS, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino) -B-0-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino(4, 3-d) oxazol-11-yl (22)-2-fluoro-3-[4-(2pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSVER 8 OF 27 CAPLUS COPYTIGHT 2004 ACS ON STN (Continued)

RN 545416-39-5 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7.9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecino(4,3-d)oxazol-11-yl 3-[5-(2-pyridinyl)-2-thienyl]propyl
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 545416-41-9 CAPLUS
Cn Carbonic acid, (3aS,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-0-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-0]oxzol-11-yl 3-[5-(2-pyrimidinyl)-2thienyl]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 545416-44-2 CAPLUS
CN Carbonic acid, (3aS, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-8-0-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino(4, 3-d) oxacol-11-yl/[22]-2-fluoro-3-[4-1pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 545416-45-3 CAPLUS
CN Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecshydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4, 3-d)oxazol-11-y1 (22)-2-fluoro-3-[4-(5pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INOEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



545416-46-4 CAPLUS
Carbonic acid, (3aS, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl) oxyj-2Hoxacyclotetradecino[4, 3-d] oxazol-11-yl (22)-2; fluoro-3-[3-(2pyrimidinyl)phenyl}-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


545416-47-5 CAPLUS
Carbonic acid, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxaco-11-yl (22)-2-fluoro-3-(4-(2pyridinyl)phenyl]-2-propenyl estet (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545416-51-1 CAPLUS
Carbonic acid, (3a5,4R,7S,9R,10R,11R,134,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-bexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-8-0-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxaco-11/y1 (22)-2-fluoro-3-(4-(3pyridazinyl)phenyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




545416-52-2 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-9-D-sylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-d]oxazol-11-yl [22)-2-fluoro-3-[4-(H-pyrazol-1yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) F

545416-49-7 CAPLUS
Carbonic acid, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-β-D-wyl-yh-hexopyranoxyl)oxy]-2Hoxacyclotetradecino(4,3-d]oxazol-11-yl,(2Z)-2-fluoro-3-[4-(3pyridinyl)phenyl]-2-propenyl ester (9C1) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.



545416-50-0 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorcotteriadecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxaco-11-yl (22)-2-fluoro-3-[4-(4pyridinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545416-53-3 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorcotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-sylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yV (2Z)-2-fluoro-3-[4-(1H-1,2,4triazol-1-yl)phenyl]-2-propenyl estp6 (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.



545416-54-4 CAPLUS
Carbonic acid, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-0-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino(4,3-d)oxaco-11-yl (22)-2-fluoro-3-(4-(4H-1,2,4triazol-4-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545416-55-5 CAPLUS
CN Carbonic acid, (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylanino)-β-D-xylo-hexopyranosylloxy]-2Hoxacyclotetradecino(4,3-d)oxazol-11-yl (2g)-2-fluoro-3-[4-(1H-1,2,3triazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 545416-57-7 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosylloxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl (22)-2-fluoro-3-[4-(1H-imidazol-1yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

N 545416-60-2 CAPLUS
Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7flucrotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranozyl]oxy)-2Hoxacyclotetradecino(4,3-d)oxazol-11-y1 (22)-2-fluoro-3-[3-methoxy-4-(1Hpyrazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 545416-61-3 CAPLUS
Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino) -β-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino[4, 3-d]oxazol-11-yl (22) -2-fluoro-3-[3-fluoro-4-(1Hpyrazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN S45416-58-8 CAPLUS
CR Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxacol-M-yl (22)-2-fluoro-3-(4-(1-methyl-1Hpyrazol-3-yl)phenyl]-2-propenyl ster (9CI) (CA INDEX NAME)

Absolute stereochemistry. Bouble bond geometry as shown.

RN 545416-59-9 CAPLUS
Carbonic acid, (3a5, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino(4, 3-d) oxazol-11-yl (22)-2-fluoro-3-[4-(1-methyl-1Hpyrazol-5-yl) phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-62-4 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-y1 [22]-2-fluoro-3-[2-fluoro-4-(Hpyrazol-1-y1)phenyl]-2-propenyl aster (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 545416-63-5 CAPLUS
CN Carbonic acid, (3a5, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluocotetadecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-9-D-xylo-hexopyranosyl]oxy]-2H-

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) oxacyclotetradecino[4,3-d]oxacol-11-yl (2Z)-2-fluoro-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 545416-64-6 CAPLUS
CN Carbonic acid, (3aS, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-P-0-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4, 3-d) oxazol-11-yl (22]-2-fluoro-3-(1-phenyl-1Hpyrazol-4-yl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown

Ph. 2 F

We 2N

S H R F He

Me 2N

R F He

N He

N

RN 545416-66-8 CAPLUS

RN 545416-69-1 CAPLUS
CN Carbonic acid, (3a5, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxzol-11-yl (22)-2-fluoro-3-(3-quinolinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 545416-70-4 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10([3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopytanosyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl (22)-2-fluoro-3-(4-quinolinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

Lil ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl (22)-2-fluoro-3-[1-(2-pyrimidinyl)H-imidazol-4-yl]-2-propenyl ester (9CI) (CA INDEX NAME)

N 545416-67-9 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-y1 (22)-2-fluoro-3-(1-pyrazinyl-1Himidazol-4-yl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

Note the property of the property of

RN 545416-68-0 CAPLUS
CN Carbonic acid, (3a5, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4, 3-d) oxazol-11-yl (22)-2-fluoro-3-(2-quinolinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545416-71-5 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl (2Z)-2-fluoro-3-(5-quinolinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 545416-72-6 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7flucrotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-mylo-hexopyranosyl]oxyl-ZHoxacyclotetradecino(4,3-d)oxacol-11-yl (22)-2-fluoro-3-(6-quinolinyl)-2propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545416-73-7 CAPLUS
Carbonic acid, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl (2Z)-2-fluoro-3-(7-quinolinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545416-74-8 CAPLUS
Carbonic acid, (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7fluorottertadecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl (22)-2-fluoro-3-(8-quinolinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN Double bond geometry as shown. (Continued)

545416-78-2 CAPLUS
Carbonic acid, [385,48,75,98,108,118,138,158,158,]-4-ethyl-7fluorcoteriadecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-mylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacyl-11-yl [22]-2-fluoro-3-(4-isoquinolinyl)-2propenyl ester [9CI] (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545416-79-3 CAPLUS
Carbonic acid, (22)-3-(6-bromo-3-pyridinyl)-2-fluoro-2-propenyl
(345,48,75,98,108,118,138,158,1548)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[3,4,6-trideoxy-3(dimethylamino)-B-D-wylo-hexopyranosyl]oxy)-2Hoxacyclotetradecino[4,3-d]oxazol-11-yi exter (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

1.11 ANSWER 8 OF 27 CAPILIS COPYRIGHT 2004 ACS OR STN (Continued)


545416-76-0 CAPLUS
Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorrott-radecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-o-xylo-hexopyranosyl]oxy]-ZHoxacyclott-radecino(4, 3-d) oxaco-11-lyl (2Z)-2-fluoro-3-(2-quinoxalinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.


545416-77-1 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-9-D-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl (22)-2-fluoro-3-(6-quinoxalinyl)-2propenyl ester (9C1) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



545416-80-6 CAPLUS
Carbonic acid, (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7fluorotatradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl]oxy]-2Hoxacyolotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(2-oxazolyl)phenyl)-2-propenyl ester (9CI) (CA INDEX NAME)



545416-81-7 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-9-0-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxaco-11-yl (22)-2-fluoro-3-[4-(5oxacyclotetradecino[4,3-d]oxaco-11-yl (22)-2-fluoro-3-[4-(5oxazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER B OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545416-82-8 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,111,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxazol-11-yl (22)-2-fluoro-3-[4-(2thiazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 545416-83-9 CAPLUS
CR Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-p-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino(4,3-d)oxacol-11-y1 (22)-2-fluoro-3-[4-(2thienyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 545416-86-2 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradacahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexpyranosyl]oxyl-2Hoxacyclotetradecino(4,3-d)oxazol-11-yl (22)-2-fluoro-3-[4-(1,2,4-oxadiazol3-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

N 545416-88-4 CAPLUS
Carbonic acid, (3a5,48,75,98,108,118,138,158,158,1-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-f(3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranoxyl]oxy)-2H-oxacyclotetradecino[4,3-d] oxazol-11-yl (22)-2-fluoro-3-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-propenyl ester (901) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown. L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545416-84-0 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,9,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxylloxy]-2Hoxacyclotetradecino(4,3-d)oxazol-11-yl (22)-2-fluoro-3-[4-(3isoxazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.



RN 545416-85-1 CAPLUS
Chronic acid, (3aS, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4, 3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(1, 3, 4-oxadiazol2-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545416-89-5 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopycanosyl]oxy]-2Hoxacyclotetradecino(4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(1-methyl-1Hindol-2-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

RN 545416-90-8 CAPLUS
CN Carbonic acid, (3a5,48,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10([3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxyl-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl (22)-2-fluoro-3-[4-(5-fluoro-2pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



545416-91-9 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7.9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-0-xylo-hexopyranoxyl)oxyl-2Hoxacyclotetradecino[4,3-d]oxacyl-11-yl (22)-2-fluoro-3-[4-(4-methyl-2pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545416-92-0 CAPLUS
Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15R)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazo-11-yl (22)-2-fluoro-3-(4-(4-methoxy-2pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545416-95-3 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorottardecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-P-0-xylo-hexopyranosyl]oxyl-ZHoxacyclotetradecino[4,3-d]oxacyl-11-yl (22)-2-fluoro-3-[5-(3-pyridinyl)-2thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545416-96-4 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-mylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacy-11-yl (22)-2-fluoro-3-[5-(4-pyridinyl)-2thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

ACS on STN L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 200 (Continued) F


545416-93-1 CAPLUS
Carbonic acid, (3aS,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-Po-sylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl,/22)-2-fluoro-3-[4-(6-methoxy-3pyridazinyl)phenyl]-2-propenyl ester (CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545416-94-2 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorottardecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-0-0-xylo-hexopyranosyl)oxyl-2Hoxacyclottardecino[4,3-d]oxacyl-11-yl (22)-2-fluoro-3-[5-{2-pyridinyl}-2thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



545416-98-6 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamio)-B-D-sylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl (22)-2-fluoro-3-[5-(2-pyrimidinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545416-99-7 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-0-xylo-hexopyranosyl]oxyl-ZHoxacyclotetradecino[4,3-d]oxacol-11-yl (22)-2-fluoro-3-(5-pyrazinyl-2thienyl)-2-propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


545417-00-3 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7.9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranoxyl]oxy]-ZHoxacyclotetradecino[4,3-d]oxacyl-11-yl (22)-2-fluoro-3-[4-(2-pyridinyl)-2thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545417-01-4 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino[4,3-d]oxacy-11-yl (22)-2-fluoro-3-[4-(3-pyridinyl)-2thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



545417-04-7 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorottertadecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexpyranosylloxyl-2Hoxacyclottardecino[4,3-d]oxaco-11-1-yl (22)-2-fluoro-3-(4-pyrazinyl-2thienyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545417-05-8 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7.9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-0-xylo-hexopyranosyl]oxyl-ZHoxacyclotetradecino[4,3-d]oxacycl-11-yl (22)-2-fluoro-3-[5-(2-pyridinyl)-3thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545417-02-5 CAPLUS
Carbonic acid, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-9-0-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxaco-11-yl (22)-2-fluoro-3-[4-(4-pyridinyl)-2thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

545417-03-6 CAPLUS
Carbonic actd, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorottardecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxyl-2Hoxacyclotetradecino(4,3-d)oxacycl-11-yl (22)-2-fluoro-3-[4-(2-pyrimidinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545417-07-0 CAPLUS
Carbonic acid, (3a5,48,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotatradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranoxyl)oxyl-ZHoxacyclotetradecino(4,3-d)oxacyclottyl-2Hoxacyclotetradecino(4,3-d)oxacyclottyl-3-fluoro-3-[5-(2-pyrimdinyl)-3thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545417-08-1 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-9-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino[4,3-d]oxaco-111-yl [22]-2-fluoro-3-(5-pyrazinyl-3thienyl)-2-propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545417-09-2 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl)oxyl-2Hoxacyclotetradecino[4,3-d)0xazol-11-yl (2z)-2-fluoro-3-[4-(2-phenyl-5pycimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

RN 545417-10-5 CAPLUS
CATOMIC acid, (22)-3-[2,2'-bithiophen]-5-yl-2-fluoro-2-propenyl
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3(dimethylamino)-9-D-xylo-hexopyranoxyl]oxyl-24oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545417-13-8 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-p-D-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxacol-11-y1 (22)-3-fluoro-3-[4-(2pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A


Page 50

N 545417-11-6 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[{3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxylloxy}-2H-oxacyclotetradecino(4,3-dloxazol-11-yl (22)-2-fluoro-3-[4-(2-pyrimidinyloxy)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

RN 545417-12-7 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl)oxyl-2Hoxacyclotetradecino(4,3-d)oxazol-11-yl (22)-2-fluoro-3-[2-fluoro-4-(2pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545417-14-9 CAPLUS
CN Carbonic acid, [3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3- (dimethylamino)-P-D-xylo-hexopyranoxyl)oxy]-2Hoxacyclotetradecino(4, 3-d)oxazol-11-yl (22)-3-fluoro-3-[4(4pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 545417-15-0 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino(4,3-d)oxazol-11-yl (22)-3-fluoro-3-[4-(5pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545417-18-3 CAPLUS
CArbonic acid, (3aS, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetrades.hydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl)oxy]-2Hoxacyclotetradecino(4, 3-d)oxazol-11-yl (2Z)-3-fluoro-3-[4-(3pyridinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 545417-16-1 CAPLUS
CN Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylantho)-P-D-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino(4, 3-d)oxacol-11-yl (22)-3-fluoro-3-[4-(2pyridinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

PAGE 1-A

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 545417-19-4 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranoxyl)oxy]-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl (22)-3-fluoro-3-(4-(4pyridinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

PAGE 1-A

LII ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

545417-20-7 CAPLUS
Carbonic acid, (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10([3,4,6-trideoxy-3-(dimethylamino)-9-D-xylo-hexopyranosyl)oxyl-ZHoxacyclotetradecin(4,3-d)oxacol-11-yl (2Z)-3-fluoro-3-(4-pyrazinylphenyl)2-propenyl estec (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545417-22-9 CAPLUS
Carbonic acid, (3a5,48,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorottetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-syllo-hexopyranosyl]oxy]-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl [22]-3-fluoro-3-[4-(H-pyrazol-1yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

PAGE 2-A

RN 545417-23-0 CAPLUS Page 52


L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

545417-21-8 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotatradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,9,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-0-xylo-hexopyranosyl]oxy]-2Hoxacyclotatradecin.[4,3-d]oxaco-11-yl (22)-3-fluoro-3-(4-(3pyridazinyl)phenyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


PAGE 1-A



L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Carbonic acid, (3a5, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecino(4,3-d)oxazol-11-yl (2Z)-3-fluoro-3-[4-(H-1,2,4triazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

545417-24-1 CAPLUS
Carbonic acid, (3a5, 4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotteradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-B-D-sylo-hexopyranosyl)oxy]-2Hoxacyclotteradecino(4,3-d)oxaco-11-yl (22)-3-fluoro-3-(4-(4H-1,2,4triazol-4-yl)phenyl)-2-propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

RN 545417-25-2 CAPLUS
CN Carbonic acid, {3a5,4R,75,9R,10R,11R,13R,15R,15aR}-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxylloxy]-2Hoxacyclotetradecino(4,3-d)oxacol-11-y1,(2Z)-3-fluoro-3-[4-(1H-1,2,3triazol-1-y1)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

PAGE 1-A

PAGE 1-A

Negan

RN 545417-28-5 CAPLUS
CATODRIC acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosylloxy]-2Hoxacyclotetradecino(4, 3-d)oxacol-11-yl (22)-3-fluoro-3-(4-(1-methyl-1Hpyraxol-3-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

PAGE 2-A

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

Me 2N S R H R F Ne O R S O R S O

PAGE 2-A

RN 545417-27-4 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-Ja,7,9,11,13,15-hexamethyl-2,6,9,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-β-D-mylo-hexopyranoxyl)oxyl-2ZHoxacyclotetradecino(4,3-d)oxazol-11-yl)(2Z)-3-fluoro-3-[4-(1H-imidazol-1yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

RN 545417-29-6 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl (22)-3-fluoro-3-[4-(1-methyl-1Hpyrazol-5-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)

PAGE 1-A

PAGE 2-A

Me Me

RN 545417-30-9 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-y1 (22)-3-fluoro-3-[4-(1-phenyl-1Hpyrazol-4-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545417-32-1 CAPLUS
CN Carbonic acid, (3a5, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecino[4, 3-d] oxazol-11-yl (2Z)-3-fluoro-3-(3-quinolinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

Page 54

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)

Me₂N. S H R P He O R S Me

RN 545417-31-0 CAPLUS
Cn Carbonic acid, (3as, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecino[4,3-0]oxazol-11-yl (2Z)-3-fluoro-3-(2-quinolinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSVER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

IT 545417-33-2P 545417-37-6P 545417-35-4P
545417-36-PS 545417-40-76 545417-38-PP
545417-39-PS 545417-46-7P 545417-42-3P
545417-48-PS 545417-46-7P 545417-48-PP
545417-50-3P 545417-52-PP
545417-50-3P 545417-52-PP
545417-50-PS 545417-52-PP
545417-68-PS 545417-61-PP
545417-68-PS 545417-76-PP
545417-73-PP 545417-71-PP
545417-73-PP 545417-71-PP
545417-73-PP 545417-71-PP
545417-73-PP 545417-71-PP
545417-73-PP 545417-71-PP
545417-78-PP 545417-71-PP
545417-80-PP 545417-80-PP
545417-91-PP
54

(Uses)
(preparation of acyl ketolide derivs. of erythromycin useful as antibacterials)

RN 545417-33-2 CAPLUS
Carbonic acid, (3a5, 4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamio)-8-D-xylo-hexopyranosyl]oxyl-2H-oxacyciotetradecino[4,3-d]oxacol-11-yl (2Z)-3-fluoro-3-(4-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 545417-34-3 CAPLUS
CN Carbonic acid, (3aS.4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl)oxyl-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl (2Z)-3-fluoro-3-(5-quinolinyl)-2propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545417-35-4 CAPLUS
Carbonic actd, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluocotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl (2Z)-3-fluoro-3-(6-quinolinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545417-38-7 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopytanosyl)oxyl-2Hoxacyclotetradecino[4,3-d]oxacycl-11-yl (22)-3-fluoro-3-(2-quinoxalinyl)-2propenyl ester (9C1) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545417-39-8 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl (22)-3-fluoro-3-(6-quinoxalinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Page 55

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545417-36-5 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecino(4,3-d)oxaco-11-y-y1 (22)-3-fluoro-3-(7-quinolinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545417-37-6 CAPLUS
Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluortottcradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl (2Z)-3-fluoro-3-(8-quinolinyl)-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry. Double bond geometry as shown.

545417-40-1 CAPLUS
Carbonic acid, (3a5,48,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideowy-3-(dimethylamino)-8-D-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl (22)-3-fluoro-3-(4-isoquinolinyl)-2propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

S45417-42-3 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,6,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranoxylloxy]-2Hoxacyclotetradecino(4,3-d)0xazol-11-yl (22)-3-fluoro-3-[4-(2oxazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545417-44-5 CAPLUS
Carbonic acid, (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl (22)-3-fluoro-3-[4-(5oxacyclotetradecino[4,3-d]oxacol-11-yl (22)-3-fluoro-3-[4-(5oxazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

PAGE 2-A

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



545417-48-9 CAPLUS
Carbonic acid, (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-sylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl (22)-3-fluoro-3-[4-(2-thienyl)phenyl]-2-propenyl ester (9Cl) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

> PAGE 1-A PAGE 2-A


\$45417-46-7 CAPLUS
Carbonic acid, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino(4,3-d)oxaco-11-yl (22)-3-fluoro-3-(4-(2thiazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

PAGE 2-A



545417-50-3 CAPLUS
Carbonic acid, (3a5,48,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorototradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradacino[4,3-d]oxazol-11-yl (22]-3-fluoro-3-[4-(3isoxazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)
PAGE 1-A

RN 545417-52-5 CAPLUS
CN Carbonic acid, (3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranoxyl)oxyl-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl (22)-3-fluoro-3-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

Me
O O Et

RN 545417-57-0 CAPLUS
CN Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3.4,6-trideoxy-3-d(dimethylamino)-9-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino[4,3-d]oxacol-11-yl (2Z)-3-fluoro-3-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A


RN 545417-54-7 CAPLUS
Carbonic acid, (Jas, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-4]oxazol-11-yl (22)-3-fluoro-3-[4-(1,2,4-oxadiazol3-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

PAGE 2-A



... J. J. He

RN 545417-59-2 CAPLUS
CN Carbonic acid, (3aS, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4, 3-d) oxacol-11-yl (2z) -3-fluoro-3-(1-methyl-1Hbenzimidazol-2-yl)-2-propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545417-61-6 CAPLUS
Carbonic acid, (22)-3-[4-(5-bromo-2-pyrimidinyl)phenyl]-3-fluoro-2propenyl (3as, 4m, 7s, 9m, 10m, 11m, 13m, 15m, 15am)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino)-6-D-uxylo-hexopyranoxyl)oxyl-2Hoxacyclotetradecino[4, 3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545417-64-9 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorottardecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(disethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacycl-11-yl (22)-3-[4-(5-ethyl-2pyrimidinyl)phenyl]-3-fluoro-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued) PAGE 2-A

545417-63-8 CAPLUS
Carbonic actd, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotteradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,9,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxyl-ZHoxacyclotteradecinof(4,3-d)oxacyl-11-Jyl (22)-3-fluoro-3-{4-(5-fluoro-2pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

PAGE 1-A

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

545417-66-1 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3.4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl)oxyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl (22)-3-fluoro-3-[4-(4-methyl-2pyrimidinyl)phenyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

L11 ANSWER B OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Contin

PAGE 2-A

RN 545417-68-3 CAPLUS
CN Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-tridecxy-3-(dimethylamino) -β-D-xylo-hexopycanosyl]oxy]-2Hoxacyclotetradecino(4,3-0]oxazol-11-yl (2Z)-3-fluoro-3-[4-(4-methoxy-2pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545417-72-9 CAPLUS
Cn Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-β-D-wylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino(4,3-d)oxacol-11-y1 (22)-3-fluoro-3-[5-(4-pyridinyl)-2thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 545417-73-0 CAPLUS
CN Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15R)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl]oxy]-2Hοxacyclotetradecino[4,3-d]oxacol-11-yl (22)-3-fluoro-3-[5-(2-pyrimidinyl)2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown. L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 545417-70-7 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[(3,4,6-trideoxy-3-(dimethylamino)-B-D-mylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-djoxazol-11-y1 (22)-3-fluoro-3-[5-(2-pyridinyl)-2thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 545417-71-8 CAPLUS
CN Carbonic acid, (385, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4, 3-d]oxacol-11-yl, (22)-3-fluoro-3-[5-(3-pyridinyl)-2thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545417-74-1 CAPLUS
CR Carbonic acid, (3as, 4a, 7s, 9a, 10a, 11a, 13a, 15a, 15aa) -4-ethyl-7fluorotetradecalydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino) -B-D-mylo-hexopyranosyl]oxy] -2Hoxacyclotetradecino(4, 3-q1 oxazol-11-yl (22) -3-fluoro-3-[5-(4-pyrimidinyl) 2-thienyl] -2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 545417-75-2 CAPLUS
Cn Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-mylo-hexopycanosyl]oxy]-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl (22)-3-fluoro-3-[5-(5-pyrimidinyl)2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

545417-77-4 CAPLUS
Carbonic actd, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosylloxyl-2Hoxacyclotetradecino[4, 3-d]oxazo-11-1-yl (22)-3-fluoro-3-(5-pyrazinyl-2thienyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545417-78-5 CAPLUS
Carbonic acid, (385,48,75,98,108,118,138,158,1588)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3.4,6-trideoxy-3-(dimethylamino)-P-0-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecin(4,3-d]oxacyl-11-yl (22)-3-fluoro-3-[4-(2-pyridinyl)-2thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545417-81-0 CAPLUS
Carbonic acid, (3aS, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15h. hexamethyl-2, 6, 8, 14-tetraoxo-10[[3, 4, 6-trideoxy-3-(dimethylamino]-β-D-xylo-hexopyranosyl]oxyl-ZHoxacyclotetradecino[4, 3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(2-pyrimidinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

S45417-82-1 CAPLUS
Carbonic acid, (3as, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl]oxyl-2Hoxacyclotetradecino[4, 3-d]oxazol-11-yl (22)-3-fluoro-3-[4-(4-pyrimidinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


545417-79-6 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacy-11-y1 (22)-3-fluoro-3-[4-(3-pyridinyl)-2thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545417-80-9 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorottertadecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4,3-d)oxacy-11-1yl (22,3-sfluoro-3-[4-(4-pyridinyl)-2thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



545417-83-2 CAPLUS
Carbonic acid, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(disethylamino)-β-0-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecino[4,3-d]oxaco-11-1yl (22)-3-fluoro-3-[4-(5-pyrimidinyl)-2-thianyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545417-84-3 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7.9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-P-0-xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacyl-11-yl (22)-3-fluoro-3-[5-(2-pyridinyl)-3thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

545417-85-4 CAPLUS
Carbonic acid, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotatradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-P--xylo-hexopyranoxyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxacyl-11-yl (22)-3-fluoro-3-[5-(3-pyridinyl)-3thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

S45417-86-5 CAPLUS
Carbonic acid, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-8-D-xyl-b-kexpyranosylloxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl (22)-3-fluoro-3-(2-phenyl-5pyrimidinyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN Double bond geometry as shown. (Continued)

PAGE 1-A

PAGE 2-A

545417-89-8 CAPLUS
Carbonic acid, (3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorottertadecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl 4-[4-(2-pyrimidinyl)phenyl]butyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545417-87-6 CAPLUS
Carbonic acid, (22)-3-(2,2'-bithiophen)-5-yl-3-fluoro-2-propenyl
(38,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3(dimethylamino)-8-0-xylo-hexopycanoxyl)oxyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

545417-88-7 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotteradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-sylo-hexopyranosyl) oxy]-2Hoxacyclotteradecino[4,3-d]oxaco-11-yl (22)-3-fluoro-2-[4-(2pyrimidinyloxy)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

545417-90-1 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B--xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-djoxazo-11-1yl (22)-2-fluoro-3-[3-(2-pyridinyl)-5isoxəzolyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

545417-91-2 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl)oxyl-2Hoxacyclotetradecino[4,3-d]oxacyl-11-lyl (22)-3-fluoro-3-[3-(2-pyridinyl)-5isoxazolyl]-2-propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545418-52-8 CAPLUS
Cn Carbamic acid, [[(2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl]oxy]-,
(3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7-fluorotetradecahydro3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10-[[3, 4, 6-trideoxy-3(dimethylamino)-9-0-sylo-hexopyranoxyl]oxy]-2H,
oxacyclotetradecino[4, 3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 545418-53-9 CAPLUS
CN Carbanic acid, [[3-(3-quinoliny1)-2-propyny1]oxy]-,
[3a5,48,75,98,108,118,138,158,1548]-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3(dimethylanino)-BD-Bylo-hexpoyranoy1]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 546127-97-3 CAPLUS
CN Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino(4, 3-d) oxazol-11-yl 5-[4-(2-pyrimidinyl)phenyl]pentyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 546127-98-4 CAPLUS
Carbonic acid, (3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl (22)-3-fluoro-3-[4-(6-methyl-3pyridazinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 545420-57-3 CAPLUS

Kydrazinecarboxylic acid, 2-methyl-2-[2-(4-pyrazinylphenyl)ethyl]-,
(3a5, 44, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7-fluorotetradecahydro3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10-[[3, 4, 6-trideoxy-3(dimethylazino)-9-D-xylo-hexopyranoxyl)axyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 545420-58-4 CAPLUS
CN Hydrazinecarboxylic acid, 2-methyl-2-[2-[4-(3-pyridazinyl)phenyl]ethyl]-,
(3a5, 4R, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7-fluorotetradecahydro3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10-[[3,4,6-trideoxy-3(dimethylamino)-9-D-xylo-hexpyranoxyl)axyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

Me2N. R P Ne R R P Ne O R S Ne

RN 546127-99-5 CAPLUS
CN Carbonic acid, (3a5, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10[(3, 4, 6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino(4, 3-d) oxazol-11-yl (2Z)-3-fluoro-3-[4-(6-methoxy-3pyridazinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)

PAGE 1-A

PAGE 2-A

546131-22-0 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-ZHoxacyclotetradecino(4,3-d)oxacol-11-yl (22)-2-fluoro-3-(4-pyrazinylphenyl)2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)

PAGE 1-A

3

PAGE 2-A

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

S45420-80-2P 545423-23-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of acyl ketolide derive, of erythromycin useful as antibacterials)
545420-80-2 CAFLUS
Carbonic acid, (JaS, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7-fluorotetradecahydro-3a, 7.9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10-[[3, 4, 6-trideoxy-3-(dimethylamino)-9-cxylo-hexopyranozyl)oxyl-ZH-oxacyclotetradecino(4, 3-d)oxacyclotetradecino(4, 3-d)oxacyclotetradecino(

Absolute stereochemistry.
Double bond geometry as shown.

545423-33-4 CAPLUS
Carbonic acid, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-10-[[2-0-acetyl-3,4,6-trideoxy-3-(dimethylamino)-B-0-xylo-hexopyranosyl)oxy]-4-ethyl-7fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-2Hoxacyclotetradecino(4,3-d)oxaco-1-1-yl (2E)-3-[4-(2-pyrimidinyl)phenyl]-2propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN SSION NUMBER: 2003:42284 CAPLUS LENT NUMBER: 138:90019

138:90019
Preparation of C12 modified erythromycin macrolides and ketolides having antibacterial activity
Chu, Daniel: Burger, Matthew, Lin, Xiaodong; Carroll, Georgia Law: Plattner, Jacobs Rico, Alice
Chiron Corporation, USA
PCT Int. Appl., 252 pp.
CODEN: PIXXD2
Patent
English
1

INVENTOR (S):

PATENT ASSIGNEE (S):

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

FAILMI	2		••••															
PATENT NO.					KIND		DATE		APPLICATION NO. DATE									
WO	WO 2003004509				2	20030116		WO 2002-US21209 20020703										
WO	WO 2003004509			A3		20030515												
	W:	AE.	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
		co,	CR.	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
		GM.	HR.	HU,	ID,	IL.	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	
		LS.	LT.	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	
		PL.	PT.	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TŤ,	TZ,	
		UA,	UG.	US,	UZ,	VN,	YU,	ZA,	ZM,	ZW,	AM,	AZ,	BY,	KG,	ΚZ,	MD,	RU.	
		TJ.	TM															
	RV:	GH.	GM,	KE,	LS,	MW,	HZ,	SD,	SL,	52,	TZ,	UG,	ZM,	ZW,	AT,	BE,	BG,	
		CH.	CY.	CZ.	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	
		PT.	SE.	SK,	TR.	BF.	BJ,	CF,	CG.	CI,	CM,	Gλ,	GN,	GQ,	G₩,	ML,	MR,	
		NE.	SN,	TD.	TG													
US	US 2003125266				A1 20030703				US 2002-190431 20020703									
E	EP 1404693				A2 20040407				EP 2002-746862 20020703									
	R:	AT.	BE.	CH.	DE.	DK.	ES.	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
														EE,				
PRIORIT	PRIORITY APPLN. INFO.:													2001				
									WO 2	002-	US21	209	¥	2002	0703			
OTHER S	OTHER SOURCE(S):					PAT	130:	9001	9									
GI																		

Antimicrobial macrolide I wherein: V is OCORx, carbonyl, caldinose moiety: Rx is H, alkyl, 10-alkyl, NH-alkyl, N-(alkyl)2: Y and Z taken together define a group X, wherein X is O, N-OH, substituted oxime: Y and Z are

LI1 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) independently H, OH, protected hydroxy, aminer T is ether, amine, alky, R is H, alkyl, alkenyl, alkenyl, alkynyl, R is H, alkyl, B is H, hydroxy protecting group; R 4 is alkyl, halogen, OH, alkoxy, alkenyl, alkynyl; R 5 is OH, amino, alkylaminor R 185 are together epoxide, carbonyl, olefin; as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compns, comprising such compds, methods of treating bacterial infections by the administration of such compds. and processes for the prepn. of the compds. Thus,

(3AS,4R,7R,9R,1GR,1S,13R,15R,15R,15R)-3a,4-diethyl-11-methoxy-7,9,11,13,15-pentamethyl-2,6,8,14-tetraoxo-1-(4-quinolin-4-yl-butyl) tetradecahydro-2H-oxacyclotetradecino[4,3-d][1,3] oxazol-10-yl-3,4,6-trideoxy-3
(dimethylamino)-D5-sylo-hexopyranoside was prepd, and tested in vitro as antibacterial agent. The pharmaceutical compns. of this invention can be administered to humans and other animals orally, rectally, parenterally, topically (as by powders, ointments, or drops), or as an oral or nasal spray, or a liq. aerosol or dry powder formulation for inhalation.

11 484670-96-4P 484671-20-7P 484671-20-1P

484671-38-7P 484671-40-1P 484671-63-8P

484671-38-7P 484671-40-1P 484671-63-8P

RL: IMF (Industrial manufacture), PAC (Pharmacological activity); SPN (Synthetic preparation); USES (Uses)

(preparation of c modified erythromycin macrolides and ketolides having antibacterial activity)

RN 484670-96-4 CAPIUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 34,4-diethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-[4-(3-pyridinyl)-1H-inidazol-1-yl]butyl]-10-([3,4,6-trideoxy-3-(dimethylamino)-Bo-vsylo-hexopyranosyl]oxy)-, (3aS,4R,7S,9R,10R,11R,13R,15R,15R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

484670-98-6 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxacole-2,6,8,14(1H,7H,9H)-tetrone,
3a,4-diethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(4-quinolinyl)buryl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-9-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

484671-20-7 CAPLUS
2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
3a,4-diethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(4-(6-methyl-3-pyridinyl)-1H-imidazol-1-yl]buryl]-10-[(3,4,6-trideoxy-3-(dimethylamino)-8-0-xylo-hexopyranosyl)oxyl-,
(3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

- Me

484671-24-1 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone,
3a,4-diethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-methyl-4-[4-(3-pyridinyl)-1H-imidazol-1-yl]pentyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-9-D-xylo-hexopyranosyl]oxy]-,
(3a5,4R,75,7R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 64

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN Absolute stereochemistry. (Continued)

484671-02-5 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
3a,4-diethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(2-quinolinyl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

484671-14-9 CAPLUS 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone, 3a,4-dieth/1-7-fjuorooctahydro-1-(4-(1H-imidazo[4,5-b])pyridin-1-yl)butyl}-11-methoxy-7,9,11,13,15-pentamethyl-10-[(3,4,6-trideoxy-3-(dimethylamino)-B-b-xylo-hexopyranoxyl)oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

484671-38-7 CAPLUS 48461-139-7 CAPUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
3a,4-diethyl-7-fluorooctahydro-1-[4-(1H-imidazo[4,5-b)pycidin-1-y)-4methylpenty]-11-methowy-7,9,11,3],15-pentamethyl-10-[[3,4,6-trideoxy-3(dimethylamino)-8-D-xylo-hexopyranosyl)oxy]-,
(3a5,4R,78,9R,10R,11R,13R,15R,15R)-(9C) (CA INDEX NAME)

Absolute stereochemistry.

484671-40-1 CAPLUS 484671-40-1 CAPUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
3a,4-diethyl-7-fluorooctahydro-1-[4-(3H-imidazo[4,5-b]pyridin-3-yl)-4methylpentyl]-11-methoxy-7,9,11,13,15-pentamethyl-10-[[3,4,6-trideoxy-3(dimethylamino]-9-D-xylo-hexopyranosyl]oxyl,
(3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 484671-63-8 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
3a-ethenyl-4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1[4-[4-[3-pyridinyl]-1H-imidazol-1-yl]butyl]-10-[[3,4,6-trideoxy-3(dinethylamino]-9-D-xylo-heropyranoxyl]oxy]-,
(3as,4R,7s,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

484671-83-2 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(lH,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-3a-[(12)-1-propenyl]-1-{4-(4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-8-0-xylo-hexpyranoxyl]oxyl-,
(3a5,4R,75,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

484673-79-2 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[3-(4-phenyl-1H-inidazol-1-yl)propyl]-10-[[3,4,6-trideoxy-2-ddimethyl-nino]-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15RR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

(Continued) L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

484671-51-4 CAPLUS
2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone,
3a,4-diethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-{3-(4-methylphenyl)-5-isoxazolyl]butyl]-10-[{3,4,6-trideoxy-3-(dimethylamino)-6-D-xylo-hexopyranosyl]oxyl-, (3a5,4R,7S,9R,10R,11R,13R,15R,15RR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

~ Me

484673-17-8 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-{4-quinolinyl}butyl]-10-[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 65

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

484671-08-1P 484671-49-0P 484671-51-4P
484673-17-8P 484673-18-9P 484673-19-0P
484673-20-3P 484673-25-6P 484673-25-9P
484673-27-0P
RL: IMF (Industrial manufacture), SPN (Synthetic preparation), PREP
(Preparation)
{preparation of c modified erythromycin macrolides and ketolides having antibacterial activity)
484671-08-1 CAPLUS
2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
3a,4-diethyl-7-fluorooctahydro-1-[4-(3H-imidazo[4,5-b]pyridin-3-yl]butyl]11-methoxy-7,9,11,13,15-pentamethyl-10-[(3,4,6-trideoxy-3-(dimethylamino)p-b-xylo-hexopyranosyl]oxy]-, (3a5,4R,7S,9R,10R,11R,13R,15R,15AR)(9CI) (CA INDEX NAME)

Absolute stereochemistry.

484671-49-0 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 3a,4-diethyl-1-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(3-phenyl-5-isoxazolyl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl-, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

484673-18-9 CAPLUS 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(4-phenyl-1H-inidazol-1-yl)butyl]-10-[(3,4,6-trideoxy-3-(dimethylanino)-B-D-xylo-hexopyranoxyl]oxy]-, (3s,4R,7s,9R,10R,11R,13R,15R,15R)-(9CI) (CA INDEX NAME) :

484673-19-0 CAPLUS
2H-Owacyclotetradecino[4,3-d]owazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-{2-quinolinyl}butyl]-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl-, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

484673-20-3 CAPLUS ZH-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15RR)-(SCI) (CA INDEX NAME)

Absolute stereochemistry.

484673-25-8 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[[3-(4-quinolinyl)propyl]amino]-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-wylo-hexopyranosyl]oxy]-, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

484673-13-4P 484673-14-5P 484673-15-6P 484673-16-7P 484673-22-5P 484673-23-6P 484673-24-7P

494673-24-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of c modified erythromycin macrolides and ketolides having antibacterial activity)
48673-13-4 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-benzoyl-3,4-6-trideoxy-3-(dimethylamino)-B-D-mylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(4-quinolinyl)butyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

484673-14-5 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(4-phenyl-1H-imidazol-1-yl)butyl]-, (335,4R,75,9R,10R,11R,13R,15R,15RR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

484673-26-9 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[{2-0-bexopyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15pentamethyl-1-[(3-(4-(3-pyridinyl)-1H-inidazol-1-yl]butyl]amino]-,
(3aS,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

(Continued)

Absolute stereochemistry.

484673-27-0 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[[3-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]mino]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,75,9R,10R,11R,33R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

484673-15-6 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino]-B-D-xylohexopyranosylloxy]-4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15pentamethyl-1-[4-(2-quinolinyl)butyl]-, (3a5,4R,75,9R,10R,11R,13R,15R,15AR)
- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

494673-16-7 CAPLUS
2H-Owacyclotetradecino[4,3-d]owazole-2,6,8,14(1H,7H,9H)-tetrone,
10-{(2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-B-D-xylohexopyranosyl]oxy]-4-ethyl-7-fluocooctahydro-11-methoxy-7,9,11,13,15pentamethyl-1-[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]-.
(3aS,4R,7S,9R,10R,11R,13R,15R,15RR)- {9CI} (CA INDEX NAME)

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

484673-22-5 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[(2-0-bexopyl-3,4,6-trideoxy-3-(dimethylamino)-9-D-xylohexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15pentamethyl-1-[3-(4-(3-pyxidinyl)-1H-imidazol-1-yl]propyl]-,
(3as,4R,73,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

484673-23-6 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[3-[4-(3-pyridinyl)-1H-imidazol-1-yl]propyl]-10-[(3,4,6-trideoxy-3-(dimethylamino)-6-b-xylo-hexopyranoyyl]oxy]-, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

484673-24-7 CAPLUS
2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[{2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl)oxy|-4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15pentamethyl-1-[(3-(4-quinolinyl)propyl)amino]-,
(3as,4R,75,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



6-O-carbamoyl ketolide derivs. of erythromycin antibacterials of the formula I: wherein RI and R2 are independently H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, provided thar RI and R2 are not both Hr RIR2 together are N atom to which they are attached, form an optionally substituted N-containing heterocycle: R3 is H, alkylamine, alkyl, alkony, alkenylamine, alkenyl, acyl, alkynylamine R4 is H, halogen, OHr R5 is a H, hydroxy protecting group: R6 is H, alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, cycloalkenyl, alkoxyalkyl, alkylthioalkyl; X and XI are together with the carbon atom to which they are attached, form CO, inthe, oxyimine; Y and YI are together with the carbon atom to which they are attached, form CO, CHOH, inine, oxyimine; were prepared These compds. are useful as antibacterial agents. Thus, carbamic acid [(2E)-3-(4-(2-pyrimidinyl)phenyl]-2-propenyl] (33.4 R. PR, R), RD, RIR, IR, IR, IR, IS, 15AR)-4-athyltetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6.8, 14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)beta-D-xylo-hexopyranosyl]oxy]-ZH-

Page 67

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) oxacyclotetradecino[4,3-d]oxazol-11-yl ester was prepd. and tested in vitro against E. coll, S. aureus, S. epidermidis, S. pneumoniae, S. pyogenes, Enterococci, Moraxella catarchalis, and H. influenzae MIC values range from 0.03 to > 16 µg/ml. These compds. are particularly useful in the treatment of community-acquired pneumonia, upper and lower respiratory tract infections, skin and soft tissue infections, meningitis, hospital-acquired lung infections, and bone and joint infections.

11 433919-44-9P 433920-43-9P 433920-43-5P 433920-45-7P 433920-45-7P 433920-51-5P 433920-52-6P 433920-75-9P 433920-75-9P 433920-75-9P 433920-76-4P 433920-75-9P 433920-76-9P 433920-76-9P 433920-76-9P 433920-75-9P 433920-75-9P 433920-76-9P 433920-75-9P (Parenacological activity): SPN (Synthetic preparation): THU (Therapeutic use): BIOL (Biological study): PREP (Preparation): USES (Uses)
(preparation carbamoyl ketolide derivs. of erythromycin useful as

(Uses)
(preparation carbamoyl ketolide derivs. of erythromycin useful as antibacterials)
(preparation carbamoyl ketolide derivs. of erythromycin useful as antibacterials)
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-([2-0-acetyl-3,4,6-trideoxy-3-(dimethylamino)-6-D-mylo-hexopyranosyl]oxy]-11-[(aminocarbonyl)oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI)
(7a YNDYS NAME) (CA INDEX NAME)

Absolute stereochemistry.

433920-41-3 CAPLUS 433920-41-3 CAPLUS
Carbamic acid, ((2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl]-,
(3aS, 4R, 7R, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7-fluorotetradecahydro3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10-[3, 4, 6-trideoxy-3(dimethylamino)-8-0-xylo-hexopyranoxyl)oxyl-ZHoxacyclotetradecino[4, 3-d] oxazol-11-yl ester (9CI) (CA INDEX NAME)

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued) PAGE 1-A

PAGE 1-A

PAGE 2-A

433920-43-5 CAPLUS
Carbamic acid, ([ZE)-3-[4-[2-pyrimidiny]]phenyl]-2-propenyl]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3(dimethylamino)-8-D-xylo-hexopyraonayl)oyn)-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

433920-46-8 CAPLUS
Carbamic acid, [(ZE)-3-[4-(1H-pyrazol-1-y1)phenyl]-2-propenyl]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3(dimethylanino)-8-0-nylo-hexopyraonayl)oxyl-2Hoxacyclotetradecino(4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

Page 68

PAGE 2-A

433920-45-7 CAPLUS
Carbamic acid, [(2E)-3-(6-quinoliny1)-2-propeny1]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3(dimethylamino)-8-D-sylo-hexopyranosyl)oyl)-2EHoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


433920-48-0 CAPLUS
Carbamic acid, (2E)-3-[4-(3-pyridazinyl)phenyl]-2-propenyl]-,
(3g.,4R,75,9R,10R,11R,13R,15R,15R)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[3,4,6-trideoxy-3(dimethylamino)-B-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino(4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A

PAGE 2-A



L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

AN 433920-49-1 CAPLUS
Carbamic acid, [(ZE)-3-(4-pyrazinylphenyl)-2-propenyl]-,
(3a5, 48, 75, 98, 108, 118, 138, 158, 15a8)-4-ethyl-7-fluorotetradecahydro3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10-[[3, 4, 6-trideoxy-3(dimethylamino)-Po-mylo-hexopyranoxylloyyl-2Roxacyclotetradecino[4, 3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) Double bond geometry as shown.

RN 433920-52-6 CAPLUS
CN Carbanic acid, [[4-(2-pyridinyl)phenyl]methyl]-,
(3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[{3,4,6-trideoxy-3(dimethylamino)-9-D-mylo-hexopyranoxyl)oxy]-2Hoxacyclotetradecino(4,3-d)oxacol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433920-57-1 CAPLUS
CN Carbanic acid, [2-[[4-(2-pyrimidinyl)phenyl]methoxy]ethyl]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9C1) (CA INDEX NAME)

Absolute stereochemistry.

Page 69

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 433920-50-4 CAPLUS
CN Carbamic acid, [[4-(4-pyrimidinyl)phenyl]methyl]-,
(3a5, 48, 75, 98, 108, 118, 158, 15aR)-4-ethyl-7-fluorotetradecahydro3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10-[[3, 4, 6-trideoxy-3(dimethylamino)-8-D-sylo-hexpyriaoxyl)oxyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433920-51-5 CAPLUS
CN Carbamic acid, [(2E)-3-[1-(2-pyrimidinyl)-1H-imidazol-4-yl]-2-propenyl]-,
(3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7-fluorotetradecahydro3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10-[(3,4,6-trideoxy-3(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2Hoxacyelotetradecino[4,3-d]oxazol-11-yl|ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

PAGE 2-A

PAGE 2-A

PAGE 2-A

Me 2M

Ne 2M

RN 433920-72-0 CAPLUS
CN Carbamic acid, [(2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl]-,
(3a5, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7-fluorotetradecahydro-14(hydroxyimino)-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8-trioxo-10-[[3, 4, 6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranoxyl)oxyl-2Hoxacyclotetradecino[4, 3-d]oxazol-11-yl ester (9Cl) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as described by E or Z.

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

PAGE 2-A

433920-73-1 CAPLUS
Carbamic acid, [(ZE)-3-[1-{2-pyrimidinyl}-1H-imidazol-4-yl]-2-propenyl]-,
[38, 48, 75, 98, 108, 118, 138, 158, 15a8)-4-ethyl-7-fluorotetradecahydro-14(hydroxyimino)-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8-trioxo-10-[[3, 4, 6-trideoxy-3-(dimethylamino)-8-b-xylo-hexopyranoxyl)oxyl-2Hoxacyclotetradecino[4, 3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as described by E or 2.

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) PAGE 2-A

433920-75-3 CAPLUS Carbamic acid, [[4-(2-pyrimidinyloxy]phenyl]methyl]-, (3as.48, 75, 98, 108, 118, 138, 158, 15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxyiminol -3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxacy-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

433920-76-4 CAPLUS
Carbamic acid, [(ZE)-3-(3-quinoliny1)-2-propeny1]-,
(38,4R,78,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[{3,4,6-trideoxy-3-(dimethylamino)-P-p-xylo-hexopyranoxyl]oxyl-ZRoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as described by E or Z.

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

433920-74-2 CAPLUS
Carbamic acid, {(2E)-3-[4-(3-pyridazinyl)phenyl]-2-propenyl]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14(hydroxyimino)-3a,7,9,1l,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy3-(dimethylamino)-9-b-xylo-hexopyranoxyl]oxyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.


PAGE 1-A



L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

433920-77-5 CAPLUS
Carbamic acid, [[4-(2-pyrimidinyl)phenyl]methyl]-,
[38,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14[hydroxyimino]-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-9-D-xylo-hexopyranoxyl]oxyl-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 433920-78-6 CAPLUS

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Carbamic acid, [(2E)-3-phenyl-2-propenyl]-, (3aS,48,7s,98,108,118,138,158,
15aR,4-ethyl-7-fluorotetradecahydro-14-(hydroxylmino)-3a,7,9,11,13,15haxamethyl-2,6,8-trioxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-Dxylo-hexopyranoxyl]oxyl-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as described by E or Z.

433920-79-7 CAPLUS
Carbamic acid, [(ZE)-3-(6-bromo-3-pyridinyl)-2-propenyl]-,
(3a5, 48, 75, 98, 108, 118, 138, 158, 15a8)-4-ethyl-7-fluorotetradecahydro-14(hydroxylanino)-3a, 7, 9, 11, 13, 15-hexamethyl-2-6, 8-trioxo-10-[[3, 4, 6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl-2Roxacyclotetradecino(4,3-d)oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as described by ${\tt E}$ or ${\tt Z}$.

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) (3aS, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR) -4-ethyl-7-fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 0, 14-tetraox-10-[[3, 4, 6-trideoxy-3-(dimethylamino)+9-b-xylo-hexpyranosyl]oxy]-2H-oxacyclotetradecino[4, 3-d] oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

PAGE 1-A

PAGE 2-A

433920-42-4


RL: RCT (Reactant): RACT (Reactant or reagent)
(preparation carbamoyl ketolide derivs. of erythromycin useful as
antibacterials)
433920-42-4 CAPLUS

2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
11-[(aminocarbonyl)ony]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15hexamethyl-10-[3,4,6-trideoxy-3-(dimethylamino)-8-D-mylonhexopytanosyl]oxy]-, (Jas,4R,7R,9R,1OR,11R,13R,15R,15aR)- (9CI) (CA INDEX
NAME)

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


433920-81-1 CAPLUS
Carbamic acid, [(ZE)-3-(3-pyridinyl)-2-propenyl)-,
(335,48,75,98,10R,11R,138,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranoxyl)oxyl-2Roxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or 2.



433922-58-8 CAPLUS Carbamic acid, [(2E)-3-[4-(4-pyrimidinyl)phenyl]-2-propenyl]-,

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) Absolute stereochemistry.



433919-43-8P 433920-71-9P 433920-80-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation carbamoyl ketolide derivs. of erythromycin useful as antibacterials) 433919-43-8 CAPLUS 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone, 11-{(aminoarbonyl)oxy}-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-0-kylo-hexopyranosyl]oxy]-, (JaS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

433920-71-9 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-actyl-3,4,6-trideoxy-3-(dimethylamino)-8-D-mylohexopyranosyl]oxy]-11-{(aminocarbonyl]oxy]-4-ethyl-7-fluorooctahydro3a,7,9.11.3,15-hexamethyl-,14-(O-actyloxime),
(3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

433920-80-0 CAPLUS
Carbanic acid, [(ZE)-3-(3-pyridinyl)-2-propenyl]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-14-{(acetyloxy):mino]-10-{[2-0-acetyl-3,4,6-trideoxy-3-(dinethylamino]-8-D-xylo-hexopyranoxyl]oxy]-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-2-hoxacyclotetradecahydro-1-djoxac2l-11-yl ester (9Cl) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as described by E or Z.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) infections in mammals comprising administering said compd. Thus, I [R, R3, R4, Y = H7 R1 = CH2CH:CH-(3-quinoly1) [III]) was prepd. Thus, I [R, Quinoly1]. III was tested in vitro for its antibacterial activity (MIC = 0.01 to > 100).

IT 342036-19-5F 342036-20-6F 342036-21-P 342036-33-2P 342036-33-3P 342036-31-1P 342036-32-2P 342036-33-9 342036-31-4P 342036-32-2P 342036-36-6F 342036-31-9P 342036-36-6F 342036-31-9P 34203

RL: PAC (Pharmacological activity); SPN (synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(preparation of 6-0-alkyl-2-nor-2-substituted ketolide derivs. having antihacterial activity)

342036-19-5 CAPLUS

2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(IH,7H,9H)-tetrone,
4-ethyl-7-fluoroostahydro-3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unkn

342036-20-8 CAPLUS 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-xylo-hexopyranosyl]oxyl-, (3a5,4R,9R,10R,11R,13R,15R,15AR)- (9CI) (1NDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN LION NUMBER: 2002:575746 CAPLUS EAN NUMBER: 137:125356

ON NUMBER:


iJ/:1/23356
Preparation of 6-0-alky1-2-nor-2-substituted
erythromycin ketolide derivatives as antibacterial
agents
Phan, Ly Tam; Or, Yat Sun; Ma, Zhenkun

INVENTOR(S): PATENT ASSIGNEE(S): SOURCE: USA
U.S. Pat. Appl. Publ., 43 pp.
CODEN: USXXCO
Patent

DOCUMENT TYPE: LANGUAGE:

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:


PATENT NO. KIND DATE APPLICATION NO. DATE US 2002103140
US 6569836
PRIORITY APPLN. INFO.:
OTHER SOURCE(S):
GI A1 20020801 B2 20030527 US 2000-727934 20001130 US 1999-168504P P 19991202 MARPAT 137:125356



AB Erythromycin ketolide derivs., such as I and II [R = H, hydroxy protecting group; R1 = alkyl, alkenyl, alkenyl-R2, alkynyl, alkynyl-R2; R2 = H, aryl, heteroaryl; R3 = H, OH, NH2; substituted amine, SePh, halogen; R4 = H, OH, F, Cl, Br, I, alkyl alkenyl, alkynyl, ether, ester, alkylamine; R3 and R4 taken together with the atoms to which each is attached forms a 3- to 6-membered aromatic or non-aromatic ring optionally containing a heteroatom, wherein the non-aromatic ring optionally containing and R4 taken together form a -CH2; epoxide, -O; Y = H, OH, NH2; amine; R5-R8 = H, alkyl, and pharmaceutically acceptable salts, ester, solvate or prodrug thereof, were prepared for their use as antibacterial agents. The invention relates to 6-O-alkyl-2-nor-2-substituted ketolide compound or a derivative thereof, a composition comprising the compound and a suitable carrier, a

carrier, a method of preparing the compound, and a method of treatment and prevention

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



342036-21-9 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluoro-7-(fluoromethyl)octahydro-3a,9,11,13,15-pentamethyl-11[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)D-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

342036-30-0 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-1l-(2-propenyloxy)-10[3,4,6-trideoxy-3-(dimethylanio)-β-D-xylo-hexopycanosyl)oxy]-,
(3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry

RN 342036-32-2 CAPLUS

14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15-pentamethyl-11-(12-propenyloxy)-10-[(3,4,6-trideoxy-3-(dimethylamino)-B-D-wylo-hexopytanoxyl]oxyl-, (3a5,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX INMEX)

Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 342036-35-5 CAPLUS
CN 2H-Oxacyclotetradecino(4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propynyloxy)10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-,
[3as,44,9R,10R,11R,13R,15R,15aF]- (9CI) (CA INDEX MAME]

Absolute stereochemistry.

RN 342036-36-6 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)trione, 4-ethyl-7,7-difluoro-3a,4,10,11,12,13,15,15a-octahydro3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-10-[[3,4,6-trideoxy-3(dimethylamino)-P-D-xylo-hexpyranoxyl]oxyl-,
(3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 342036-33-3 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15pentamethyl-11-(2-propynyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)β-D-xylo-hexopyranoxyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 342036-37-7 CAPLUS
CN 14.1-(Nitrilosthano)-24-0-macyclotetradecino[4,3-d]omazole-2,6,8(7H,9H)trione, 4-ethyl-7,7-diffluoro-3a,4,10,11,12,13,15,15a-octahydro3a,9,11,13,15-pentamethyl-11-(2-propynylony)-10-[[3,4,6-trideoxy-3(dimethylamino)-8-D-xylo-hexopyranosyl]oxyl-,
(3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 342036-38-8 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-[(3-(5-quinoxalinyl)-2-propenyl)oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hoxopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA
INDEX NAME)

342036-39-9 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

342036-40-2 CAPLUS 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d] oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranoxyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15R,158R)-(9CI) (CA NDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

342036-43-5 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propymyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-rylo-hexoyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

342036-44-6 CAPLUS
14,1-(Nitrilosthano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8[7H,9H)trione, 4-ethyl-7,7-difluoro-3a,4,10,11,12,13,15,15a-octahydro3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6trideoxy-3-dimethylamino)-B-D-rsylo-hexopyranosyl]oxy](3aS,4R,9R,1DR,11R,13R,15R,15R)- [9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

(Continued) L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN


342036-41-3 CAPLUS 14,1-[Nitriloethano] -2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H) trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15pentamethyl-11-[(3-(3-quinolinyl)-2-propynyl)oxy]-10-[[3,4,6-trideoxy-3(dimethylamino]-6-p-xylo-hexopyranosyl]oxy]-, (3as,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

342036-42-4 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-[(3-(5-quinoxalinyl)-2-propenyl]oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-β D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15R)- (9CI) INDEX NNBL

Absolute stereochemistry. Double bond geometry unknown.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



342036-45-7 CAPLUS 14,1-(Nitriloethano) -2H-oxacyclotetradecino[4,3-d] oxazole-2,6,8 (7H,9H) trione, 4-ethyl-7,7-difluoro-3a,4,10,11,12,13,15,15a-octahydro3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propynyl]oxy]-10-[[3,4,6trideoxy-3-(dimethylamino)-6-D-xylo-hoxopyranosyl]oxy](3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

342036-56-0 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2-propenyl)-10-{[3,4,6-trideoxy-3-(dimethylamino)-B-D-mylo-hexopyranosyl)oxy]-, (3a5,4R,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)

RN 342036-57-1 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2-propynyl)-10-[{3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15R,15RR)- (9CI)
CA INDEX
NAME

Absolute stereochemistry.

RN 342036-58-2 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino(4,3-d)oxazole-2,6,8 (7H,9H)trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,9,11,13,15-pentamethyl-7-(2-propenyl)-10-{(3,4,6-trideoxy-3(dimethylamino)-9-D-xylo-hexopyranoxyl)oxy]-,
(3as,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 342036-61-7 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluoroctahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-[3-(3-quinolinyl)-2-propynyl]-10-[{3,4,6-trideoxy-3-(dimethylaminol-B-D-xylo-hexopyranosyl]oxyl-, (3a5,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CAINDEX NAME)

Absolute stereochemistry.

RN 342036-62-8 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-[3-(3-quinolinyl)-2-propenyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-p0-xylo-hexpyranoxyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown. L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 342036-59-3 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,9,11,3,15-pentamethyl-7-(2-propynyl)-10-[6],4,6-trideoxy-3(dimethylamino)-B-D-mylo-hexopyranosyl]oxyl-,
(3as,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 342036-60-6 CAPLUS
CN ZH-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-f[lorocotahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-[3-(3-quinolinyl)-2-propenyl]-10-[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranoxyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 342036-63-9 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,9,11,13,15-pentamethyl-7-[3-(3-quinolinyl)-2-propynyl]-10-[(3,4,6tridoxy-3-(dimethylamino)-P0-xylo-hexopycanoxyl)oxy]-,
(3as,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 444300-05-4P 444300-06-5P 444300-07-6P 444300-13-4P 444300-14-5P 444300-15-6P 444300-16-7P 444300-17-0P 444300-18-9P 444300-19-0P 444300-29-P 444300-27-0P 444300-28-1P 444300-29-2P 444300-30-5P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(Reactant or reagent)
(prepn. of 6-0-alky1-2-nor-2-substituted ketolide derivs. having
antibacterial activity)
RN 444300-05-4 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(HH,7H,9H)-tetrone,
10-[[2-0-benzoy1-3,4,6-trideoxy-3-(dimethylamino)-B-D-xylohexopyranoxylloxy]-4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11[[3-(3-quinolinyl)-2-propenyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

444300-06-5 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-{[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-4-ethyl-7,7-difluocooctahydro-3a,9,11,13,15-pentamethyl11-{[3-(3-quinolinyl)-2-propenyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) hexopyranosyloxyl-4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propynyloxy)-, (3a5,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

444300-15-6 CAPLUS
14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8 (7H,9H)-trione, 10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-9-D-xylo-bexoyyranosyl]oxy]-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15-pentamethyl-11-[2-propenyloxy]-,
[3aS,4R,9R,10R,11R,13R,15R,15RN]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

444300-16-7 CAPLUS
14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazola-2,6,8(7H,9H)-trione, 10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-p-0-xylo-bexopyranosyl]oxy]-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15-pentamethyl-11-[2-propynyloxy)-,
(3aS,4R,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

444300-07-6 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-bexoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-4-ethyl-7-fluoro-7-(fluoromethyl)octahydro3,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-,
(3a5,4R,9R,10R,11R,13R,15R,15aB)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

444300-13-4 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxylloxy)-4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-, (3a,48,9R,108,11R,13R,15R,15aR)-9(SI) (CA INDEX NAME)

Absolute stereochemistry.

444300-14-5 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

444300-17-8 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-жylo-hexopyranosyl]oxy]-4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-[2-propenyloxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

444300-18-9 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propynyloxy)-, (3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

RN 444300-19-0 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino(4,3-d)oxazole-2,6,8(7H,9H)trione, 10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-B-D-xylohexopyranosyl]oxyl-4-ethyl-7,7-difluoro-3a,4,10,11,12,13,15,15a-octahydro3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-,
(3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry

RN 444300-20-3 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8 (7H,9H)trione, 10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-0-xylohexopyranosyl]oxy]-4-ethyl-7,7-difluoro-3a,4,10,11,12,13,15,15a-octahydro3a,9,11,13,15-pentamethyl-11-(2-propynyloxy)-,
(3a5,4R,9R,10R,11R,13R,15R,15R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 444300-29-2 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)trione, 10-[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11methoxy-3a,9,11,13,15-pentamethyl-7-(2-propenyl)(3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 444300-30-5 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)trions, 10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopycanosyl]oxyl-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11methoxy-3a,9,11,13,15-pentamethyl-7-(2-propynyl)(3a5,4R,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 444300-27-0 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-bencyyl-3,4,6-trideoxy-3-(dimethylamino]-β-D-xylohexopycanosyl]oxy]-4-ethyl-7-[luorooctahydro-11-methoxy-3a,9,11,13,15pentamethyl-7-(2-propenyl)-, (3aS,4R,9R,10R,11R,13R,15R,15RR]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

RN 444300-28-1 CAPLUS
CN 2R-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone,
10-[[2-O-benzoyl-3-4,6-trideoxy-3-(dimethylamino)-B-D-xylohexopyranosyl]oxyl-4-ethyl-7-fluorooctahydro-11-methoxy-3a,9,11,13,15pentamethyl-7-(2-propynyl)-, (3a5,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

10/075,635

NSVER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN 110N NUMBER: 2002:466704 CAPLUS

DOCUMENT NUMBER:

137:20549
Preparation of tricyclic erythromycin derivatives as antibacterial agents Wu, Yong-jin USA
U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCCO
Patent
English

INVENTOR(S): PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE US 2002077302 A1 20020620
PRIORITY APPLN. INFO.:
OTHER SOURCE(S): CASREACT 137 US 2000-557528 20000423 US 1999-130913P P 19990423 CASREACT 137:20549; MARPAT 137:20549

The invention relates to the preparation of tricyclic erythromycin derivs. I wherein R, R5 are independently alkyl, alkenyl, alkynyl, R1-R4 are independently H, alkyl, alkenyl, alkynyl, R2R3 together with the carbon to which they are attached form a 3-10 membered heterocyclic ring; R6 is H, ester, acyl; R7 is H, alkyl, ether, mmine, halo, and to pharmaceutically acceptable salts, solvates and prodrugs thereof. The activity of the compuds. of the present invention against bacterial and protozoa pathogens is demonstrated by the compound's ability to inhibit growth of defined strains of human or animal pathogens (no data). Thus, I wherein R is Me; R2-R4 and R6 are each H, R5 is Me, R7 is F, and R1 is 3-quinolin-5-y1-propyl, was prepared and tested as antibacterial agent. 43421-02-19 43421-03-29 43421-04-39
43421-05-19 43421-05-5P 43421-04-19
43421-05-19 43421-05-5P 43421-09-1P
434221-91-2P 43421-22-3P 43421-90-1P
434221-91-2P 43421-22-3P 43421-90-1P
434221-91-2P 43421-32-6P 43421-99-0P
4343221-91-3P 434321-39-6P 43421-99-0P
434322-00-6P 434321-3D-9P 43421-99-0P

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

434321-84-3 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15hexamethyl-18-[3-(4-quinolinyl)propyl]-10-[[3,4,6-trideoxy-3(dimethylamino)-β-0-xylo-hexopyrtanosyl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 434321-85-4 CAPLUS
CN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-Page 78

L11 ANSVER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
434322-03-9P 434322-04-0P 434322-05-1P
434322-06-2P 434322-07-3P 434322-08-4P
434322-09-5P 434322-13-8P 434322-11-9P
434322-12-0P 434322-13-1P 434322-14-2P
434322-13-9P 434322-13-7P 434322-20-0P
434322-18-6P 434322-13-7P 434322-20-0P
434322-21-1P 434322-22-P 434322-23-3P
434322-24-4P 434322-23-8P 434322-23-3P
434322-30-2P 434322-33-3P
434322-30-2P 434322-31-3P 343322-24-P
434322-30-2P 434322-31-3P 343322-32-4P
434322-30-2P 434322-31-6P 434322-35-7P
RL: BSU (Biological study, unclassified); IMF (Industrial manufacture); SPM (Synthetic preparation); USES (USes)
(prepn. of tricyclic erythromycin derivs. as antibacterial agents)
RN 44321-82-1 CAPLUS
RN 444321-82-1 CAPLUS
RN 414-1(Indomethanimino)-2H-oxacyclotetradecino(4,3-d)oxazole2,6,8 (JaH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(4-3-yr)dinyl)-1H-inidazol-1-yl)propyl)-10-([3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosylloxyl-,
(JaS,4R,9R,10x,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

434321-83-2 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino(4,3-d)oxazole2,6,8 (3H,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15heptamethyl-18-[3-(4-quinolinyl)propyl)-10-[(3,4,6-trideoxy-3(dimethylamino)-9-D-xylo-hexopyranosyl)oxy]-,
(3a5,4R,9R,10R,11R,13R,155,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
2,6,8 (3aH,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15heptamethyl-18-[3-(5-quinolinyl)propyl]-10-[[3,4,6-trideoxy-3(dimethylanino)-8-D-xylo-hexpoyranosyl)oxy]-,
(3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

434321-86-5 CAPUS
4H-1,14-[Iminomethanimino]-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(34H,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15hexamethyl-18-(3-(5-quinolinyl)propyl)-10-[(3,4,6-trideoxy-3(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
(3a5,44,9R,10R,11R,13R,155,158N)- (9CI) (CA INDEX NAME)

RN 434321-87-6 CAPLUS
CN 4R-1,14-(Iminomethanimino)-2H-oxacyclotetradecino(4,3-d]oxazole2,6,8 (3aH,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15heptamethyl-18-[3-(8-quinolinyl)propyl)-10-[3,4,6-trideoxy-3(dimethylamino)-6-0-xylo-hexopyranosyl)oxyl-,
(3as,4R,9R,10R,11R,13R,15S,15aR)-(9C1) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continue

RN 434321-89-8 CAPLUS
CN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH, 7H)-trione, 7-fluorooctahydro-11-methoxy-18-[3-(7-methoxy-4quinolinyl)propyl]-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3(dimethylamino)-8-D-xylo-hexopyranoxylloxy]-,
(3as,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 434321-90-1 CAPLUS

Page 79

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 434321-88-7 CAPLUS

CN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (34H,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15hexamethyl-18-[3-(8-quinolinyl)propyl)-10-[(3,4,6-trideoxy-3(dimethylamino)-P0-vylohexopyranosyl)oxy]-,
(3as,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 4H-1,14-([minomethanimino]-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH,7B]-trione. 4-e-thyl-17-fluorooctahydro-1l-methoxy-18-[3-(7-methoxy-4-quinolinyl)propyl]-3a,7,9,11,13,15-hexamethyl-10-[{3,4,6-trideoxy-3-(dinterhylamino]-6-D-xylo-hexopyranosylloxy](3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 434321-91-2 CAPLUS
CN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15heptamethyl-18-[3-(4-phenyl-1H-imidazol-1-yl)propyl]-10-[[3,4,6-trideoxy-3(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA NNEX NAME)

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
434321-92-3 CAPLUS
CN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15hexamethyl-18-[3-(4-phenyl-1H-imidazol-1-yl)propyl]-10-[[3,4,6-trideoxy-3(dimethylamino)-8D-bxylo-hexopyranoxyl]oxy]-,
(3as,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

434321-93-4 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d] oxazole-2,6,8 (3H,7B)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(4-pytidinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylanino)-8-D-xylo-hexopyranoxyl]oxyl-,
(3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

434321-94-5 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(34),7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.

434321-97-8 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (34H,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15heptamethyl-18-[3-(2-pyridinyl)propyl)-10-[[3,4,6-trideoxy-3(dimethylanino)-8-0-8ylo-hexopyranosyl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

434321-98-9 CAPLUS
4H-1,14-[iminomethanimino]-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH,78)-trione, 4-ethyl-7-fluorooctahydro-1l-methoxy-3a,7,9,11,13,15hexamethyl-18-[3-(2-pyridinyl)propyl]-10-[(3,4,6-trideoxy-3(dimethylamino]-β-D-xylo-hexopyranosyl)oxyl-,
(3as,4R,9R,10R,11R,13R,15s,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) hexamethyl-18-[3-(4-pyridinyl)propyl]-10-[[3,4.6-trideoxy-3-(dimethylamino)-9-0-xylo-hexopyranosyl)oxyl-, (3as,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

434321-95-6 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyolotetradecino[4,3-d]oxazole-2,6,8 (3AH,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(3-pyridinyl)propyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl)oxy]-,
(3a5,48,98,108,11R,13R,155,15a8)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

434321-96-7 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino(4,3-d]oxazole-2,6,8 (3AH,7H)-trione, 4-ethyl-7-fluorooctahydro-1l-methoxy-3a,7,9,11,13,15-hexamethyl-18-{3-(3-pyridinyl)propyl}-10-[(3,4,5-trideoxy-3-(dimethylamino)-β-0-kylo-hexopyranosyl]oxyl-,
(3a5,4R,9R,10R,11R,13R,13S,15S,15AH)- (SCI) (CA INDEX NAME)

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

434321-99-0 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15heptamethyl-18-[3-(4-(3-pyridinyl)-1H-imidazol-1-yl]propyl]-10-[[3,4,6trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl-,
(3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

434322-00-6 CAPLUS
4H-1,14-(Iminomethaniaino)-2H-oxacyelotetradecino[4,3-d]oxazole2,6,8 (3aH,7H)-trione, 7-fluorooctahydro-11-methosy-3a,4,7,9,11,13,15heptamethyl-18-(3-phenylpropyl)-10-{(3,4,6-trideoxy-3-(dimethylamino)β-0-sylo-hexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,155,15aR)- (9CI)
(CA INDEX NAME)

434322-01-7 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15hexamethyl-18-(3-phenylpropyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)β-D-wylo-hexopyranosyl]oxyl-, (3a5,4R,9R,10R,11R,13R,155,15aR)- (9CI)
(CA INDEX NAME)

434322-02-8 CAPLUS
4H-1,14-[iminomethanimino]-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH,7H]-trione, 7-fluoro-18-[3-(3-fluorophenyl)propyl]octahydro-11methoxy-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3(dimethylamino)-8-D-sylo-bexopyranosyl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

434322-05-1 CAPLUS
4H-1,14-[Iminomethanimino]-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (34H,7m)-trione, 18-{3-(1,2-dihydro-3H-imidazo[4,5-b]pyridin-3yl)propyl]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl10-{[3,4,6-trideoxy-3-(dihaethylamino)-B-D-xylo-hexopyranosyl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

434322-06-2 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino{4,3-d}oxazole2,6,8 (3aH,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15heptamethyl-18-[3-(2-phenyl-5-thiazolyl)propyl}-10-[[3,4,6-trideoxy-3(dimethylanino)-P-D-mylo-hexopyranosyl)oxyl-,
(3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


434322-03-9 CAPLUS
4H-1,14-([minomethanimino]-2H-oxacyclotetradecino(4,3-d]oxazole2,6,8 (34H,7H)-trione, 4-ethyl-7-fluoro-18-[3-(3fluorophenyl)propyl]octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10[(3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl]oxy]-,
(3a5,4R,9R,10R,11R,13R,155,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


 $\label{eq:continuous} 434322-04-0 \quad CAPLUS \\ 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8 (3AH,7H)-trione, 18-[3-\{1,2-dlhydro-3H-imidazo[4,5-b]pyridin-3-yl)propyl]-7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-10-[3,4,6-trideoxy-3-(dimethylamino)-\beta-0-xylo-hexopyranosyl]oxy]-, (3as,4R,9R,10R,11R,13R,15s,15sR)-(9CI) (CA INDEX NAME)$

Absolute stereochemistry.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



434322-07-3 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15hexamethyl-18-[3-(2-phenyl-5-thiazolyl)propyl]-10-[{3,4,6-trideoxy-3(dimethylamino)-8-D-xylo-hexopyranosyl]oxyl-,
(3aS,4R,9R,10R,11R,13R,15S,15aR)- (9C1) (CA INDEX NAME)



434322-08-4 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8[3H,7H]-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15heptamethyl-18-[3-[2-(2-pyridinyl)-4-thiazolyl]propyl]-10-[[3,4,6-trideoxy3-(dimethylamino)-9-0-xylo-hexopyranoxyl)oxyl-,
(3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

RN 434322-09-5 CAPLUS
CN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (38H,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15hexamethyl-18-(3-[2-(2-pyridinyl)-4-thiazolyl]propyl]-10-[[3,4,6-trideoxy3-(dimethylamino)-6D-xylo-hexopyranosyloxyl-,
(3a5,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 434322-10-8 CAPLUS
CN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (34H,7H)-trione, 18-[3-(IH-benzimidazol-1-yl)propyl]-7fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-10-[(3,4,6trideoxy-3-(disethylamino)-8-0-xyl-hexopyr-anoyl)oxy]-,

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) Double bond geometry unknown.

AN 434322-13-1 CAPLUS
AN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino(4,3-d]oxazole2,6,8 (3M,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl11-[(3-(4-pyridinyl)-2-propenyl]oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)β-D-sylo-hexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,155,15aR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

RN 434322-14-2 CAPLUS
CN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6.8 (3aH, TH)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11[3-(4-pyridinyl)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-Dxylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) (3as,4R,9R,10R,11R,13R,15s,15aR) - (9CI) (CA INDEX NAME)

RN 434322-11-9 CAPLUS

CN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH, 7H)-trione, 18-(3-(1H-benzimidazol-1-yl)propyl]-4-ethyl-7fluocooctahydro-11-methoxy-3a,7,9,11,13,15-bexamethyl-10-([3,4,6-trideoxy3-(dimethylamino)-6-D-xylo-hexopyranoxyl]oxy](3a5,4R,9R,10R,11R,13R,155,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 434322-12-0 CAPLUS

(N 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH, 7H)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11[[3-(4-pyridinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 434322-15-3 CAPLUS

CN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3AH, 7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl11-[3-(4-pyridinyl)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-Dxylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA
INDEX NAME)

RN 434322-16-4 CAPLUS
CN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3AH,7H)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11[3-(4-quinolinyl)propoxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-P-Dxylo-hexopyranoxyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA
INDEX NAME)

434322-17-5 CAPLUS
4H-1,14-{Iminomethanimino}-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH, 7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl11-[3-(4-quinolinyl)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β0-xylo-hexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

434322-20-0 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH,7H)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11[3-(5-quinolinyl)propoxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-8-Dxylo-hexopyranoxyl)oxy]-, (3a5,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NNHE)

Absolute stereochemistry

434322-21-1 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl11-[3-(5-quinolinyl)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-βD-wylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA

Page 83

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN Absolute stereochemistry. Double band geometry unknown. (Continued)

434322-19-7 CAPLUS 4H-1,14-[Ininomethanimino]-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8 (3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(4-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3a5,48,9R,10R,11R,13R,158,158H,19,19CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN INDEX NAME) (Continued)

Absolute stereochemistry.

434322-22-2 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3H-1,7H)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11[[3-(5-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)β-D-xylo-hexopytanozyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

434322-23-3 CAPLUS $\begin{array}{lll} 434322-23-3 & CAPLUS \\ 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d] oxazole-2,6.8 (3aH,7H)-trione, 4-ehpl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-1[[3-(4-quinolinyl)-2-propenyl] oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-<math>\beta$ -D-xylo-hexopyranosyl] oxy]-,

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) (3a5,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 434322-24-4 CAPLUS
CN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino(4,3-d)oxazole2,6,8 (3aH,7H)-trione, 7-fluorooctahydro-11-[3-(IH-indol-4-yl)propoxy]3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-p0-xylo-hexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

RN 434322-25-5 CAPLUS
CN 4H-1,14-[[ainomethanimino]-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-[3-(1H-indol-4-yl)propoxy]-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) 2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-[{3-(1H-indol-4-yl)-2-propenyl]oxy]-3a,7,9,11,13,15-hexamethyl-10-[{3,4,6-trideoxy-3-(dimethylamino)-#D-xylo-hexopyranoxyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 434322-28- CAPIUS
CN 4H-1,14-[[minomethanimino]-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH, HB)-trione, 7-fluorcoctahydro-3a,4,7,9,11,13,15-heptamethyl-11[3-(8-quinolinyl)propoxy]-10-[{3,4,6-trideoxy-3-(dimethylamino]-β-Dxylo-hexopyranoxyl]oxy]-, (3a5,4R,9R,10R,11R,13R,155,15aR)- (9CI) (CA
INOEX NAME)

Absolute stereochemistry

RN 434322-29-9 CAPLUS
CN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH, 7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl11-[3-(8-quinolinyl)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) (dimethylamino)-β-D-жylo-hexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,155,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry

RN 434322-26-6 CAPLUS
CN 4H-1,14-{Iminomethanimino}-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3AH, 7H)-trione, 7-fluorooctahydro-11-[[3-(1H-indol-4-y1)-2propenyl]oxy]-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3(dimethylamino)-6D-sylo-hexopyranosyl]oxy]-,
(3a5,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

RN 434322-27-7 CAPLUS
CN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
D-xylo-hexopyranosyl]oxyl-, (3a5,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 434322-30-2 CAPLUS

CN 4H-1,14-(Iminomethanimino)-ZH-oxacyclotetradecino[4,3-d]oxazole2,6,8 (3aH, TH)-crione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11[[3-(8-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

RN 434322-31-3 CAPLUS
CN 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-

Page 84

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) 11-[[3-(8-quinoliny1)-2-propeny1]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-kylo-hexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15S,15aR)-(9C1) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

434322-32-4 CAPLUS 4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8 (3aH,7H)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11-[2-(4-pyridinylmethyl)amino]ethoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,155,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl11-[2-[(4-quinolinylmethyl)amino|ethoxy]-10-[[3,4,6-trideoxy-3(dimethylamino)-9-D-xylo-hexopyranoyyl)oxy]-,
(3as,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

A34321-81-09
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic erythromycin derivs. as antibacterial agents)
434321-81-0 CAPLUS
41-1.14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2.6,8(3aH,7H)-trione, 10-[[2-0-acstyl-3,4,6-trideoxy-3-(dimethylamino)6-0-xylo-hexpyranoxyljoxyl-4-ethyl-7-fluorooctahydro-11-methoxy3a,7,9,11,13,15-hexamethyl-18-[3-[4-(3-pyridinyl)-1H-imidazol-1-yl]propyl](3a5,4R,9R,10R,11R,13R,155,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSYER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 434322-33-5 CAPLUS
CN 4H-1,14-([minomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (34H,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl11-[2-[(4-pyridinylmethyl)amino]ethoxy]-10-[[3,4,6-trideoxy-3(dimethylamino)-B-D-sylo-hexopyranoxylloxy]-,
(3as,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

434322-34-6 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8 (3aH,78]-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11-[2-[4-quinolinylmethyl]amino]ethoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-6-D-xylo-hexopyranosyl]oxy]-, (3aS,48,98,108,11R,13R,15S,15SR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

434322-35-7 CAPLUS
4H-1,14-(Iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

NSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN ION NUMBER: 2002:449692 CAPLUS NT NUMBER: 137:20548

137:20548
Preparation 6-O-carbamoyl ketolide derivatives of erythromycin useful as antibacterials Henninger, Todd C., Yu, Xiaodong C.
Ortho-McNeil Pharmaceutical, Inc., USA PCT. Int. Appl., 162 pp.
CODEN: PIXXO2

INVENTOR (S): PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: English 2 LANGUAGE:

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PAT	TENT	NO.		KI	ND	DATE			A	PPLI	CATI	ON N	ο.	DATE					
									-										
WO	2002046204			A	1	2002	0613	WO 2001-US47530 20011205											
	¥:	AE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN.		
		co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,		
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KΡ,	KR,	KZ,	LC,	LK.	LR.		
		LS,	LT.	LU,	LV,	MA,	MD,	MG,	MX,	MN,	MW,	MX,	MZ,	NO.	NZ,	PH,	PL		
		PT,	RO,	RU,	SD,	SE.	SG,	SI,	SX,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	UG,		
		UZ,	VN.	YU,	ZA,	ZM,	ZW.	AM,	AZ,	BY.	KG,	KZ.	MD,	RU.	TJ.	TH			
	RW	: GH,	GM.	KE,	LS,	MW.	MZ,	SD,	SL.	SZ.	TZ.	UG.	ZM,	ZW.	AT,	BE.	CH,		
		CY,	DE.	DK.	ES,	FI.	FR,	GB,	GR.	IE.	IT.	LU.	MC.	NL.	PT.	SE.	TR		
		BF.	BJ.	CF.	CG,	CI.	CM,	GA,	GN.	GQ.	GW.	ML.	MR.	NE.	SN.	TD.	TG		
US	647	2372		В	1	2002	1029		Ü	5 20	01-7	7378	9	2001	0201				
US 2003013663			A1 20030116																
ΑU	200	20307	08	A5 20020618				A	U 20	02-3		20011205							
EP				A1 20030917				E	P 20	01-9	0	20011205							
	R:	AT,	BE.	CH,	DE.	DK,	ES,	FR,	GB.	GR.	IT.	LI.	LU,	NL.	SE.	MC.	PT.		
		7 8	CT.	t.T	īν	ET.	PO.	WV	~v	21	TD								

PRIORITY APPLN. INFO.:

US 2000-251547 P 20001206

US 2001-773788 A 20001201

OTHER SOURCE(S):

MARPAT 137:20548

OTHER SOURCE(S):

6-O-carbamoyl ketolide derivs. of erythromycin antibacterials of the formula I: wherein Rl and R2 are independently H, alkyl, alkenyl, alkynyl,

ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) 433920-41-3 CAPLUS Carbamic acid, [(2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl]-, (3a5,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3-(disethylamino)-8-D-sylo-hexopyranosyl)oxyl-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

PAGE 2-A

433920-43-5 CAPLUS
Carbamic acid, [(2E)-3-[4-{2-pyrimidinyl)phenyl}-2-propenyl]-,
(3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3(dimethylamino)-8-0-xylo-hexopyraonayl)oxyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 86

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) cycloalkyl, cycloalkenyl, provided thar R1 and R2 are not both Hr R1R2 together are N atom to which they are attached, form an optionally substituted N-contg. heterocycler R3 is H, alkylamine, alkyl, alkowy, alkenylamine, alkenyl, acyl, alkynylamine R4 is H, halogen, OHr R5 is a H, hydrowy protecting group; R6 is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, arylalkyl, arylalkenyl, alkynyl, cycloalkyl, cycloalkenyl, alkowyalkyl, alkylthioalkyl; X and X1 are together with the carbon atom to which they are attached, form CO, imine, owynimine; Y, and Y1 are together with the carbon atom to which they are attached, form CO, CHOH, imine, owynimine were prepol. These compds, are useful as antibacterial agents. Thus, carbamic acid ([22]-3-{4-(2) pyrimidinyl)phenyl]-2-propenyl]-(3a5,4R,7R,9R,10R,11R,13R,15R,15AR)-4-ethyltetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-([3,4,6-trideoxy-3-(dimethylamino)beta-D-wylo-hexopyranosylloxyl-2H-oxacyclottradecino(4,3-d)oxacol-11-yl ester was prepd. and tested in vitro against E. coli, S. aureus, S. epideraidis, S. pneumoniae, S. pyogenes, Enterococci, Morawella catarchalis, and H. influenzae M1C values range from 0.03 to > 16 µg/mL. These compds, are particularly useful in the treatment of community-acquired pneumonia, upper and lower respiratory tract infections, skin and soft tissue infections, meningitis, hospital-acquired lung infections, and bone and joint infections. 433919-44-9P 433920-41-3P 433920-51-5P 433920-45-7P 433920-51-9P 433920-51-9P 433920-75-9P 43392

RL: PAC (Pharmacological activity): SPN (Synthetic preparation): THU (Therapeutic use): BIOL (Biological study): PREP (Preparation): USES

(preparation carbamoyl ketolide derivs. of erythromycin useful as

(preparation carbamoyi ketolide derivs. of erythromycin useful as antibacterials) 433919-44-9 CAPUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-0-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-11-[(aminocarbonyl)oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,3,15-hexamethyl-, (3aS,4R,7S,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN ouble bond geometry as shown. (Continued)

PAGE 1-A

PAGE 2-A

433920-45-7 CAPLUS
Carbantc acid, [(ZE)-3-(6-quinoliny1)-2-propeny1]-,
[38,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3(dimethylamino)-6-0-xylo-hexopyranosyl)oxyl-2Hoxacyclotetradecinol(4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 433920-46-8 CAPLUS
CN Carbamic acid, [[2E]-3-[4-(1H-pyrazol-1-y1)phenyl]-2-propenyl]-,
[3as, 4x, 7s, 9x, 10x, 11x, 13x, 15x, 15xx]-4-ethyl-7-fluorotetradecahydro3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 6, 14-tetraoxo-10-[[3, 4, 6-trideoxy-3(dimethylamino)-9-D-xylo-hexopyranoxyl]oxyl-2Hoxacyclotetradecino[4, 3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

RN 433920-49-1 CAPLUS
Cn Carbamic acid, ([2E]-3-(4-pyrazinylphenyl)-2-propenyl]-,
[385, 48, 75, 98, 108, 118, 138, 158, 158R)-4-ethyl-7-fluorotetradecahydro3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10-[[3,4,6-trideoxy-3(dimethylamino)-B-D-sylp-hexopyranoxyl]oxyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

PAGE 1-A

PAGE 2-A

RN 433920-48-0 CAPLUS
CN Carbamic acid, [(2E)-3-[4-(3-pyridazinyl)phenyl]-2-propenyl]-,
(3a5,48,75,98,108,118,138,158,15a8)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3(dimethylamino)-#0-sylo-hexopyranoxyl]oxyl-24oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 433920-50-4 CAPLUS

CN Carbamic acid, [[4-(4-pyrimidinyl)phenyl]methyl]-,
(385,4R,75,9R,10R,11R,13R,15R,15RR)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2.6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3(dimethylamino)-PD-xylo-hexopyranoxyl]oxyl-24oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

433920-51-5 CAPLUS
Carbamic acid, [(2E)-3-[1-(2-pyrimidinyl)-1H-imidazol-4-yl]-2-propenyl]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15AR)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[{3,4,6-trideoxy-3(dimethylamino)-9-0-psylo-hexopyranoxyl)oxyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

433920-52-6 CAPLUS
Carbamic acid, [[4-(2-pyridinyl)phenyl]methyl]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-([3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecinol(4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) Absolute stereochemistry.

433920-57-1 CAPLUS

433920-5/-1 CAPUS
Carbamic acid, [2-[4-(2-pyrimidinyl)phenyl]methoxylethyl]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,6,14-tatrazoxo-10-[(3,4,6-trideoxy-3(dimethylamino)-8-D-mylo-hexopyranosyl)oxyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

(Continued)

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)

PAGE 1-A

PAGE 2-A

433920-72-0 CAPLUS
Carbamic acid, [(ZE)-3-[4-(2-pyrimidiny1)pheny1]-2-propeny1]-,
(38.5,48,78,98,108,118,138,158,158R)-4-ethyl-7-fluorotetradecahydro-14(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-crioxo-10-[[3,4,6-trideoxy-3-(dimethylmino)-8-D-xylo-hexopyranoxyl)oxyl-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or 2.

PAGE 2-A

433920-73-1 CAPLUS
Carbamic acid, [(2E)-3-[1-(2-pyrimidinyl)-1H-imidazol-4-yl]-2-propenyl]-,
(3as, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7-fluorotetradecahydro-14(hydroxyimino)-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-9-0-xylo-hexopyranosyl]oxy]-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.

433920-74-2 CAPLUS
Carbamic acid, [(ZE)-3-[4-(3-pyridazinyl)phenyl]-2-propenyl]-,
(385,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-{(3,4,6-tridecxy-3-(dimethyl-amino)-9-b-xylo-hexopyranoxyl)oxyl-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

PAGE 1-A

Absolute stereochemistry. Double bond geometry as described by E or 2.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN Double bond geometry as described by E or 2. (Continued)

433920-77-5 CAPLUS
Carbamic acid, [[4-(2-pyrimidinyl)phenyl]methyl]-,
(JaS, 4R, 7S, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7-fluorotetradecahydro-14(hydcoxyinino)-3a, 7, 9, 11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

433920-75-3 CAPLUS
Carbamic acid, [[4-(2-pyrimidinyloxy)phenyl]methyl]-,
(385,48,75,98,108,118,138,158,158)-4-ethyl-7-fluorotetradecahydro-14(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy3-(dimethylamino)-9-D-xylo-hexopyranoxyl)oxyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

433920-76-4 CAPLUS
Carbamic acid, [(ZE)-3-(3-quinoliny1)-2-propeny1]-,
(3a, 4R, 75, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7-fluorotetradecahydro-14(hydroxyimino)-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8-trioxo-10-[[3, 4, 6-trideoxy-3-(dimethylamino)-8-P-xylo-hexopyranoxyl) oxyl)-ZHoxacyclotetradecino[4, 3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

433920-78-6 CAPLUS
Carbamic acid, [(2E)-3-phenyl-2-propenyl]-, (3as,4R,75,9R,10R,11R,13R,15R, 15R,15R)-4-4-thyl-7-fluorotetradecahydro-14-(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranoxyl)0y]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as described by E or Z.

433920-79-7 CAPLUS
Carbamic acid, [(2E)-3-(6-bromo-3-pyridinyl)-2-propenyl]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15R)-4-ethyl-7-fluorotetradecahydro-14(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[{3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl}oxy]-2H-

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) oxacyclotetradecino[4,3-d]oxacycl-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or 2.

433920-81-1 CAPLUS
Carbamic acid, [(ZE)-3-(3-pyridinyl)-2-propenyl]-,
(3a5,48,75,98,10R,11R,13R,15R,15eR)-4-ethyl-7-fluorotetradecahydro-14[hydroxyimino]-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy3-(dimethylamino)-B-D-xylo-hexopyranoxyl)oxyl-ZHoxacyclotetradecino[4,3-d]oxazol-11-yl-ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as described by E or Z.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN


PAGE 1-A

PAGE 2-A

433920-42-4
RL: RCT (Reactant): RACT (Reactant or reagent)
(preparation carbamoyl ketolide derivs. of erythromycin useful as
antibacterials)
433920-42-4 CAPLUS
2H-Owacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
11-([aminocarbonyl)oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-sylohexopyranosyl]oxy]-, (JaS,4R,7R,9R,1OR,11R,13R,15R,15RR)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.


L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



433922-58-8 CAPLUS
Carbamic acid, [(ZE)-3-[4-(4-pyrimidinyl)phenyl]-2-propenyl]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3(dimethylamino)-β-0-xylo-hexopyranoxyl)oxyl-2Hoxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



433919-43-8P 433920-71-9P 433920-80-0P
RL: RCT (Reactant): SPN (Synthetic preparation): PREP (Preparation): RACT (Reactant or reagent)
(preparation carbamoyl ketolide derivs. of erythromycin useful as antibacterials)
433919-43-8 CAPLUS
2H-Owacyclotetradecino [4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
11-{(aninoarbonyl)oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-{(3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,1OR,11R,13R,1SR,1SaR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

433920-71-9 CAPLUS

433920-71-9 CAPLUS
2H-OxacyClotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-0-xylohexopyranosyl]oxy]-11-[(aminocarbonyl)oxy]-4-ethyl-7-fluorooctahydro3a,7,9,11,73,15-hexamethyl-,14-(0-acetyloxime),
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

10/075,635

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

433920-80-0 CAPLUS
Carbamic acid, [(ZE)-3-(3-pyridinyl)-2-propenyl]-,
[38, 48, 75, 78, 10R, 11R, 13R, 15R, 15R]-14-{(acetyloxy) imino]-10-{{2-0-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl]oxy]-4-ethyl-7-flucortetradecahydro-3a,7,9,11,3,15-hexamethyl-2,6,8-trioxo-ZH-oxacyclotetradecino{4,3-d}oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as described by ${\bf E}$ or ${\bf Z}_{\bullet}$

REFERENCE COUNT:

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

(Uses)
(preph. of tricyclic erythromycin derivs. as Protozoacides and antibacterial agents)
422572-03-0 CAPLUS
1,14-(Itainomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro3a,4,7,9,11,13,15-heptamethyl-11-[3-(8-quinoliny)|propoxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-8-0-xylo-hexopyranosyl)oxy],
(3as,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

422572-05-2 CAPLUS
1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(PH,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro3a,7,9,11,13,15-hexamethyl-11-[3-(8-quinolinyl)propoxy]-10-{[3,4,6-trideoxy-3-cldimethylamino]-9-D-xylo-hexopyyranoxyl]oxyl-,
(3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 91

ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:39227 CAPLUS
100CHONT NUMBER: 156:369948
Preparation of tricyclic erythromycin derivatives as Protozoacides and antibacterial agents
Wu, Yong-Jin
USA
U.S. Pat. Appl. Publ., 12 pp.
CODEN: USAXCO
Patent

DOCUMENT TYPE: Patent English

LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

US 2002061856 A1 20020523
PRIORITY APPLIN. INFO:
OTHER SOURCE(S): MARPAT 132 APPLICATION NO. 20000424

Tricyclic erythromycins I wherein R is alkyl, alkenyl, alkynyl, wherein one or two cathons of said alkyl, alkenyl, and alkynyl groups are optionally replaced by a heteroatoms RI-R3 are independently H, alkyl, alkenyl, alkynyl, heterocycle; R2 and R3 together with the carbon to which they are attached form a 3 to 10 membered carbocyclic ring in which one or two carbons are optionally replaced by a heteroatom; R4 is H, alkyl, OH, alkoxy, aryloxy, amine, halor R5 is alkyl, alkenyl, and alkynyl, R6 is H, ester, acyl; were prepared and used in the treatment of bacterial and Protozoa infections. Thus, I (R - Her, RI = 3-quinolinf-4-yl-propyl; R2, R3, R4, R6 = H; R5 = Me) was prepared and tested in mice for its antibacterial activity (no data).

122572-03-09 ### 222572-03-29 ### 222572-07-49 ### 222572-03-09 ### 222572-03-29 ### 222572-03-09 ### 2

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) 422572-07-4 CAPLUS 1,14-[Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8 (7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,4,7,9,11,13,15-heptamethyl-11-[[3-(8-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamio)-β-D-xylo-hexopyranoxyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

422572-09-6 CAPLUS
1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(7R,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro3a,7,9,11,13,15-hexamethyl-11-[[3-(8-quinolinyl)-2-propenyl]oxy]-10[[3,4,6-trideoxy-3-(dimethylamino]-8-D-xylo-hexopyranosyl]oxy]-,
[336,4R,9R,10R,11R,13R,15R,15aR]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

RN 422572-13-2 CAPLUS
CN 1.14-[[minomethanonitrilo]-2H-oxacyclotetradecino[4,3-d] oxazole2,6,8 (7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro3a,7,9,11,13,15-hexamethyl-11-[2-[(4-pyridinylmethyl) amino]ethoxy]-10[[3,4,6-trideoxy-3-(dimethylmamino]-P-D-xylo-hexopyranosyl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

N 422572-15-4 CAPLUS
N 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro3a,4,7,9,11,13,15-heptamethyl-11-[2-[(4-quinolinylmethyl)amino]ethoxy]-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
(3a5,44,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
422571-57-1P 422571-59-3P 422571-61-7P
422571-63-9P 422571-55-1P 422571-67-3P
422571-63-9P 422571-71-9P 422571-73-1P
422571-75-3P 422571-71-9P 422571-73-1P
422571-76-1P 422571-83-3P 422571-75-5P
422571-81-1P 422571-83-9P 422571-91-3P
422571-93-9P 422571-93-9P 422571-91-3P
422571-93-9P 422571-95-7P 422571-97-9P
R1: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Uses)
(prepn. of tricyclic erythromycin derivs. as protozoacides and antibacterial agents)
N 422571-16-2 CAPLUS
1,14-(Ininomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,4,7,9,11,13,15-haptamethyl-18-[3-(4-quinolinyl)propyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-Po-xylo-hexopyranosyl]oxyl-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 422571-18-4 CAPLUS
CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino(4,3-d]oxazole2,6,8 (7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(4-quinoliny1)propy1]-10-[[3,4,6trideoxy-3-[dimethylamino)-Po-sylo-hexpyranosyl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.

RN 422572-17-6 CAPLUS
CN 1, 14-([ainomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8 (7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,7,9,11,13,15-hexamethyl-11-[2-[(4-quinolinylmethyl)amino]ethoxy]-10-[[3,4,6-trideoxy-3-(dimethylamio)-β-D-xylo-hexopyranoxyl]oxy]-,(3a5,48,98,10R,11R,13R,15R,15R)-(5CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 422571-16-2P 422571-10-4P 422571-20-8P 422571-22-0P 422571-24-2P 422571-26-4P 422571-28-6P 422571-30-0P 422571-32-2P 422571-34-4P 422571-36-6P 422571-34-6P 422571-40-2P 422571-42-4P 422571-44-6P 422571-46-8P 422571-48-0P 422571-55-9P 422571-51-5P 422571-53-7P 422571-55-9P

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 422571-20-8 CAPLUS
CN 1, 14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(7H,9H)-tcinoe, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,4,7,9,11,13,15-heptamethyl-18-[3-(5-quinolinyl)propyl]-10-[[3,4,6trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

RN 422571-22-0 CAPLUS

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 1,14-{Iminomethanonitrilo}-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 [7H,9H]-trione, 4-ethyl-7-f[uoro-3a,4.10,11,12,13,15,15a-octahydro-11methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(5-quinolinyl)propyl]-10-[[3,4,6trideoxy-3-(dimethylamino)-B-D-xylo-hexopycanosyl]oxyl-,
(3a5,48,9R,10R,11R,13R,15R,15R)-(SCI) (CA INDEX NAME)

Absolute stereochemistry.

RN 422571-24-2 CAPLUS
CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,4,7,9,11,13,15-heptamethyl-18-[3-(8-quinolinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl]oxy](3a5,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 422571-28-6 CAPLUS
CN 1,14-{[Iminomethanonitrilo]-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy18-[3-(7-methoxy-4-quinolinyl)propyl]-3a,4,7,9,11,13,15-heptamethyl-10[[3,4,6-trideoxy-3-(dimethylamino]-9-D-xylo-hexopyranoxyl]oxy]-,
(3as,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 422571-30-0 CAPLUS

Page 93

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 422571-26-4 CAPLUS
CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 [7H,9H]-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(8-quinolinyl)propyl]-10-[[3,4,6trideoxy-3-(dimethylamino)-B-D-xylo-hexopycanosyl]oxyl(3a5,4R,9R,10R,11R,13R,15R,15R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Lil ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 [7E,9H]-trione, 4-ephyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11methoxy-18-[3-(7-methoxy-4-quinolinyl)propyl]-3a,7,9,11,13,15-hexamethyl10-[[3,4,6-trideoxy-3-(dimethylamino]-B-0-xylo-hexopyranosyl]oxy]-,
(3aS,4R,9R,1OR,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 422571-32-2 CAPLUS
CN 1.14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d] oxazole2.6,8 (7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,4,7.9,11,13,15-heptamethyl-1θ-[3-(4-phenyl-1H-imidazol-1-γ1)propyl]-10[[3.4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl]oxy]-,
(3as,4R,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
422571-34-4 CAPLUS
1,14-(Iminomethanonitrilo)-ZH-oxacyclotetradecino[4,3-d]oxazole2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11methoxy-3a,7,9,11,13,15-hexamethyl-18-(3-(4-phenyl-HH-imidazol-1yl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-P-D-xylohexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

422571-36-6 CAPLUS
1,14-[Iminomethanonitrilo]-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,4,7,9,11,13,15-heptamethyl-18-[3-(4-pyridinyl)propyl]-10-[{3,4,6trideoxy-3-(dimethylamino]-9-D-xylo-hexopyranoxyl]oxy]-,
(3as,4R,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

422571-38-8 CAPLUS
1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) (3as,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

422571-44-6 CAPLUS
1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d] oxazole2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,4,7,9,11,13,15-heptamethyl-19-[3-(2-pyridinyl)propyl]-10-[[3,4,6-tridoxy-3-(dimethylamino)-B-0-xylo-hexopyranoyl)oxyl,
(3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

422571-46-8 CAPLUS
1,14-[Iminomethanonitrilo]-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (7R,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(2-pyridinyl)propyl]-10-[[3,4,6trideoxy-3-2'(dimethylamino]-9-D-xylo-hexopyranosyl]oxyl-,
(3as,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) 2,6,8 (7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-(3-(4-pyridinyl)propyl)-10-({3,4,6-trideory-3-(dimethylamino)-p8-psylo-hexpyranosyl)oxy)-, (3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

422571-40-2 CAPLUS
1,14-{Iminomethanonitrilo}-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,4,7,9,11,13,15-heptamethyl-18-[3-(3-pyridinyl)propyl)-10-[(3,4,6-tridoxy-3-(dimethylamino)-Pb-Pxylo-hexopyromoxyl)oyp] (9C1) (CA

Absolute stereochemistry.

422571-42-4 CAPLUS
1,14-{Iminomethanonitrilo}-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-3-gyridinyl)propyl]-10-[[3,4,6trideoxy-3-(dimethylamino)-β-D-xylo-hexopycanosyl]oxy]-,

L11 ANSWER 14 OF 27 CAPLU COPYRIGHT 2004 ACS on STN (Continued)

422571-48-0 CAPLUS
1,14-{Iminomethanonitrilo}-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,4,7,9,11,3,15-heptamethyl-11B-[3-[4-(3-pyridinyl)-1H-imidazol-1yl]propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-P-D-xylohexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

422571-50-4 CAPLUS
1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,4,7,9,11,13,15-heptamethyl-18-(3-phenylpropyl)-10-([3,4,6-trideoxy-3(dimethylamino)-8-0-xylo-hexopyranosyl]oxyl-,
(3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

422571-51-5 CAPLUS
1,14-{Iminomethanonitrilo}-2H-oxacyclotetradecino(4,3-d]oxazole2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-{4-(3-pyridinyl)-HI-imidazol-1yl]propyl]-10-[{3,4,6-trideoxy-3-(dimethylamino)-P-D-xylohexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

422571-53-7 CAPLUS 422571-53-7 CAPLUS.
1.14 - (Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11methoxy-3a,7,9,11,13,5-hexamethyl-18-(3-phenylpropyl)-10-[(3,4,6-trideoxy3-(dimethylamino)-8-D-xylo-hexopycanosyl)oxyl-,
(383,48,98,10R,11R,13a,158,15aN, - (9C1) (CA INDEX NAME)

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

422571-59-3 CAPLUS 1,14-{Iminomethanonitrilo}-ZH-oxacyclotetradecino[4,3-d]oxazole-2,6,8 (7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-18-[3-(3H-imidazo[4,5-b]pyridin-3-yl)propyl)-11-methoxy-3a,4,7,9,11,3,15-heptamethyl-10-[(3,4,6-trideoxy-3-(dimethylamino)- β -D-xylohexopyranosyl]oxy]-, (3a5,4R,9R,10R/11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

422571-61-7 CAPLUS
1.14-(Ininomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2.6,9 (7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,4,7,9,11,13,15-heptamethyl-18-(3-{2-phenyl-5-thiazolyl)propyl}-10[[3,4,6-trideoxy-3-(dimethylamio)-PD-wylo-hexopyranosyl]oxy]-,
[3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry

Absolute stereochemistry.

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN Absolute stereochemistry. (Continued)


422571-55-9 CAPLUS
1,14-{Iminomethanonitrilo}-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(7R,9H)-trione, 7-fluoro-18-[3-(3-fluorophenyl)propyl]3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl10-[(3,4,6-trideoxy-3-(dimethylamino)-B-D-wylo-hexopyranoayl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

422571-57-1 CAPLUS
1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-18-{3-(3-fluorophenyl)propyl]3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,33,15-hexamethyl-10[3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranoyl]oxy]-,
[3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2084 ACS on STN (Continued)



422571-63-9 CAPLUS
1,14-(Iminomethanonitrilo)-ZH-oxacyclotetradecino[4,3-d]oxazole2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-18[3-(3H-inidazo[4,5-b])pyridin-3-yl)propyl]-11-methoxy-3a,7,9,11,13,15hexamethyl-10-{[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

422571-65-1 CAPLUS
1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(2-phenyl-5-thiazolyl)propyl]-10[3,4,6-trideoxy-3-(dimethylamio)-B-D-vylo-hexopyranosyl)oxy]-,
(3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

422571-67-3 CAPLUS
1,14-{Iminomethanonitrilo}-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8[7,8]+1-rione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,4,7,9,11,13,15-heptamethyl-18-[3-[2-(4-pyridinyl)-4-thiazolyl]propyl]10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-wylo-hexopycanosyl]oxy]-,
(3a5,48,9R,10R,11R,13R,15R,15R)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

422571-69-5 CAPLUS

4225/1-169-5 CAPLUS
1,14-[in:obs-CAPLUS
1,14-[in:obs-CAPLUS
2,6,8(7H,9H)-trione, 18-[3-(1H-benzimidazol-1-yl)propyl]-7-fluoro3,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,4,79,11,13,15-heptamethyl10-[[3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-,
(335,44,9,10,118,138,158,158,16,16)-[9CI] (CA INDEX NARE)

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.

422571-75-3 CAPLUS
1,14-(Iminomethanonitrilo) -2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro3a,4,7,9,11,13,15-heptamethyl-11-[{3-4(-pyridinyl)-2-propenyl]oxy}-10[(3,4,6-trideoxy-3-(dimethylamino)-β-0-kylo-hexopyranosyl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

422571-77-5 CAPLUS
1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d] oxazole2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro3a,7,9,11,13,15-hexamethyl-11-[[3-(4-pyridinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-didimethylamino]-8D-0xylo-hexopyranoxyl]oxyl(Jas,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN Absolute stereochemistry. (Continued)

422571-71-9 CAPLUS
1,14-{Iminomethanonitrilo}-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(7H;9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-[2-(4-pyridinyl)-4thiazolyl]propyl]-10-[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylohexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

422571-73-1 CAPLUS
1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (7H,9H)-trione, 18-[3-(1H-benzimidazol-1-yl)propyl]-4-ethyl-7-fluoro3,4,10,11,12,13,15,15a-octahydro-11-eethoxy-3a,7,9,11,13,15-hexamethyl-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
(3as,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



422571-79-7 CAPLUS
1,14-{Iminomethanonitrilo}-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro3a,4,7,9,11,13,15-heptamethyl-11-[3-(4-quinolinyl)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino]-B-D-xylo-hexopyranoxyl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

422571-81-1 CAPLUS
1.14-(Iminosethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro3a,7,9,11,13,15-hexamethyl-11-[3-(4-quinolinyl)propoxy]-10-[{3,4,6-trideoxy-3-(dimethylamino)-6-D-xylo-hexopy(anoxyl)propoxy]-,
(3aS,4R,9R,10R,11R,13R,15R,15R)-(9CI) (CA INDEX NAME)

422571-83-3 CAPLUS
1,14-{Iminomethanonitrilo}-2H-oxacyclotetradecino(4,3-d)oxazole2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro3a,4,7,9,11,13,15-heptamethyl-11-[[3-(4-quinolinyl)-2-propenyl]oxy]-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-wylo-hexopyranoxyl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

422571-85-5 CAPLUS
1,14-{Iminomethanonitrilo}-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
3a,7,9,11,13,15-hexamethyl-11-[(3-(4-quinolinyl)-2-propenyl]oxy]-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-rxylo-hexopyranoxyl]oxy]-,
[3a5,48,98,108,118,138,158,158]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

422571-87-7 CAPLUS
1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(7R,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro3a,4,7,9,11,13,15-heptamethyl-11-[3-(5-quinolinyl)propoxy]-10-[{3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-,
3as,4R,9R,10R,11R,13R,15R,158R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

422571-89-9 CAPLUS
1,14-{Iminomethanonitrilo}-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro3a,7,9,11,13,15-hexamethyl-11-[3-(5-quinolinyl]propoxy]-10-[(3,4,6trideoxy-3-(dimethylamino]-B-0-xylo-hexopytranoxyl]oxyl-,
(3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

422571-91-3 CAPLUS
1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d] oxazole2,6,8 (7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15a-octahydro3a,4,7,9,11,13,15-heptamethyl-11-[{3-(5-quinolinyl)-2-propenyl]oxy]-10[{3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,

Page 97

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) (3as, 4R, 9R, 10R, 11R, 13R, 15R, 15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



422571-93-5 CAPLUS
1,14-[Iminomethanonitrilo]-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8[7],8]+trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro3a,7,9,11,13,15-hexamethyl-11-[[3-(5-quinolinyl)-2-propenyl]oxy]-10[[3,4,6-trideoxy-3-(dimethylamino]-8-D-svylo-hexopyranosyl]oxy]-,
[3aS,4R,9R,10R,1]R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

422571-95-7 CAPLUS
1,14-{Iminomethanonitrilo}-2H-oxacyclotetradecino{4,3-d}oxazole-2,6,8(7H,9H)-trione, 11-{3-(1H-benzimidazol-4-yl)propoxy}-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethyl-aminol-9-D-xylo-hexopy(zanoxyl)goxy]-, (3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

422571-97-9 CAPLUS
1,14-{Iminomethanonitrilo}-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(RM,9H)-trione, 11-{3-(1H-benzimidazol-4-yl)propoxy}-4-ethyl-7-fluoro3a,4,10,11,12,13,15,15a-octahydro-3a,7,9,11,13,15-hexamethyl-10-[{3,4,6urideoxy-3-(dimethylamino)-8-0-wylo-hexopyranoxyl)oxyl(JaS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

422571-99-1 CAPLUS
1,14-{Ininomethanonitrilo}-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8(7H,9H)-trione, 11-[[3-{IH-benzimidazol-4-yl}-2-propenyl]oxy]-7fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,4,7,9,11,13,15-heptamethyl-10[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranoxyl]oxy]-,
(3a5,4R,9R,10R,11R,13R,15R,15R)-(9C1) (CA INDEX NAME)

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
and antibacterial agents)
RN 42257-211-0 CAPLUS
CN 1,14-[Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (7H,9H)-crione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro3a,4,7,9,11,13,15-heptamethyl-11-[2-[(4-pyridinylmethyl)amino]ethoxy]-10[[3,4,6-trideoxy-3-d(dimethylamino]-Po-xylo-hexopyramoxyl]oxy]-,
[3as,4R,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN Absolute stereochemistry.
Double bond geometry unknown. (Continued)

422572-01-8 CAPLUS
1,14-[Iminomethanonitrilo]-2H-oxacyclotetradecino[4,3-d]oxazole2,6,8 (7M,9H)-trione, 11-[[3-(1H-benzimidazol-4-y1)-2-propenyl]oxy]-4-ethyl7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,7,9,11,13,15-hexamethyl-10[[3,4,6-trideoxy-3-(dimethylamino]-6P-D-xylo-hexopyranosyl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

IT 422572-11-0P
RJ: BSU (Biological study, unclassified): SPN (Synthetic preparation): THU (Therapeutic use): BIOL (Biological study): PREP (Preparation): USES (Uses)
(reduction agent; preparation of tricyclic erythromycin derivs. as Protozoacides



INVENTOR (5):

PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

	D 3.7	PERM	NO		WIT	מיא	DATE				DDIT	~***	ON M	^	DATE					
	I A	E 24 1	NO.		KI.	n D	DATE			^		~~ I		٠.	DALE					
							2002			w	0 20	01-0	5322	78	2001	1019				
	WO 2002032919			A	3	20020919														
		w:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,		
			CO.	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC.	EE,	ES,	FI,	GB,	GD,	GE,	GH,		
			GM,	HR.	HU.	ID,	IL.	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,		
			LS.	LT.	LU.	LV.	MA.	MD.	MG.	MK.	MN.	MW.	HX.	MZ.	NO.	NZ.	PH.	PL.		
			PT.	RO.	RU.	SD.	SE,	SG.	SI.	SK.	SL.	TJ.	TM.	TR.	TT.	TZ.	UA.	UG.		
							ZW.													
		RW:	GH.	GM.	KE.	LS.	MW,	MZ.	SD.	SL.	SZ.	TZ.	UG.	ZW.	AT.	BE.	CH.	CY.		
							FR,													
							CH,											,		
	211	200																		
								AU 2002-13267 20011016 EP 2001-981637 20011016												
	E.F		28534																	
		R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,		
			IE.	SI.	LT.	LV.	FI.	RO.	MK.	CY.	AL.	TR								
RTO	RIT	Y API	PLN.	INFO					- 1	US 2	000-	2407	77P	P	2000	1016				
															=::::					

WO 2001-US32278 W 20011016 CASREACT 136:310123; MARPAT 136:310123 OTHER SOURCE(S):

Macrolide erythromycins I wherein D1 is C.tplbond.C, CH=CH, Y1 soxazole, oxazole, isothiazole, dihydroisoxazole, dihydrooxazole; X is H, F_1 A1 is

Lil ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) aryl, hetercaryl; Rl is H, hydroxyl protecting group, were prepd. for treating bacterial infections while avoiding the concomitant liability of gastrointestinal intolerance. Thus, I wherein Dl is C. tplbond.C, Yl is isoxazol-3,5-diyl, Al is pyrid-2-yl, X is fluoride, Rl is hydrogen was prepd. and demonstrated an unexpected gastrointestinal tolerance. The total daily dose of the compds. administered to a patient in single or divided doses can be in ants. from about 0.1 to about 200 mg/kg body vt. or preferably from about 0.25 to about 100 mg/kg body vt. This enhanced gastrointestinal tolerability represents a significant advantage for the compds. of this invention. These compds. vill have an improved side effect profile when compared with the erythromycin derivs, of the prior art. Patients consuming these compds. vill have an improved side effects typically assocd with erythromycin derivs, of the prior art. Patients consuming these compds, will experience a reduced incidence of nausea, vomiting, gastrointestinal discomfort, cramping, and other GI side effects typically assocd with erythromycin therapy. The compds. showed antibacterial activity in vitro with MIC's in a range of about 0.004 µg/ml. to about 128-µg/ml, in a more preferred range, the compds, inhibited the growth of bacteria with MIC's in a range of about 0.004 µg/ml to about 2 µg/ml. and in a most preferred range, the compds, inhibited the growth of bacteria with MIC's in a range of about 0.004 µg/ml to about 4 µg/ml. I.
1 412046-93-69 412047-22-69 412047-24-69
412047-26-99 412047-22-90 412047-30-99
RL: PAC (Pharmacological activity): SPN (Synthetic preparation): THU (Therapeutic use): SIOL (Biological study): PREP (Preparation): USES (Uses)
(preparation of antibacterial 6-0-substituted erythromycin derivs, having improved gastrointestinal tolerancal

(Uses)
(preparation of antibacterial 6-O-substituted erythromycin derivs. having improved gastrointestinal tolerance)
412046-93-6 CAPLUS
2H-OxacyClotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-{[3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propynyl]oxyl-10-[[3,4,6-trideoxy-3-(dimethylamino]-6-D-xylo-hexopyranosyl]oxyl-,
(3aS,4R,7S,9R,1OR,11R,13R,15R,15BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

412047-22-4 CAPLUS 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone, 11-[[3-[3-(3-chloroimidazo[2,1-b]thiazol-2-yl]-5-isoxazolyl]-2-

L11 ANSWER 15 OF 27 CAPLUS COPYPIGHT 2004 ACS on STN (Continued)

412047-28-0 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
11-[[3-[3-3,4-difluorophenyl]-5-isoxazolyl]-2-propynyl]oxy]-4-ethyl-7fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3(dimethylamino)-B-D-xylo-hexopytanosyl)oxy]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

412047-30-4 CAPLUS 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-{[3-[3-(5-pyrimidinyl)-5-isoxazolyl]-2-propynyl] oxyl-10-[[3,4,6-trideoxy-3-(dimethylamino]-60-xylo-hexopyranoxyl]oxyl-, (3aS,4R,7S,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry

L11 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) propynyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[(3,4,6-tridosyr-3-(dimethylamino)-#D-xylo-hexopyranosyl]oxy]-, (3a5,4R,7R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

412047-24-6 CAPLUS 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[3-(5-thiazolyl)-5-isoxazolyl]-2-propyhyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)+B-D-xylo-hexppyranosyloxy]-, (3,4,6-trideoxy-3-(38,4R,75,9R,10R,11R,13R,15S,75R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Me₂N

412047-26-8 CAPLUS 2H-Oxacycloterradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorootahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[3-{2-thiazolyl}-5-isoxazolyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino]-β-D-wylo-hexopycanosyl]oxy]-, (3a5,48,75,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

412047-34-8 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[3-(2-methyl-2H-tetrazol-5-yl)-5-isoxazolyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-8-D-sylo-hexopyranosyl]oxy]-, (3aS,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

412047-42-8 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[3-(3-quinolinyl)-5-isoxazolyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimathylamino]-B-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)


412046-92-5 412047-23-5 412047-25-7
412047-27-9 412047-29-1 412047-31-5
412047-33-9 412047-43-9
RL: RCT (Reactant) RACT (Reactant or reagent)
(preparation of antibacterial 6-0-substituted erythromycin derivs. having improved gastrointestinal tolerance)
412046-92-5 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propynyloxy)-, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

412047-23-5 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-{[2-0-bexoyl-3,4,6-trideoxy-3-(dimethylamino)-P-D-xylohexopyranoxyl]oxy]-11-{[3-[3-(3-chloroimidazo[2,1-b]thiazol-2-yl)-5isoxazolyl]-2-propynyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15hexamethyl-, (3a5,8R,75,9R,10R,11R,13R,15R,15aR)-(9C1) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



412047-29-1 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-#-D-mylohexpoyranoxylloxy]-1-[[3-[3-[3,4-difluorophenyl)-5-isoxazolyl]-2propynyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-,
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

L11 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

412047-25-7 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11[[2-[3-[5-thizazolyl]-5-sisoxazolyyl]-2-propyyl]oxy](3as,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute Stereochemistry.

412047-27-9 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[{2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11[[3-[3-(2-thiacolyl)-5-isoxazolyl]-2-propynyl]oxy](3as,4R,7s,9R,10R,11R,13R,15R,15aB)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

412047-31-5 CAPLUS
2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranoxylloxyl-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11[[3-[3-(5-pyrimidinyl)-5-isoxazolyl]-2-propynyl]oxyl-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

412047-35-9 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-bexoyl-3,4,6-crtideoxy-3-(dimethylamino)-B-D-xylohexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11[[3-[3-(2-methyl-2H-tetrazol-5-yyl)-5-isoxazolyl]-2-propynyl]oxy]-,
[3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

412047-43-9 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-{[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-\$-D-xylohexopyranoxylloxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11[[3-{3-(3-quinolinyl)-5-isoxazolyl]-2-propynyl]oxy]-,
(3as,4R,7s,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

412046-91-4P

RI: RCT (Reactant): SPN (Synthetic preparation): THU (Therapeutic use): BIOL (Biological study): PREP (Preparation): RACT (Reactant or reagent): USES (Uses)

USSS (Uses)
(preparation of antibacterial 6-O-substituted erythromycin derivs. having improved gastrointestinal tolerance)
412046-91-4 CAPLUS
2H-Owacyclotetradecino(4,3-d) oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[(2-O-benzoyl-3,4,6-trideoxy-3-d(dimethylamino)-B-D-xylo-hexopyrancyyloxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11[(3-13-(2-pyridinyl)-5-jacoxazolyl)-2-propynyloxy]-,
(3as,4R,75,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 16 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN SSION NUMBER: 2002:314956 CAPLUS MENT NUMBER: 136:340937 Preparation of erythromycin ketolides as antibacteria agents
Hlasta, Dennis; Henninger, Todd C.; Grant, Eugene B.;
Khosla, Chaitin; Chu, Daniel T. W.; Ashley, Gary
Ortho-HcNeil Pharmaceutical, Inc., USA
PCT Inc. Appl., 108 pp.
CODE: PIXMO2 Preparation of erythromycin ketolides as antibacterial INVENTOR(S): PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: English 6

EN	rı	NFO	KMAT I	UNI																
	PAT	ENT	NO.		KI	ND	DATE			A	PPLI	CATIO	ON NO	٠.	DATE					
										-										
,	'n	2002	20329	18	A	2	2002	0425		·	0 20	01-11	53211	19	2001	1012				
				A3 20030103				-			• •									
									AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,											
		w:																		
															GB,					
			GM,	HR,	ΗU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	ĸR,	ΚZ,	LC,	LK,	LR,		
			LS,	LT,	LU,	LV.	MA.	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PH,	PL,		
			PT.	RO.	RU.	SD.	SE.	SG.	SI.	SK.	SL.	TJ.	TM.	TR.	TT,	TZ.	UA.	UG.		
															TJ,					
		Dt.J	: GH,														~u	CV		
		N= .																		
															PT,			Br,		
															SN,		TG			
-	US	6590	0083		В	1	2003	0708		U	S 20	00-6	91540)	2000	1018				
	ΑU	2002	20132	14	A	5	2002	0429		A	U 20	02-1	3214		2001	1012				
	EΡ	1345	5953		A	2	2003	0924		E	P 20	01-9	81580)	2001	1012				
			AT,														MC.	PT.		
		••••					FI.						,	,	,	,		,		
UK	111	API	PLN.	INFO	. :										2000					
															1999					
										US 1	999-	1313	83P	P	1999	0428				
										US 1	999-	1401	75P	P	1999	0618				
										lle ī	000-	1721	640	D	1000	1217				

US US US US US US US WO MARPAT 136:340937

OTHER SOURCE(S):

L11 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS OR STN (Continued)

L11 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

The present invention includes erythromycin ketolides I wherein: X is hydrogen or halide, R is hydrogen or a substituted or unsubstituted moiety wherein the moiety is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclo, arylalkyl, arylalkenyl, or -ORa wherein Ra is a substituted or unsubstituted moiety selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocycloalkenyl, heterocycloalkynyl, arylalkynyl, heterocycloalkyl, arylalkynyl, heterocycloalkyl, arylalkyl, arylalkenyl, arylalkynyl, heterocycloalkyl, heterocycloalkynyl, arylalkynyl, arylalkenyl, arylalkynyl, arylalkyn, arylalkynyl, arylalkenyl, arylalkynyl, arylalkynyl, arylalkynyl, arylalkynyl, arylalkynyl, arylalkynyl, heterocycloalkynyl, arylalkynyl, arylal

301320-09-2 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(3-quinolinyl)-2-propenyl)oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-9-Drxylo-hexopycanosyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CAINDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

413592-00-4 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(6-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

L11 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

413592-12-8 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(7-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown

413592-15-1 CAPLUS 2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluoro-11-[[3-(6-fluoro-3-quinoliny1)-2-propeny1]oxy]octahydro-3a,7,9,11,13,15-hexamethy1-4-propy1-10-[[3,4,6-trideoxy-3-(dimethylamino)-6-p-xylo-hexopyranoxylloxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

L11 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN


413592-04-8 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-[[3-(6-methoxy-3-quinoliny1)-2-propeny1]oxy]-3a,7,9,11,13,15-hexamethy1-4-propy1-10-[(3,4,6-trideoxy-3-(dimethy1amino)-6-D-xylo-hexopytanosy1]oxy]-, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

413592-07-1 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(6-quinoxalinyl)-2-propenyl]oxy]-10-[(3,4,6-trideoxy-3-(dimethylaminoD-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (CA INDEX NAME)


Absolute stereochemistry. Double bond geometry unknown.

L11 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN



413592-17-3 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
11-[[3-(6-chloro-3-quinolinyl)-2-propenyl]oxy]-7-fluorooctahydro3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-0-xylo-hexopyranoxyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



413592-22-0 CAPLUS 2H-Oxacyclotetradacino[4,3-d]oxacycle-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(3-pyridinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

301320-11-6

301320-11-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of erythromycin ketolides as antibacterial agents)
301320-11-6 CAPLUS
2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-bexopy.3-4,6-trideoxy-3-(dimethylamino)-B-D-xylohexopyranosylloxy|-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2propenyloxy)-4-propyl-, (3aS,4R,75,9R,10R,11R,13R,15R,15R)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) alkenyl, alkynyl, ether, ester, alkylamine; R2 and R3 taken together with the atoms to which each is attached forms a 3-to 6-membered arom, or non-arom, cting optionally contains one to two double bonds or R2 and R3 taken together form a ~CH2, epoxide, or ~0; Y is H, OH, NH2, amine were prepd. as antibacterial agents. The present invention relates to 6-O-alkyl-2-nor-2-substituted ketolide compd. or a defiv. thereof, a compn. comprising the compd. and a suitable carrier, a method of prepg. the compd.; and a method of treatment and prevention of in mammals comprising administering said compd. Thus, I (R = Bz, Rl = CH2C.tplbond.C-(3-quinoly); R2R3 ~CH2; Y = H) was prepd. and tested in vitro for its antibacterial activity (MIC = 0.01 to > 128).

17 342036-19-59 42036-20-89 342036-22-29 342036-33-39 342036-33-39 342036-33-39 342036-37-79 342036-32-89 342036-33-39 342036-31-19 342036-32-89 342036-33-99 342036-31-39 34203

Absolute stereochemistry. Double bond geometry unknown

342036-20-8 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7,7-difluocooctahydro-3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-Dxylo-hexopyranosyl]oxy]-, (3as,4R,9R,10R,11R,13R,15R,15aR)- (9CI) [NDEX NAME)

Page 103

ANSWER 17 OF 27
SSION NUMBER:
2001:416950 CAPLUS
135:19871
Preparation of macrolide erythromycin
6-0-alkyl-2-nor-2-substituted ketolide derivatives as
antibacterial agents
Phan, Ly Tams Or, Yat Sun, Ma, Zhenkun
Abbott Laboratories, USA
CE:
CE:
CT Int. Appl., 101 pp.
CODEN: PIXXD2
PAEANT
CODEN: PIXXD2
PAEANT

INVENTOR(S): PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: Patent English

LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

> PATENT NO. KIND DATE APPLICATION NO. DATE A2 A3 20010607 WO 2001040241 WO 2001040241 WO 2000-US32767 20001201

W0 2001040241 A3 20011213

W: CA, JP, MX

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

EP 1233971 A2 20020828 EP 2000-982357 20001201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR

JP 2003527347 T2 20030916 US 1999-453261 A 19991202

W0 2000-US12767 W 20001201 2 20030916 JP 2001-540996 20001201 US 1999-453261 A 19991202 WO 2000-US32767 W 20001201 MARPAT 135:19871

OTHER SOURCE(S):

Macrolide erythromycins I R is hydrogen or a hydroxy protecting group: R1 is selected from the group consisting of optionally substituted alkyl, alkenyl-q1 alkenyl-q2 alkynyl: and alkynyl-q2 q1 selected from the group consisting of: hydrogen: aryl: substituted aryl: heteroaryl: substituted heteroaryl: R2 is H, OH, NHZ, substituted maine, Sefh, halogen: R3 is selected from the group consisting of: hydrogen: OH: F, Cl, Br or I: alkyl

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

342036-21-9 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone,
4-ethyl-7-fluoro-7-(fluoromethyl)octahydro-3a,9,11,13,15-pentamethyl-11[[3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)B-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

342036-30-0 CAPLUS 2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-10-([3,4,6-trideoxy-3-(dimethylamino)-B-O-xylo-hexopyranosyl)oxyl-, 383,48,9R,108,118,13R,158R,158R]-(SCI) (CA INDEX NAME)

342036-31-1 CAPLUS
2H-Oxacyclotetradecino (4,3-d) oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propynyloxy)-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopycanosyl]oxy]-,
[3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

342036-35-5 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7,7-dif[lucrooctahydro-3a,9]1,13,15-pentamethyl-11-(2-propynyloxy)0-[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosy]oxy]-,
(3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

342036-36-6 CAPLUS
14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d] oxazole-2,6,8 (7H,9H)trione, 4-ethyl-7,7-difluoro-3a,4,10,11,12,13,15,15a-octahydro3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-10-[{3,4,6-trideoxy-3(dimethylamino]-B-0-xylo-hexopyranoxyl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

342036-33-3 CAPLUS
14,1-(Nitriloethano)-2H-oxacyclotetradecino(4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15-pentamethyl-11-(2-propynyloxy)-10-[[3,4,6-trideoxy-3-(dimethylanino)-B-D-sylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

342036-34-4 CAPLUS
2H-Oxacyclotetradecinc[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7,7-difluorocctahydro-3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)10-[(3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl)oxy]-,
(3a5,4R,9R,10R,11R,13R,15R,15aR)- [9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

342036-37-7 CAPLUS
14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)trione, 4-ethyl-7,7-difluoro-3a,4,10,11,12,13,15,15a-octahydro3a,9,11,13,15-pentamethyl-11-(2-propynyloxy)-10-[[3,4,6-trideoxy-3(dimethylamino)-B-0-xylo-hexopyryanoxyl)oxyl-,
(3aS,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

342036-38-8 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-[[3-(5-quinoxalinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-βD-xylo-hexopyranosyl]oxy]-, (3as,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.


RN 342036-39-9 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctabyto-3a,9,11,13,15-pentamethyl-11-[{3-(3-quinolinyl)2-propyyl]oxy]-10-[{3,4,6-trideoxy-3-(dimethylamino)-p-D-xylohexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.

RN 342036-40-2 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15pentamethyl-11-[(3-(3-quinolinyl)-2-propenyl]oxy]-10-[(3,4,6-trideoxy-3(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-,
(3a5,4x,9x,10x,11x,13x,15x,15ax)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-43-5 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tettone,
4-ethyl-7,7-dif[luorooctahydro-3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propynyl]oxy]-10-[[3,4,6-ttideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl]oxy]-, (3as,4R,9R,10R,11R,13R,15R,15RR)- (9CI) (CA
INDEX NAME)

RN 342036-44-6 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d] oxazole-2,6,8 (7H,9H)trione, 4-ethyl-7,7-difluoro-3a,4,10,11,12,13,15,15a-octahydro3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranoyl]oxy]-,
[3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 342036-41-3 CAPLUS
CN 14,1-(Nitriloethano) -2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15pentamethyl-11-[[3-(3-quinolinyl)-2-propynyl)oxy]-10-[[3,4,6-trideoxy-3(dimethylamino)-8D-sylo-hexpyranoxylloxy]-,
(3aS,4R,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 342036-42-4 CAPLUS
CN 2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-[(3-(5-quinoxalinyl)-2-propenyl)oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl)oxy]-, (3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 342036-45-7 CAPLUS
CN 14,1-(Nitrileethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8 (7H,9H)trione, 4-ethyl-7,7-difluoro-1a,4,10,11,12,13,15,15a-octahydro3a,9,11,13,15-pentamethyl-11-[[3,(3-quinolinyl)-2-propynyl]oxy]-10-[[3,4,6trideoxy-3-(dimethylanino)-B-b-xylo-hexopyranoxyl]oxy]-,
(3as,4R,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 342036-56-0 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2propenyl)-10-[[],4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

342036-57-1 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorootahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2-propynyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

342036-58-2 CAPLUS
14,1-(Mitriloethano)-2H-oxacyclotetradecino[4,3-d] oxazole-2,6,8 (7H,9H)trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,9,11,13,15-pentamethyl-7-(2-propenyl)-10-[[3,4,6-trideoxy-3(dimethylanino)-9-0-xylo-hexopyreanoxyl]oxyl-,
(3aS,4R,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

342036-61-7 CAPLUS 2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-[3-(3-quinolinyl)-2-propynyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl-, (3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

342036-62-9 CAPLUS
14,1-{Nitriloethano}-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-[3-(3-quinolinyl)-2-propenyl]-10-[[3,4,6-trideoxy-3-d[dimethylamino]-8-D-sylo-hexopycanosyl]osylogyl, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

342036-59-3 CAPLUS
14.1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2-propynyl)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopycanosylloxy)-,(3aS,4R,9R,10R,11R,13R,15R,15R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

342036-60-6 CAPLUS
2H-Owacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-[3-(3-quinolinyl)-2-propenyl]-10-[(3,4,6-trideoxy-3-(dimethylamino)-B-Dwylo-hexpyranosyl]oxy]-, (3as,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

342036-63-9 CAPLUS
14,1-(Mitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,9,11,13,15-pentamethyl-7-[3-(3-quinolinyl)-2-propyyl]-10-[(3,4,6tridoxy-3-(dimethylamino)-B-0-sylo-hexopytamoxyl]oxyl,
(3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

L11 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN 255510N NUMBER: 2000:756722 CAPLUS DAUMENT NUMBER: 133:295621

133:296621
Preparation of erythromycin macrolides as potential antiinfective agents
Chu, Daniel T. W., Ashley, Gary W.
Xosan Biosciences, Inc., USA
PCT Int. Appl., 104 pp.
CODEN: PIXXO2

INVENTOR(S): PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: LANGUAGE: LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE IE, 51
BR 2000010680
US 6395710
JP 2003523938
NZ 515027
US 2002055472
US 6514944
US 2002119938
US 6593302
US 6593302
US 20022156028
US 200320782
US 200320782
US TITTY APPLIN. IN A A1 B2 20030218 ZA 2001-9444 US 2002-75466 20011115 20020213 B2 20030105
A1 20021024
A1 20031106
US 1999-129729P P 19990416
US 1999-129729P P 19990416
US 1999-12154P P 19991217
US 1999-173164P P 19991217
US 1999-173805P P 19991230
US 1999-173805P P 19991230
US 2000-55015 A 20000414
US 2000-551162 A1 20000414
US 2000-550164 W 20000414
US 2000-750470 A1 20001227 20020829 20030715 PRIORITY APPLN. INFO .:

OTHER SOURCE(S):

L11 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

301320-09-2P
RL: RCT (Reactant): SPN (Synthetic preparation): PREP (Preparation): RACT (Reactant or reagent)
(preparation of erythromycin macrolides as potential antiinfective

to)
301320-09-2 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-tylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI)
INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

L11 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Title compds. I, wherein R1 is H; substituted or unsubstituted alkyl (1-10C); substituted or unsubstituted alkynyl (2-10C); substituted or unsubstituted aryl (4-14C); substituted or unsubstituted aryl (4-14C); substituted or unsubstituted aryl (4-14C); substituted or unsubstituted arylalkyl (5-20C); or ORI is replaced by H; R2 is H or halogen; R3 is H or a protecting group; R4 is Me, unsubstituted alkyn (3-10C); substituted or unsubstituted alkynyl (2-10C); substituted or unsubstituted or unsubstituted arylalkynyl (2-20C); substituted or unsubstituted arylalkynyl (5-20C); substituted or unsubstituted arylalkynyl (5-20C); substituted or unsubstituted arylalkenyl (5-20C); substituted or unsubstituted amidoarylalkyn (5-20C); or substituted or unsubstituted amidoarylalkynyl (5-20C); or or unsubstituted or unsubstit

Absolute stereochemistry

```
ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN SION NUMBER: 2000:756529 CAPLUS 133:296619
                                                                                                                                                                                                                133:296619
Preparation of ketolide erythromycins as antibacterial agents
Hlasta, Dennis, Henninger, Todd: Grant, Eugener Khosla, Chaitin: Chu, Daniel Ortho-McNeil Pharmaceutical, Inc., USA: Kosan Biosciences, Inc.
PCT Int. Appl., 112 pp.
CODEN: PIXXD2
Patent
English
6
INVENTOR(S):
PATENT ASSIGNEE(S):
DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
                                           PATENT NO.
                                                                                                                                                                                                   KIND DATE
                                                                                                                                                                                                                                                                                                                                                                                          APPLICATION NO. DATE
                                    PATEIT NO. KIND DATE

### APPLICATION NO. DA
                                                                                                                                                                                                                                                                                                                                                          JP 2000-611919 20000413
ZA 2001-9444 20011115
US 2002-124988 20020417
US 1999-129729P P 19990428
US 1999-140175P P 19990428
US 1999-172154P P 19991217
US 1999-172154P P 19991217
US 1999-172154P P 19991217
US 1999-173804P P 19991230
US 1999-173804P P 19991230
US 1999-173805P P 19991230
US 1999-173805P P 19991230
US 2000-0510276 W 200000413
US 2000-551162 Al 20000414
PRIORITY APPLN. INFO .:
```

OTHER SOURCE(S): MARPAT 133: 296619

Ketolide antibacterials I wherein, X is H,halogen; R is selected from H, aryl, heterocyclo, cycloalkyl, alkyl, alkenyl; R1 is selected from H, alkyl, alkenyl, alkynyl; R2 is selected from H, COCH3 and Bz; R3 is selected from H and alkow; were prepared as antibacterial agents. These compds, are erythromycin analogs useful in the treatment of bacterial and protozoal infections and in the treatment of other conditions involving gastric motility. Thus, I (R = R4, R1 = Me, R2 = X = H, R3 = OMe) was prepared and tested for its in vitro antibacterial activity (MIC range is from 0.03 to > 16 Mg/mL).
300841-16-1P 300841-32-1P 300841-33-2P 300841-16-1P 300841-42-3P 300841-39-BP 300841-40-1P 300841-42-3P 300841-49-BP 300841-59-BP 300841-50-BP 300841-55-BP 300841-78-3P 3008

L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

300841-35-4 CAPLUS
ZH-Owacyclotetradecino(4,3-d]owazole-2,6,8,14(1H,7H,9H)-tetrone,
7-fluorooctahydro-11-hydroxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-phenyl-1H-iaidzol-1-yl)butyl]-10-[(3,4,6-trideoxy-3-(dimethylanino)-P-0-xylo-hexopyranosyl)oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

300841-37-6 CAPLUS 2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluocootchhydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-phenyl-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-wylo-hexopyranosyl]oxy]-, (3a5,4R,7S,9R,1OR,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
7-fluorooctahydro-1-[4-(1H-imidazo[4,5-b]pyridin-1-y1]butyl]-11-methoxy3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)B-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)(9CI) (CA INDEX NAME)

Absolute stereochemistry

300841-32-1 CAPLUS 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-hydroxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-quinolinyl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy)-, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

300841-33-2 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-quinolinyl)butyl]-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

300841-39-8 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluoroocahydro-11-hydroxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-(3-pyridinyl)-1H-imidazol-1-yl]butyl}-10-[[3,4,6-trideoxy-3-(dimethylamino)-6-D-wylo-hexopyranoxyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15RR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

300841-40-1 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
7-fluorocotahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-8-0-xylo-hexopyranoyyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,1SR,1SR,1SR)(9CI) (CA INDEX NAME)

300841-42-3 CAPLUS
2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone,
7-fluorooctahydro-11-hydroxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-pyridinyl)butyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxyl-, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

300841-44-5 CAPLUS 2H-Oxacyclotetradecino (4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-pyridinyl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

300841-46-7 CAPLWS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
7-fluorooctahydro-11-hydroxy-1-[4-(3H-imidazo[4,5-b]pyridin-3-y1)butyl]3a,4,7,9,11,13,15-heptamethyl-10-[(3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosy1]oxy]-, (3aS,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

300841-50-3 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-1-[4-(1H-imidazo[4,5-b]pyridin-1-y1]butyl]-11-methox; 3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-wylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

300841-51-4 CAPLUS
2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone,
7-fluorooctahydro-11-hydroxy-3a,7,9,11,13,15-hexamethyl-4-propyl-1-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]-10-[[3,4,6-trideoxy-3-(dinethylanino)-8-D-xylo-hexopycanosyl]oxy]-,
(3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

LII ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

300841-47-8 CAPLUS

3UD#41-47-8 CAPLUS
2H-ONacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
7-fluorooctahydro-1-[4-(3H-imidazo[4,5-b]pyridin-3-y1)butyl]-11-methoxy3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino]-PD-xylo-hexopyranosyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

300841-49-0 CAPLUS 2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-hydroxy-1-[4-(1H-imidazo[4,5-b]pyridin-1-yl]butyl]-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

300841-52-5 CAPLUS
2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
7-fluorootahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-4-propyl-1-[4-{4-(3-pyridinyl)-1H-inidazol-1-yl]butyl]-10-[[3,4,6-trideoxy-3-(dimethylanino)-β-0-xylo-hexopyranosyl)oxy]-,
(3aS,4R,75,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry

300841-53-6 CAPLUS 2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-1-[4-(1H-inidazo[4,5-c]pyridin-1-y1)buty1]-11-methoxy-3a,7,9,11,13,15-hexamethy1-4-propyl-10-[(3,4,6-trideoxy-3-(dimethylamino)-6-b-sylo-hexopyranoxyl)oxy]-, (3a5,4R,7S,9R,10R,11R,13R,15R,15R)-(9CI) (CA INDEX NAME)

L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

300841-55-8 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-1-[4-(3H-imidazo[4,5-c]pycidin-3-yl)butyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(disethylamino)-6-D-sylo-hexopytanoyyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

300841-56-9 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-4-propyl-1-[4-(9H-purin-9-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

300841-61-6 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,7-fluorooctahydro-11-hydroxy-3a,7.9,11,13,15-hexamethyl-4-propyl-1-[(2E)-4-[4-(5-pyrinidinyl)-1H-imidazol-1-yl]-2-butenyl]-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyroxnoxyl]oxyl-,(3aS,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-B

300841-62-7 CAPLUS

Page 110

L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

300841-58-1 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-4-propyl-1-[4-(7H-purin-7-yl)butyl)-10-([3,4,6-tridoxy-3-(dimethylamino)-9-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX

Absolute stereochemistry.

300841-59-2 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-1-[{2E}-4-(1H-imidazo[4,5-b]pyridin-1-y1)-2-butenyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimeth)Jainio]-8-D-xylo-hexopyyranosyl]oxy]-, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
7-fulorooctahydro-11-hydroxy-1-[4-[H-inidazo[4,5-b] pyridin-1-y]) butyl]3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)B-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)(9CI) (CA INDEX NAME)

Absolute stereochemistry.

300841-64-9 CAPLUS 2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-hydroxy-1-[4-(3H-imidazo[4,5-b]pyridin-3-yl]butyl]-3a,7,9,11,13,15-hexamethyl-4-propyl-10-[(3,4,6-trideoxy-3-(dimethylamino)-6-p-xylo-hexopyranoxyl]oxy]-, (3a5,4R,7S,9R,10R,11R,13R,15R,15aB)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

300841-65-0 CAPLUS 2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorocotahydro-1-[4-(3H-imidazo[4,5-b]pyridin-3-yl]butyl]-1l-methoxy-3a,7,9,11,13,15-hexamethyl-4-propyl-10-[(3,4,6-trideoxy-3-(dimethylamino)-6-b-xylo-hexopyranoxyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

300841-67-2 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethenyl-7-fluorooctahydro-11-hydroxy-3a,7,9,11,13,15-hexamethyl-1-[4-(4-phenyl-1H-inidazol-1-yl)butyl]-10-[(3,4,6-trideoxy-3-(dimethylamino)-p-b-xylo-hexopyranozyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15R)-(9CI) (CA INDEX INME)

Absolute stereochemistry.

300841-69-4 CAPLUS
2H-OxacyCladedino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethenyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[4-(4-phenyl-1-finidazol-1-yl)buryl]-10-[[3,4,6-trideoxy-3-(dimethylamino]β-D-mylo-hexopyranosyl]oxyl-, (3a5,4R,75,9R,10R,11R,13R,15R,15R)(9CI) (CA INDEX NNBL)

Absolute stereochemistry.

300841-74-1 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethenyl-7-fluorooctahydro-11-hydroxy-3a,7,9,11,13,15-hexamethyl-1-[4-[4-(5-pyrinddinyl)-1H-imidazol-1-yl]butyl]-10-[[3,4,6-trideoxy-3-(dimethylanino)-β-D-xylo-hexopyranoxyl]oxy]-,
(3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

300841-76-3 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethenyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[4-(4-(5-pyriaddinyl)-1H-imidazol-1-yl]butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl]oxyl-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

300841-71-8 CAPLUS 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethenyl-7-fluorooctahydro-11-hydroxy-3a,7,9,11,13,15-hexamethyl-1-[4-{4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]-10-[{3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

300841-72-9 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethenyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[4-[4-(3-pyridinyl)-1H-inidazol-1-yl]butyl]-10-[[3,4,6-trideoxy-3-(dimethylanino]-B-0-xylo-bexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT \2004 ACS on STN (Continued)

300841-78-5 CAPLUS 2H-Oxacyclotertadecino(4,3-d)cxazcle-2,6,8,14(1H,7H,9H)-tetrone,4-e-thenyl-7-fluorocotahydro-11-hydroxy-1-[4-(3H-imidazc)(4,5-b)pyridin-3-y)butyl]-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-6-b-xylo-hexpyrancyl]oxy]-, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

300841-79-6 CAPLUS
2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethenyl-7-fluorooctahydro-1-(4-(3H-imidazo[4,5-b]pyridin-3-yl)butyl]-11methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)B-D-xylo-hexopyranoxyl]oxy)-, (3as,4R,7S,9R,1DR,11R,13R,15R,15RR)(9CI) (CA INDEX NAME)

1.11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

301320-09-2 CAPLUS 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3as,4R,7s,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

IT

301320-11-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ketolide crythromycins as antibacterial agents)
301320-11-6 CAPLUS
2H-Oxacyclotetradecino(4,3-d) oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[{2-0-bexopyl-3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosylloxy)-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propenyloxy)-4-propyl-, (3aS,4R,7S,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN ACCESSION NUMBER: 2000:680385 CAPLUS DOCUMENT NUMBER: 133:238249 TITLE: Preparation of 0.000

133:238249
Preparation of 2-halo-6-0-substituted erythromycin ketolides as antibacterial agents
Phan, Ly Tam; Or, Yat Sun; Chu, Daniel T.; Platter, Jacob J.; Chen, Yan; Clark, Richard F.
Abbott Laboratories, USA
U.S., 27 pp.
CODEN: USKXAM
Patent

INVENTOR(S):

PATENT ASSIGNEE(S): SOURCE:

Patent English

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

KIND DATE PATENT NO. APPLICATION NO. DATE US 6124269 A 20000926
PRIORITY APPLN. INFO:
OTHER SOURCE(S): MARPAT 133:2 20000926 US 1998-154294 19980916 US 1997-63700P P 19971029

2-Halo-6-O-substituted ketolide derivs. I (R = H, hydroxy protecting group; Rl = alkyl, aryl, heteroaryl, substituted amine, CH2CH:CHY, CH2C.tplbond.cf; Y = H, aryl, heteroaryl, vinyl, substituted vinyl; X = H, Y = O:XY = CH2CH2) and pharmaceutically acceptable salts and esters thereof having antibacterial activity having a formula STRI composition comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of ampound

a compound of the invention, and processes for their preparation Thus, I (R=X=H,

CH2CH:CH2, Y = 0) was prepared and tested for its antibacterial activity (MIC = 0.003 to > 129).
223507-97-99 223508-01-09P 223508-03-0P
223508-04-1P 223508-06-3P 223508-09-6P
223508-10-9P 223508-11-0P 223508-12-1P
223508-12-3P 223508-11-3P 223508-16-5P
223508-17-6P 223508-18-7P 223508-19-8P
223508-01-01P 223508-21-2P 223508-22-3P
223508-23-4P 223508-24-5P 223508-25-6P

Page 112

L11 ANSWER 19 OF 27 CAPLUS OPPYRIGHT 2004 ACS on STN (Continued) HoC

ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
223508-26-7P 223508-28-9P 223508-29-0P
223508-30-3P 223508-31-4P 223508-32-5P
223508-30-6P 223508-31-4P 223508-32-5P
RL: BAC [Biological activity or effector, except adverse); BSU (Biological study, unclassified); SFN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-halo-60-substituted erythromycin ketolides as antibacterial agents)
223507-97-9 CAPLUS
14.1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluor-3a, 4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[(3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopycanosyl]oxy]-, (3as,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

223508-01-8 CAPLUS
14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8 (7H,9H)-trione,7-chloro-4-ethyl-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[(3,4,6-trideoxy-3-(dimethylamino)-B-D-wylo-hexopyranosyl]oxyl-, (3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CAINDEN NAME)

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

223508-03-0 CAPLUS
14,1-(Nitrilosthano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione,7-bromo-4-ethyl-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl-, (3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


233508-04-1 CAPLUS
2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propenyloxy)-10[[3,4,6-trideoxy-3-(dimethylamino)-6-D-xylo-hexopyranosylloxy]-,
3as,48,75,98,10R,118,138,158,158h- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

223508-06-3 CAPLUS 2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-(3-quinolinyl)-2-propenyl]oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



223508-11-0 CAPLUS
Carbemic acid, [3-[3-[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7.9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxacyl-11-yl]osyl-1-propenyl]-6-quinolinyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

223508-12-1 CAPLUS
2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone,
11-[[3-(6-anino-3-quinolinyl)-2-propenyl]oxy]-4-ethyl-7-fluorooctahydro3a,7,9,11,13,15-hexamethyl-10-{[3,4,6-trideoxy-3-(dimethylamino)-β-Dxylo-hexopyranosyl]oxy}-, (3aS,4R,7S,9R,10R,11R,13R,15R,15AR)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN Double bond geometry unknown. (Continued)


223508-09-6 CAPLUS
2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(6-nltro-3-quinoliny])-2-propenyl]oxy]-0,[[3,4,6-tridcoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,7S,9R,10R,11R,13R,15R,15R)- (9CI) (CA

Absolute stereochemistry. Double bond geometry unknown.

223508-10-9 CAPLUS 2H-Owacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-phenyl-2-propenyl)oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylohexopyranosyl]oxy]-, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



223508-13-2 CAPLUS
2H-Oxacyclotetradecino(4,3-d) oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-(6-quinolinyl)-2-propenyl)ayy]-10-[(3,4,6-trideony-3-(dimethylanino)-8-D-xylo-hexopyranosyl)oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

223508-14-3 CAPLUS 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(1,8-naphthyridin-3-yl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-6-p-xylo-hexopyranoxyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15R)-[9CI) (CA INDEX NAME)

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 223508-16-5 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorocotahydro-3a,7,9,11,13,15-hexamethyl-11-[{3-(6quinoxalinyl)-2-propenyl]oxy]-10-[{3,4,6-trideoxy-3-(dimethylamino)-βD-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 223508-17-6 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
11-[(3-[6-(dinethylamino)-3-quinolinyl]-2-propenyl]oxy]-4-ethyl-7fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3(dinethylamino)-p0-exylo-hexopyranoxyl]oxy]-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 223508-20-1 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorocotahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[6(methylamino)-3-quinolinyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3(dimethylamino)-8-D-xylo-hexpyranoxyl]oxy]-,
(3a5,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

RN 223508-21-2 CAPLUS
CN 6-Quinolinecarboxaldehyde, 3-[3-[[(3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-kylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown. L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 223508-18-7 CAPLUS
CN 6-Quinolinemethanesulfonamide, 3-[3-[[(3as,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl)oxyl-2H-oxaccyolotetradecino(4,3-d)oxazol-11-yl]oxy]-1-propenyl]- (9C1) (CA INDEX NAME)

Absolute stereochemistry. Bouble bond geometry unknown.

RN 223508-19-8 CAPLUS
CN 6-Quinolinecarboxamide, 3-[3-[(3as,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-mylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-22-3 CAPLUS
CN 6-Quinolinecarboxaldehyde, 3-[3-[{[3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxacol-11-yl]oxyl-1-propenyl]-, 6-oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 223508-23-4 CAPLUS
CN 6-Quinolinecarboxaldehyde, 3-{3-{{[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-{{[(3,4,6-trideoxy-3-{dimethylaminol-9-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino{4,3-d]oxazol-11-yl]oxy]-1-propenyl]-, 6-hydrazone
(9CI) (CA INDEX NAME)

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 223508-24-5 CAPLUS
CN 6-Quinolinecarboxaldehyde, 3-[3-[((3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-4]oxazol-11-ylloxyl-1-propenyl]-,
6-[(1-methylethylidene)hydrazone] (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 223508-25-6 CAPLUS
CN 3-Pyridinecarbonitrile, 5-[3-{([3aS,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopytanosyl)oxy]-2H-oxacyclotetradecino(4,3-d]oxazol-11-yl]oxy]-1-propenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 223508-29-0 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-f[lurocotahydro-3a,7,9,11,13,15-hexamethyl-11-[[4-oxo-4-(2-thienyl)-2-butynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-Dxylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15RR)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

RN 223508-30-3 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
11-[(4-(6-chloro-3-pycidinyl)-4-oxo-2-butynyl]oxy]-4-ethyl-7fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3(dimethylamino]-9-D-xylo-hexopyranosylloxyl-,
(3as,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 223508-28-9 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluoroctahydro-3a,7,9,11,13,15-hexamethyl-11-[(4-oxo-4-phenyl-2-butynyl)oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3as,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



N 223508-31-4 CAPLUS
N 221-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-(3-quinolinyl)-2-propynyl]oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 223508-32-5 CAPLUS
CN 8-Quinolinesulfonamide, 3-[3-[[(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,911,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)goxy]-2R-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propynyl]- (9CI) (CA INDEX NAMR)

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

223508-33-6 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 11-[(3-[2,2-bithiophen]-5-yl-2-propynyl)oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xyl-6-hexpyranoxyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

.

Absolute stereochemistry. Me 2N

223508-34-7 CAPLUS
2H-Owacyclotetradecino[4,3-d]owazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-{[3-[5-(2-pyridinyl)-2-thienyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranoxyl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN Absolute stereochemistry. (Continued)

223508-07-4 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-bexoyl-3,4,6-trideoxy-3-(dimethylamino)-p-D-xylohexopyranosyl]oxy]-4-ethyl-7-fluorcoctahydro-3a,7,9,11,13,15-hexamethyl-11[[3-(3-quinolinyl)-2-propenyl]oxy]-, (3aS,4R,7S,9R,1OR,11R,13R,1SR,15aR)(9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

293309-29-2 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[{2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino]-\$-D-xylohexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11(2-propenyloxy)-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


ΙT

223308-27-8
RL: RCT (Reactant): RACT (Reactant or reagent)
(preparation of 2-halo-6-0-substituted erythromycin ketolides as antibacterial agents)
223508-27-8 CAPLUS
ZH-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-acetyl-3,4,6-tridecxy-3-(dimethylamino)-B-D-xylo-hexopycanoxyl)oxyl-4-ethyl-7-fluorootahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propynyloxy)-, (3aS,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

223507-98-OP 223508-07-4P 293309-29-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-halo-6-O-substituted erythromycin ketolides as antibacterial agents)
223507-98-O CAPLUS
14.1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-P-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,3,15-hexamethyl-, (3a5,4R,9R,10R,11R,13R,15R,15R)-(9CI) (CA INDEX NAME)

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT:

THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/075,635

LT ANSWER 21 OF 27
ACCIDENT NUMBER:
DCUMBNT NUMBER:
TITLE:
INVENTOR(S):
PATENT ASSIGNEE(S):
SOURCE:

LT ANSWER 21 OF 27
CAPLUS COPYRIGHT 2004 ACS ON STN
2000:553251 CAPLUS
133:120575
Preparation of erythromycins as
Denis, Alexis; Fromentin, Claud
Hoechst Nazion Roussel, Ft. 133:120575
Preparation of erythromycins as antibacterial agents
benis, Alexis: Fromentin, Claude: Heckmann, Bertrand
Hoechst Marion Roussel, Fr.
Eur. Pat. Appl., 17 pp.
CODEN: EPYKUW
Patent DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

APPLICATION NO. PATENT NO. KIND DATE DATE 20000822 JP 2000-21454
B1 20011106 US 2000-497651
E 20030215 AT 2000-400286
F3 20030516 ES 2000-400286
FR 1999-1292 A
MARPAT 133:120575 ES 2186615
PRIORITY APPLN. INFO.:
OTHER SOURCE(S):
GI

Macrolide erythromycins I (R = heterocycle, X = CH2, NH; n = 1-8; Y = H, halogen; Z = H, acyl) were prepared as antibacterial agents. Thus, 11,12-dideoxy-3-de[(2,6-dideoxy-3-de:[2,1-3-0-methyl-a-L-ribo-hexopyranoxyl)oxy]-6-0-methyl-3-0xo-12,11-[oxycarbonyl[[4-[4-(1H-indol-3-yl)-1H-imidazol-1-yl]-butyl]-iminol]-erythromycin was prepared and tested in

L11 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

PAGE 1-B

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT REFERENCE COUNT:

L11 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) vitro for its antibacterial activity (MIC for S. aureus = 0.02-0.150

μg/cm3). 285569-19-9P 285569-47-3P

285569-19-9P 285569-47-3P
RL: RAC [Biological activity or effector, except adverse); BSU [Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREF (Preparation); USES (Uses) (preparation of erythromycins as antibacterial agents)
285569-19-9 CAPLUS
2-Furancarboxamide, N-[1-[4-([3as,4R,7s,9R,10R,11R,13R,15R,15AR)-4-ethyl-7-fluoroddecahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxn-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl-2H-oxacyclotetradecino[4,3-d]oxazol-1(4H)-yl]butyl]-1H-imidazol-4-yl]- (GCI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

285569-47-3 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-1-[4-(4-(iH-indol-3-yl)-iH-inidazol-1-yl]butyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranozyl]oxy]-, (3aS,4R,75,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

```
ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN
SION NUMBER: 2000:535153 CAPLUS
ENT NUMBER: 133:135545
                                                                                                                                                                                    133:135545
Preparation of ketolide antibiotics erythromycin derivatives as antibacterial and antiprotozoal agents Kaneko, Takushir McMillen, William Thomas Pfizer Products Inc., USA
PCT Inc. Appl., 32 pp.
CODEN: PIXXO2
Patent
English .
1
INVENTOR(S):
PATENT ASSIGNEE(S):
SOURCE:
 DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
                             PATENT NO.
                                                                                                                                                                                                                                                                                                                                    APPLICATION NO.
                                                                                                                                                                                                                DATE
                                                                                                                                                                                , LV, FI, RO
A 2001106 BR 1999-16969 19991228
A 20021015 EE 2001-394 19991228
T2 20021022 JP 2000-596017 19991228
E 20040115 AT 1999-959627 19991228
A 20030217 AZ 2001-5580 20010706
A 20020329 BG 2001-105730 20010725
A 20010919 NO 2001-3680 20010725
BY 2002-105730 20010725
BY 2002-105730
 PRIORITY APPLN. INFO.:
 OTHER SOURCE(S):
```

L11 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Macrolide erythromycins I (R = H,acyl, Bn, benzylomycarbonyl, alkylsilyl; Rl = alkyl; R2 = heterocycle, aryl; R3 = H, alkyl; R4 = halogen, CN; X1 = O, -CRSR6-, -NRS-; R5, R6 = H, alkyl; X2 = O, substituted oxine) were prepared as antibacterial and antiprotozoal agents. Thus, I (R = H; Rl = Me; R2 = NH(CH2)3R7; R3 = Et, R4 = F) was prepared and tested in mice for its antibacterial and antiprotozoal activities. 286462-85-99 286462-86-09 286462-80-19 286462-90-89 296462-90-89 286462-9

286462-98-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SFN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of ketolide antibiotics erythromycin derivs. as antibacterial

bacterial
and antiprotozoal agents)
286462-85-9 CAPLUS
2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[[3-[4-(3-pyridinyl)-1H-imidazol-1-yl]propyl]amino]-10-[[3,4,6-trideoxy-3-(dimethylamino]-8D-xylo-hexopyranoyl]oxy],-14-(O-methyloxime),
(3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN Absolute stereochemistry. (Continued)

286462-88-2 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
1-[3-[4,5-bis(acetyloxy)-1H-imidazol-1-yl]propyl]amino]-4-ethyl-7fluoroottahydro-1l-methoxy-3a,7,9,11,13,15-hoxamethyl-10-[{3,4,6-trideoxy-3-(dimethylamino]-β-D-xylo-hexopyranoxyl]oxyl(3a5,4R,75,9R,10R,11R,13R,15R,15R)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

286462-89-3 CAPLUS
2H-Owacyclotetradecino[4,3-d]owazole-2,6,8,14(1H,7H,9H)-tetrone,
1-[[3-(6-amino-9H-purin-9-y1)propy]]amino]-4-ethyl-7-fluorooctahydro-11methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)6-D-xylo-hexopyranoyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15R)(9CI) (CA INDEX NAME)

Absolute stereochemistry

L11 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

286462-86-0 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-([3-[4-[3-pyridinyl]-1H-imidazol-1-yl]butyl]amino]-10-[[3,4,6-trideoxy-3-(dimethylamino]-D-xylo-hexopyranoxyloxyl-,14-(O-methyloximm),
33s,48,75,98,108,118,138,138,158R)-(SCI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

CAPLUS

286462-87-1 CAPLUS
2H-OxacyClotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[{3-(2-phenyl-1H-imidazol-1-yl)propyl]amino]-10-[{3,4,6-trideoxy-3-(dimethylamino)-8-D-sylo-hexopyranosyl]oxy]-,
(3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

L11 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

286462-90-6 CAPLUS
2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
1-[3-[5-(4-chloropheny1)-2H-tetrazol-2-y1]propy1]amino]-4-ethy1-7fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethy1-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-p-xylo-hexopyranosyl]propy1,3a,4,75,9R,10R,11R,13R,15R,15aR]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

286462-92-8 CAPLUS
2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[[3-[4-(2-propenyl)-1H-imidazol-1-yl]propyl] maino]-10-[[3,4,6-trideoxy-3-(dimethylamino]-9-0-pylo-hexopyranosyl]oxyl,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

L11 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

286462-94-0 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-{{3-(5-phenyl-2H-tetrazol-2-yl)propyl]amino]-10-[{3,4,6-trideoxy-3-(dimethylamino]-B-0-ylo-hexapyranosyl)oxyl-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

286462-96-2 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
1-[[3-[6-(2-chlorophenyl)-2H-tetrazol-2-yl]propyl]amino]-4-ethyl-7fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 2H-Oxacyclotetradecino(4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[(2-0-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranoxyl]oxyl-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15hexamethyl-1-[(3-[4-(3-pyridinyl)-lH-imidazol-1-yl]propyl]amino]-,
14-(0-methyloxime), (3aS,4R,7s,9R,1OR,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


286462-98-4 CAPLUS Acetanide, N-[2-[1-{3-{[(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorododeahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxaco-1-(4H)-yl]amino)propyl]-1H-imidazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 286463-00-1P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)
(preparation of ketolide antibiotics erythromycin derivs. as antibacterial and antiprotozoal agents)
RN 286463-00-1 CAPLUS

ANSWER 23 OF 27
SSION NUMBER:
2000:367056 CAPLUS
SSION NUMBER:
2000:367056 CAPLUS
133:4901
E: Preparation of erythromycins as antibacterial agents
Denis, Alexis
NTOR(S):
Denis, Alexis
Hoechst Marion Roussel, Fr., Aventis Pharma. S.A.
Eur. Pat. Appl., 16 pp.
CODEN: EEXXDW
PATH
UNGE: Path
IN ACC. NUM. COUNT: 1
INTORDATION: ACCESSION NUMBER: DCUMENT NUMBER: TITLE: INVENTOR(S): PATENT ASSIGNEE(S): SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
EP 1004592		EP 1999-402907	19991123
	CH, DE, DK, ES, F LT, LV, FI, RO	R, GB, GR, IT, LI, LU,	NL, SE, MC, PT,
FR 2786198		FR 1998-14782	19981124
AU 9959522	A1 20000525	AU 1999-59522	19991117
	A 20001120 B1 20020827	ZA 1999-7176 US 1999-442681	
JP 2000159790 NO 9905745	A2 20000613	JP 1999-331141	19991122
CN 1263101	A 20000816	NO 1999-5745 CN 1999-127394	19991123
KR 2000057017 AT 245160	A 20000915 E 20030815	KR 1999-52014 AT 1999-402907	19991123 19991123
BR 9905735	A 20000808	BR 1999-5735 US 2002-188394	19991124
US 6664398	B2 20031216		
PRIORITY APPLN. INFO	.:	FR 1998-14782 A US 1999-442681 A3	
OTHER SOURCE(S):	MARPAT 133:49		



L11 ANSYER 23 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) carboxylate) were prepd. as antibacterial agents. Thus, 11,12-dideoxy-3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-e-L-ribohexopyranosyl)oxy|-6-O-methyl-3-O-methyl-1-1-[oxycarbonyl[(4-(3-(3-pytidinyl)-1H-pytazol-1-yl]butyl]imino]]-erythromycin was prepd. and tested in vite for its antibacterial activity (MIC = 0.04-0.6 µ/CM3).

IT 270251-28-09 270251-31-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified): SPN (Synthetic preparation): TFU (Therapeutic use); BIOL (Biological study): PREP (Preparation): USS (Uses) (deriva. of erythromycin, their process of preparation and their application

Absolute stereochemistry.

270251-31-5 CAPLUS Z/UZ1-31-3 CARUS

2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H) -tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[4-[4-(3-pytidinyl)-1H-pyrazol-1-yl]butyl]-10-[[3,4,6-tideoxy-3-(dimethylamino)β-D-mylo-hexopyranosyl]oxy]-, (3a5,4R,7S,9R,1OR,11R,13R,15R,15R)(9CI) (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 24 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN CESSION NUMBER: 2000:335421 CAPLUS COMMENT NUMBER: 132:322074 132:322074
Preparation of erythromycin derivatives as antibiotics Agouridas, Constantin; Denis, Alexis; Fromentin, Claude
Hoechst Harion Roussel, Fr.
PCT Int. Appl., 13 pp.
CODEN: PIXXO2
Patent
French INVENTOR (S):

PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: French

PAT	ENT	NO. 0278		KI	D	DATE			λ	PPL	ıc	ATIC	N NC	٥.	DATE			
VO	2000	0278	57	A	2	2000	0518		¥	0 1	99	9-F	R271	 В	1999	1109		
WO	2000	0278	57	A:	3	2000	0817											
	W:	AE.	AL.	AU.	BA,	BB,	BG,	BR,	CA,	CN	١,	CR,	CU,	CZ,	DM,	EE,	GD,	GE,
		HR,	HU,	ID,	IL,	IN,	IS,	ΚP,	KR,	LC	:,	LK,	LR,	LT,	LV,	MG,	MK,	MN,
											١,	TT,	UA,	UZ,	VN,	YU,	ZA,	AM,
		AZ,	BY,	KG,	ΚZ,	MD,	RU,	TJ,	TM									
	RW:	GH,												BF,	ВJ,	CF,	CG,	CI,
		CM,	GΑ,	GN,	G₩,	ML,	MR,	NE,	SN,	TE	١,	TG						
FR	278	612 20132 11436		A:	1	2000	0512		F	R 1	99	8-1	4145		1998	1110		
US	2002	20132	81	A.	1	2002	0131		U	5 1	.99	9-4	3314	6	1999	1103		
JP	2000	1436	89	A:	2	2000	0526		J	P 1	99	9-3	1801	5	1999	1109		
EP	101	5669 5669		A:	1	2000	0705		E	P 1	.99	9-4	0278	3	1999	1109		
EP	101	5669		В:	1	2003	0219											
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GF	١,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
		AT, IE, 5236 10 379 3365 509 138 20287 7257 10022 10038 10003	SI,	LT,	Ŀ۷,	FI,	RO											
BR	991	236		A		2002	0108		В	R 1	99	9-1	5236		1999	1109		
SI	206	10		c		2002	0228		5	I 1	99	9-2	0091		1999	1109		
ΑT	232	379		E		2003	0315		Α	т 1	99	9-4	0278	3	1999	1109		
ES	218	365		T	3	2003	0701		E	S 1	99	9-4	0278	3	1999	1109		
NZ	511	509		A		2003	0725		N	Z 1	99	9-5	1160	9	1999	1109		
PΤ	101	5669		т		2003	0731		P	T 1	99	9-4	0278	3	1999	1109		
ΑU	766	138		В:	2	2003	1009		A	U 2	200	0-1	0526		1999	1109		
US	200	20287	81	A.	1	2002	0307		υ	5 2	200	0-7	3416	2	2000	1211		
US	640	7257		B	2	2002	0618											
NO	200	10022	72	A		2001	0710		N	0 2	200	1-2	272		2001	0509		
ZA	200	10038	01	A		2002	0510		2	A 2	200	1-3	801		2001	0510		
HR	200	10003	35	A.	1	2002	0630		H	R 2	200	1-3	35		2001	0510		
HR	200	10335		В	1	2003	0831											
lTi	(AP	PLN.	INFO	-:					FR 1	998	1-1	414	5	A	1998	1110		
		PLN.						- 1	US 1	999	-4	331	46	AЗ	1999	1103		
								1	3 0 1	999)-F	R27	18	v	1999	1109		
3 50	DURC	E(S):			MAR	PAT	132:	3220	74									

OTHER SOURCE(S):

L11 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

REFERENCE COUNT: THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Erythromycin derivs. I, wherein X represents a hydrogen atom or a halogen atom and Z represents a hydrogen atom or an acid radical and the additive salts with acids were prepared as antibiotics. Thus, 11,12-dideoxy-3-de-[(2,6-dideoxy-3-de-ethyl-3-0-enthyl-3-f-i-ibohexopyranoxyl)oxyl-6-0-methyl-3-oxo-12,11-[oxycarbonyl-[(4-[4-(4-aminophenyl)-1H-imidazol-1-yl]butyl]imino]]-erythromycin was prepared and tested in vitro for its antibacterial activity against Streptococcus pyogenes and pneumoniae (MIC = 0.3-2.5 µg/CM3).
267000-51-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); TRU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of erythromycin derivs. as antibiotics)
267000-51-1 CAPUS
ZH-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 1-[4-(4-aminophenyl)-1H-imidazol-1-yl]butyl]-4-ethyl-7-fluorooctahydro-1l-methoxy-3a,7,9,11,31,51-shamethyl-10-[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxylloxy]-, (CA INDEX NAME)

I

L11 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

PAGE 1-B

~ NH2

267000-52-29

267000-52-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of erythromycin derivs. as antibiotics)
267000-52-2 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-([2-0-actyl-3,4,6-trideoxy-3-(dimethylamino)-9-D-xylo-hexopyranosyl]oxy]-1-[4-[4-(4-aminophenyl)-1H-imidazol-1-yl]butyl]-4-ethyl-7-[luoroocahydro-1]-methoxy-3a,7,9,11,3,15-hexamethyl-,
(3aS,4R,7S,9R,1OR,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

C11 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN ACCESSION NUMBER: 2000:289282 CAPLUS 132:279475 Preparation of antib-Preparation of macrolide erythromycins as antibacterial agents Agouridas, Constantin; Bretin, Francois; Denis, Alexis; Fromentin, Claude Rocchat Marion Roussel, Fr. Fr. Demande, 28 pp. CODEN: FRXXBL Patent French PATENT ASSIGNEE(S): SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO	. DATE
FR 2784682	A1 2000042	PR 1998-12937	19981015
FR 2784682	B1 2002120	16	
US 6352983	B1 2002030	5 US 1999-41602	19991008
JP 2000128896	A2 2000050	9 JP 1999+290869	19991013
EP 1000952	A2 200005	T EP 1999-40252	19991014
EP 1000952	A3 2004010)2	
		FR, GB, GR, IT, LI,	LU, NL, SE, MC, PT,
IE, SI.	LT, LV, FI, RO)	
US 2002111319	A1 2002081	us 2002-75635	20020213
PRIORITY APPLN. INFO	.:	FR 1998-12937	A 19981015
		US 1999-416022	A1 19991008
OTHER SOURCE(S):	MARPAT 13	2:279475	

Macrolide erythromycins I (A = N, NO; R = H, hydroxyalkyl, aryloxyalkyl; R1 and R2 = H, alkyl; Z = H, acyl) were prepared as antibacterial agents. Thus, [3as-(3aR,4.5*,7R*,9s*,105*,115*,135*,15a*)]-4-ethyl-7-fluora,3,4,10,1,12,13,15+a-cottahydro-11-aethoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethyl-amino)-B-D-xylo-hexopycanosyl]oxy]-14,1-(nitriloxthano)-2H-oxacyclottradesino(4,3-dloxacole-2,6,8(9H)-trione was prepared and tested in vitro for its antibacterial activity (MIC = 0.02-1.2 µg/cm3).

µg/cm3). 263904-89-8P 263904-92-3P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

Page 121

L11 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-B

~ NH2

ANSWER 25 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) BIOL (Biological study): PREP (Preparation): USES (Uses) (prepn. of macrolide erythromycins as antibacterial agents) 263904.89-8 CAPLUS (14.1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxacol-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15AR)- (9CI) (CAINDEX NAME)

Absolute stereochemistry.

263904-92-3 CAPLUS
14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-18-(hydroxymethyl)-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[(3,4,6-trideoxy-3-(dimethylamino)-Po-xylo-hexopyranosyl)qnyl-,
(3aS,4R,75,9R,10R,11R,13R,15R,15aR,18R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

263904-91-2P 263904-95-6P 263904-99-0P 263905-00-6P

RESERT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or respent) (Preparation of macrolide erythromycins as antibacterial agents)

L11 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 263904-91-2 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino(4,3-d)oxazole-2,6,8 (7H,9H)trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,7,9,11,13,15-hexamethyl-10-[(3,4,6-trideoxy-3-(dimethylamino)-2-0(trimethylailyl)-PD-xylo-hexopyranoxylloxyl-,
(3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

263904-95-6 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[{2-0-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-1-[(IR)-1-(hydroxymethyl)-2(phenylmethyl)amino]ethyl]-11-methoxy-3-3,7,9,11,13,15-hexamethyl-,
(3a5,4R,7S,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

263904-99-0 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-1-[(1R)-1-(hydroxymethyl)-2[(phenylmethyl) amino]ethyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-10[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl]oxy]-,
(3as,4R,75,9R,10R,11R,13R,15R,15R)-(SCI) (CA INDEX NAME)

ANSWER 26 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

1999:659085 CAPLUS

1999:659085 CAPLUS

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819

111:257819


111:257819

111:257819

111:257819 INVENTOR(S): PATENT ASSIGNEE(S): SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE

EP 949268 81 19991013 EP 1999-400843 19990407
EF 949268 81 20031210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO
FR 2777282 B1 20010420
US 6121432 A 20000919 US 1999-273846 19990322
US 6121432 A 20000919 US 1999-8580 19990320
CN 1235162 A 19991107 CN 1999-104853 19990407
CN 1130370 B 20031216
AT 256139 E 20031216
AT 156199 E 20031215 AT 1999-400843 19990407
FRIORITY APPLIN. INFO.:
OTHER SOURCE(S): HARPAT 131:257819
GI



Macrolide erythromycins I (λ = OH; B = H; λB = carbonate, carbamate; Z = H, acyl, alkyl) were prepared Thus, 11, 12-dideoxy-3-de[(2,6-dideoxy-3-C-methyl-3-0-methyl-3-0-methyl-3-0-methyl-3-oxo-12,11-[oxycarbonyl[4-[-3-pyridinyl]-1H-imidazol-1-yl]-

Page 122

L11 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN Absolute stereochemistry. (Continued)

263905-00-6 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, $1-(1R)-2-anino-1-(hydroxymethyl)ethyl]-4-ethyl-7-fiuorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[(3,4,6-trideoxy-3-(dimethylamino)-\beta-D-xylo-hexopytanosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15RR)-(9CI) (CA INDEX NAME)$

Absolute stereochemistry.

L11 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued) butyl]imino]erythromycin A was prepd.

17 244307-30-2E R.

RI: RCT (Reactant): SPN (Synthetic preparation): PREP (Preparation): RACT (Reactant or reagent): (Preparation of 2-fluoro-3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-\u03c4-L-ribohexopyranosyl)oxyl-6-O-methyl-3-oxo-erythromycin derivs.)

RN: 244307-90-2 CAPLUS
CN: 2H-Oxacyclotetradecinc[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-([2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-9-D-mylo-hexopyranosyl]oxyl-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[4-4]-4-(3-pyridinyl)-1H-imidzol-1-yl]butyl]-, (3as,4R,7s,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 27 OF 27
ACCESSION NUMBER:
DOCUMENT NUMBER:
1999:299484 CAPLUS
130:312023
11TILE:
INVENTOR(5):
PATENT ASSIGNEE(5):
SOURCE:
POOLUMENT TYPE:
DOCUMENT TYPE:
POOLUMENT TYPE:
PATENT ASSIGNEE(5):
POOLUMENT TYPE:
POOLUMENT TYPE:
PATENT ASSIGNEE(5):
POOLUMENT TYPE:
PATENT ASSIGNEE(5):
POOLUMENT TYPE:
PATENT ASSIGNEE(5):
POOLUMENT TYPE:
PATENT ASSIGNEE(5):
PATEN

DOCUMENT TYPE: LANGUAGE:

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

A1 19990506 APPLICATION NO. DATE WO 1998-US22989 19981029 PATENT NO. 9921871 A1 19990506
W: AL, MA, AT, AU, AZ, BA, BB, BB, BB, BB, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, WY, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZV, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RY; GH, GM, KE, LS, MY, SD, SZ, UG, ZV, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NI, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
19912881 A1 19990517
19512881 A1 19990517
1951289 B4 B2 20020815
1951286 A1 20000816
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO WO 9921871 EP 1027362 A1
R: AT, BE, CH, I
SI, FI, RO
BR 9813319 A
J 92001521039 T2
NZ 503822 A
NO 2000002190 A ..., LI, LU, NL, SE,

20000822 BR 1998-13319 19981029

2 20011106 JP 2000-517980 19981029

2 20021220 NZ 1998-503822 19981029

2 20000629 NO 2000-2190 20000427

2 20010131 BG 2000-104434 2000515

VS 1997-959881 A 199971029

VS 1998-154239 A 199801029

MARPAT 130:312023

OTHER SOURCE(S):

BG 104434 PRIORITY APPLN. INFO.:

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

223508-01-8 CAPLUS
14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)rione, 7-chloro-4-ethyl-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy3a,7,9,11,13,15-hexamethyl-10-[(3,4,6-trideoxy-3-(dimethylamino)-8-Dxylo-hexopyranosyl]oxyl-, (3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

223508-03-0 CAPLUS
14,1-{Nitriloethano}-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,9 (7H,9H)-trione, 7-broso-4-e-thyl-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl-, (3a5,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Macrolide erythromycins I (R is hydrogen or a hydroxy protecting group; RI = alkyl optionally substituted with one or more substituents, ; X is F, Cl, Br, IrCHZCH:GHY, wherein Y is selected from the group consisting of H, aryl, heteroaryl, -CH:CHZ, CH:CH-aryl, CH:CH-heteroaryl, and aryloyl) were prepared as antibacterial agents. Thus, I (R = H, RI = CHZCH:CHZ, X = F) was prepared and tested for its antibacterial activity (MICs = 0.2-100 $\mu_{\rm M}/{\rm mL}$).

prepared as antibacterial agents. Thus, I (R = H, R1 = CH2CH:CH2, X = F) was prepared and tested for its antibacterial activity (MICs = 0.2-100 µg/ml).

223507-97-9F 223508-01-8F 223508-03-0F
223508-04-1F 223508-10-9F 223508-19-6P
223508-10-9F 223508-11-0F 223508-12-P
223508-13-9F 223508-18-7F 223508-12-P
223508-23-17-6F 223508-18-7F 223508-19-8F
223508-23-4F 223508-21-2F 223508-23-6F
223508-23-9F 223508-21-2F 223508-23-6F
223508-23-9F 223508-31-4F 223508-32-5F
223508-33-9F 223508-31-4F 223508-32-5F
223508-33-6F 223508-31-4F 223508-32-5F
223508-33-6F 223508-31-4F 223508-31-5F
223508-37-9F 223508-31-4F 223508-31-5F
223508-37-9F 223508-31-4F 223508-31-5F
223508-37-9F 223508-31-4F 223508-31-5F
223508-37-9F 223508-31-4F 223508-31-5F
223507-97-9F (R1) SP (Synthetic preparation); MIC (Therapeutic use); BIOL (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SFN (Synthetic preparation); TRU (Therapeutic use); BIOL (Biological activity or effector); USES (Uses) (preparation of 2-halo-6-O-substituted ketolide erythromycins as antibacterial agents)
225507-97-9 CAPLUS
14.1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d] oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15-hexdcay-3-dimethylanno)-β-D-xylo-hexopyranosyl]oxyl-, (3a5,4R,9R,10R,11R,13R,15R,15AR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

223508-04-1 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propenyloxy)-10[(3,4,6-trideoxy-3-(dimethylamino)-P-D-sylo-hexopyranosyl)oxy]-,
(3a5,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

223508-06-3 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxacyle-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-(3-quinolinyl)-2-propenyl]oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)- β -D-xylohexopyranosyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)


L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 223508-09-6 CAPLUS
CN 2H-Oxacyclotetradecinc[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluoroctahydro-3a,7,9,11,13,15-hexamethyl-11-{[3-(6-nltro-3-quinolinyl)-2-propenyl]oxy]-10-{[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-13-2 CAPLUS
CN 2R-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(6-quinolinyl)2-propenylloxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylohexopyranosyl]oxy]-, (3a5,4R,7S,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 223508-14-3 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-{{3-(1,8-naphthyridin-3-yl)-2-propenyl]oxy}-10-{{3,4,6-trideoxy-3-(dimethylamino)B-D-xylo-hexopyranoxyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15R)(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 223508-11-0 CAPLUS
CN Carbamic acid, [3-[3-[{(3as,4R,7s,9R,10R,11R,13R,15R,15R,1-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl)oxy]-ZH-oxacyclotetradecino(4,3-d)oxacol-11-propenyl]-6-quinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

RN 223508-12-1 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
11-[3-(6-amino-3-quinoliny1)-2-propeny1]oxy]-4-ethyl-7-fluorooctahydro3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-Dxylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15RR)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry. Double bond geometry unknown

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-16-5 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(6-quinoxalinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoxyl]oxy]-, (3a5,4R,75,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 223508-17-6 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
11-[3-[6-(dimethylamino)-3-quinolinyl]-2-propenyl]oxy]-4-ethyl-7fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3(dimethylamino)-8-D-sylo-hexopyranosylloxy]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 223508-18-7 CAPLUS
CN 6-Quinolinemethanesulfonamide, 3-[3-[{[3a5,4R,75,9R,10R,11R,13R,15R,15aR}-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexpyranoxyl]oxyl-2H-oxacycolotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 223508-19-8 CAPLUS
CN 6-Quinolinecarboxamide, 3-[3-[{[3aS,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-[luorotetradecahydro-3a,7.9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

Continued)

OHC

Negative Reserved From the Reserved Rese

RN 223508-22-3 CAPLUS
CN 6-Quinolinecarboxaldehyde, 3-[3-[[[3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-P-0-xylo-hexopyranosyl]oxyl-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxyl-1-propenyl]-, 6-oxime (9CI) (CA INDEX NAME)

RN 223508-23-4 CAPLUS
6-Quinolinecarboxaldehyde, 3-[3-[[(3a5,4R,75,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino(4,3-d]oxazol-11-yl]oxy]-1-propenyl]-, 6-hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AN 223508-20-1 CAPLUS


CM 2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluoroctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-[6(methylamino)-3-quinolinyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3(dimethylamino)-6-D-xylo-hexopyranosyl]oxy]-,
(3a5,4R,75,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

RN 223508-21-2 CAPLUS
CN 6-Quinolinecarboxaldehyde, 3-[3-[[(3a5,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-0-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-24-5 CAPLUS
CN 6-Quinolinecarboxaldehyde, 3-[3-[[(3as, 4R, 7s, 9R, 10R, 11R, 13R, 15R, 15aR)-4-ethyl-7-fluorotetradecahydro-3a, 7, 9, 11, 13, 15-hexamethyl-2, 6, 8, 14-tetraoxo-10-[(3, 4, 6-trideoxy-3-(dimethylamino)-8-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[(4, 3-d) 0xazol-11-yl]oxy]-1-propenyl]-, 6-[(1-methylethylidene)hydrazone] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

RN 223508-25-6 CAPLUS
CN 3-Pyridinecarbonitrile, 5-[3-[{(3as,4R,7s,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexaethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3-(dinethylamino)-β-D-xylo-hexopyranosyl)oxyl-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxyl-1-propenyl]- (9CI) (CA INDEX NAME)

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

223508-26-7 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propynyloxy)-10[3,4,6-trideoxy-3-(dimethylamino)-6-D-xylo-hexopyranosyl]oxy}-,
(3aS,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. HC

223508-28-9 CAPLUS 2H-Oxacyclotetradecino(4,3-d) oxazole-2,6,8,14(1H,7H,9H)-tetrone,4-ethyl-7-fluoroottahydro-3a,7,9,11,13,15-hexamethyl-11-[(4-oxo-4-phenyl-2-butynyl) oxy]-10-((3,4,6-trideoxy-3-(dimethylamino)-B-D-wylo-hexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

223508-31-4 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[{3-(3-quinolinyl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-9-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15RR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

223508-32-5 CAPLUS
8-Quinolinesulfonamide, 3-[3-[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosylloxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

223508-29-0 CAPLUS 2H-Owacyclotetradecino[4,3-d]oxazole-2,6,8,14[1H,7H,9H]-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[4-oxo-4-(2-thienyl)-2-butynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-B-D-xylo-hexopyranosyl]oxy]-, (3a5,4R,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

223508-30-3 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
11-[4-(6-chloro-3-pyridinyl)-4-oxo-2-butynyl]oxy]-4-ethyl-7fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3(dimethylamino)-6-D-sylo-bexopyranosyl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

223508-33-6 CAPLUS 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(lH,7H,9H)-tetrone, 11-[(3-(2,2'-bithiophan]-5-yl-2-propynyl)oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-rylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

223508-34-7 CAPLUS
2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-{5-(2-pyridinyl)-2-pcinynyl)oxy]-10-([3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-,
(3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


223507-98-0P 223508-05-2P 223508-07-4P 223508-27-8P

223508-27-8P
RL: RCT (Reactant), SPN (Synthetic preparation), PREP (Preparation), RACT (Reactant or reagent)
(preparation of 2-halo-6-0-substituted ketolide erythromycins as antibacterial agent)
223507-98-0 CAPLUS
14,1-(Mitriloethano)-2H-oxacyclotetradecino(4,3-d)oxazole-2,6,8 (7H,9H)-trione, 10-[[2-0-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-P-D-mylo-hexopyranosyl)oxyl-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-, (3as,4R,9R,10R,11R,13R,15R,15R)(9CI) (CA INDEX NAME)

Absolute stereochemistry.

223508-05-2 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[(2-0-acety)-3,4,6-trideoxy-3-(dimethylamino)-B-D-xylohexopycanoxyl]oxyl-4-ethyl-7-fluorootahydro-3a,7,9,11,13,15-hexamethyl-11(2-propenyloxy)-, (3aS,4R,7S,9R,10R,11R,13R,15R,15R)- (9CI) (CA INDEX

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT 2

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN NAME) (Continued)

Absolute stereochemistry.

223508-07-4 CAPLUS
2H-Oxacyclotetradecino[4,3-d] oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[{2-0-bexcyl-3,4,6-trideoxy-3-(dimethylamino)-B-D-xylohexopyranosylloxyl-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-bexamethyl-11[[3-(3-quinolinyl)-2-propenyl]oxyl-, (3a5,4R,7S,9R,10R,11R,13R,15R,15aR)(9GI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

223508-27-8 CAPLUS
2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-0-acetyl-3,4,6-trideoxy-3-(dimethylamino]-β-0-xylohexopyranoxyl]oxy]-4-ethyl-7-fluorootahydro-3a,7,9,11,13,15-hexamethyl-11(2-propynyloxy)-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)